Programme book Brussels EXPO Nov 28-30, 2012

Transcription

k
oo
b
e
m
am
r
g
Pro
PO
X
E
els
12
s
s
0
u
2
,
r
B
-30
8
2
Nov
www.ophthalmologia.be
TOUGH
but Gentle
A Clear choice in glaucoma
(bimatoprost ophthalmic solution) 0,1mg/ml
1. NAAM VAN HET GENEESMIDDEL LUMIGAN 0,1 mg/ml oogdruppels, oplossing. 2. KWALITATIEVE EN KWANTITATIEVE SAMENSTELLING Eén ml oplossing bevat 0,1 mg bimatoprost. Hulpstof: Eén ml oplossing bevat 0,2 mg benzalkoniumchloride.
Voor een volledige lijst van hulpstoffen, zie rubriek 6.1. 3. FARMACEUTISCHE VORM Oogdruppels, oplossing. Kleurloze tot lichtgele oplossing. 4. KLINISCHE GEGEVENS 4.1 Therapeutische indicaties: Vermindering van verhoogde intra-oculaire druk
in chronisch open kamerhoek glaucoom en oculaire hypertensie bij volwassenen (als monotherapie of als aanvullende behandeling met bètablokkers). 4.2 Dosering en wijze van toediening: De aanbevolen dosis is eenmaal daags een druppel in het
(de) aangetaste oog (ogen), ‘s avonds toegediend. De eenmaal daagse dosis mag niet worden overschreden aangezien frequentere toediening het effect van de intra-oculaire drukverlaging kan verminderen. Wanneer er meer dan één topicaal ophtalmisch
geneesmiddel wordt gebruikt, dient tussen de verschillende toedieningen minstens 5 minuten wachttijd te zitten. Gebruik bij kinderen en adolescenten (beneden de 18 jaar): LUMIGAN wordt niet aanbevolen voor gebruik bij kinderen jonger dan 18
jaar, door een gebrek aan gegevens over veiligheid en werkzaamheid. Gebruik bij lever- en nierfunctiestoornissen: LUMIGAN is niet onderzocht bij patiënten met nier- of matige tot ernstige leverfunctiestoornissen en dient daarom met voorzichtigheid
te worden gebruikt bij dergelijke patiënten. Bij patiënten met een geschiedenis van een milde leveraandoening of een abnormaal alanine aminotransferase (ALT), aspartaat aminotransferase (AST) en/of bilirubine basiswaarde had bimatoprost 0,3 mg/ml
oogdruppels, oplossing gedurende 24 maanden geen nadelig effect op de leverfunctie. 4.3 Contra-indicaties: Overgevoeligheid voor het werkzame bestanddeel of voor één van de hulpstoffen. Voor LUMIGAN 0,1 mg/ml bestaat een contra-indicatie voor
patiënten waarbij in het verleden een negatieve reactie op benzalkoniumchloride werd vermoed waardoor het gebruik ervan is gestopt. 4.8 Bijwerkingen: In een Fase III klinische studie van 12 maanden kreeg ongeveer 38% van de patiënten behandeld
met LUMIGAN 0,1 mg/ml oogdruppels, oplossing last van bijwerkingen. De meest frequent gemelde bijwerking was conjunctivale hyperemie (meestal zeer licht tot mild en van een non-inflammatoire aard) bij 29% van de patiënten. Ongeveer 4% van de
patiënten zijn gestopt met de therapie ten gevolge van bijwerkingen in de studie van 12 maanden. De volgende bijwerkingen werden gemeld tijdens klinische onderzoeken met LUMIGAN 0,1 mg/ml oogdruppels, oplossing. De meeste waren oculair, mild
en geen ervan was ernstig: Zeer vaak (≥1/10); vaak (≥1/100 tot <1/10), soms (≥1/1.000 tot <1/100); zelden (≥1/10.000 tot <1/1.000); zeer zelden (<1/10.000) voorkomende bijwerkingen worden gerangschikt volgens het Systeem Orgaanklassen in
tabel 1 naar afnemende ernst binnen elke frequentiegroep: Zenuwstelselaandoeningen: Soms - Hoofdpijn. Oogaandoeningen: Zeer vaak - Conjunctivale hyperemie; Vaak - Keratitis punctata, oogirritatie, oogpruritus, groei van wimpers; Soms - Asthenopie,
wazig zien, conjuctivale aandoening, conjunctivaal oedeem, irishyperpigmentatie, madarose. Maagdarmstelselaandoeningen: Soms - Misselijkheid. Huid- en onderhuidaandoeningen: Vaak - Ooglid-erytheem, ooglidpruritus, hyperpigmentatie van huid,
hypertrichose; Soms - Droge huid, korsten op het ooglid, ooglidoedeem, pruritus. Algemene aandoeningen en toedieningsplaatsstoornissen: Vaak - Irritatie op de plek van inbrengen. Bij klinische studies zijn meer dan 1.800 patiënten behandeld met LUMIGAN
0,3 mg/ml. Wanneer de gegevens van Fase III monotherapie en aanvullend LUMIGAN 0,3 mg/ml gebruik worden gecombineerd zijn de meest gemelde bijwerkingen: groei van wimpers bij maximaal 45% in het eerste jaar met de incidentie van nieuwe
gevallen afnemend tot 7% na 2 jaar en 2% na 3 jaar, conjunctivale hyperemie (meest zeer licht tot mild en waarschijnlijk van een non-inflammatoire aard) bij maximaal 44% in het eerste jaar met de incidentie van nieuwe gevallen afnemend tot 13% na
2 jaar en 12% na 3 jaar en oculaire pruritis bij maximaal 14% van de patiënten in het eerste jaar met de incidentie van nieuwe gevallen afnemend tot 3% na 2 jaar en 0% na 3 jaar. Minder dan 9% van de patiënten zijn gestopt in verband met bijwerkingen
in het eerste jaar met de incidentie van additioneel staken door de patiënt van 3% na zowel 2 en 3 jaar. Extra bijwerkingen die tijdens klinische experimenten met LUMIGAN 0,3 mg/ml werden gemeld, staan vermeld in Tabel 2. De tabel bevat eveneens
de bijwerkingen die zich bij beide formules, maar met een andere frequentie hebben voorgedaan. De meeste bijwerkingen waren oculair, mild tot matig en geen ervan was ernstig: Binnen iedere frequentiegroep zijn de bijwerkingen gerangschikt naar
afnemende ernst: Zenuwstelselaandoeningen: Vaak - Hoofdpijn; Soms - Duizeligheid. Oogaandoeningen: Zeer vaak - Oculaire pruritis, groei van wimpers; Vaak - Corneale erosie, oculair branden, allergische conjunctivitis, blefaritis, verslechtering van visuele
scherpte, asthenopie, conjunctivaal oedeem, gevoel van vreemd lichaam, oculaire droogte, oogpijn, fotofobie, tranen, oogafscheiding, gezichtstoornis, versterkte irispigmentatie, donker worden van wimpers; Soms - Retinale bloeding, uveïtis, cystoïd
maculair oedeem, iritis, blefarospasme, ooglidretractie; Onbekend - Enoftalmos. Bloedvataandoeningen: Vaak - Hypertensie. Huid- en onderhuidaandoeningen: Vaak - Pigmentatie van peri-oculaire huid; Soms - Hirsutisme. Algemene aandoeningen en
toedieningsplaatsstoornissen: Soms - Asthenie. Onderzoeken: Vaak - Abnormale leverfunctietest. 6.1 LIJST VAN HULPSTOFFEN Benzalkoniumchloride, Natriumchloride, Dinatriumwaterstoffosfaat, heptahydraat, Citroenzuur, monohydraat, Zoutzuur of
natriumhydroxide (om pH aan te passen), Gezuiverd water. 7. HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN Allergan Pharmaceuticals Ireland, Castlebar Road, Westport, Co. Mayo, Ierland. 8. NUMMERS VAN DE VERGUNNING
VOOR HET IN DE HANDEL BRENGEN EU/1/02/205/003-004.
1. DÉNOMINATION DU MÉDICAMENT LUMIGAN 0,1 mg/ml, collyre en solution. 2. COMPOSITION QUALITATIVE ET QUANTITATIVE Un ml de solution contient 0,1 mg de bimatoprost. Excipient : Un ml de solution contient 0,2 mg de chlorure de benzalkonium.
Pour la liste complète des excipients, cf. section 6.1. 3. FORME PHARMACEUTIQUE Collyre en solution. Solution incolore à légèrement jaune. 4. DONNÉES CLINIQUES 4.1 Indications thérapeutiques : Réduction de la pression intraoculaire élevée chez les
patients adultes atteints de glaucome chronique à angle ouvert ou d’hypertonie intraoculaire (en monothérapie ou en association aux bêta-bloquants). 4.2 Posologie et mode d’administration : La posologie recommandée est d’une goutte dans l’œil ou
les yeux atteints une fois par jour, administrée le soir. La dose ne doit pas dépasser une instillation par jour, un usage plus fréquent pouvant diminuer l’efficacité sur la baisse de pression intraoculaire. En cas d’utilisation concomitante de plusieurs médicaments
ophtalmiques à usage local, chacun doit être administré à un intervalle d’au moins 5 minutes. Utilisation chez les enfants et les adolescents (moins de 18 ans) : En l’absence de données de sécurité et d’efficacité, l’utilisation de LUMIGAN n’est pas
recommandée chez les enfants de moins de 18 ans. Utilisation en cas d’insuffisance hépatique ou rénale : LUMIGAN n’a pas été étudié chez les malades atteints d’insuffisance rénale ou d’insuffisance hépatique modérée à sévère. En conséquence, il doit être
utilisé avec précaution chez ces patients. Chez les patients ayant un antécédent de maladie hépatique bénigne ou des taux de base anormaux d’alamine aminotransférase (ALAT), d’aspartate aminotransférase (ASAT) et/ou de bilirubine, aucun effet délétère sur la
fonction hépatique n’a été observé avec le collyre contenant 0,3mg/ml de bimatoprost sur 24 mois. 4.3 Contre-indications : Hypersensibilité à la substance active ou à l’un des excipients. LUMIGAN 0,1 mg/ml est contre-indiqué chez les patients ayant présenté
précédemment des réactions secondaires susceptibles d’être liées au chlorure de benzalkonium ayant conduit à une interruption de traitement. 4.8 Effets indésirables : Dans l’étude clinique de Phase III menée sur douze mois, environ 38% des patients traités
par LUMIGAN, 0,1 mg/ml ont eu des effets indésirables. L’effet indésirable le plus fréquent était l’hyperhémie conjonctivale survenant chez 29% des patients ; la plupart du temps, l’hyperhémie était minime à légère et de nature non-inflammatoire. Environ 4
% des patients ont interrompu le traitement en raison d’effets indésirables. Les effets indésirables décrits ci-dessous ont été rapportés pendant les essais cliniques du LUMIGAN, collyre 0,1 mg/ml. La plupart étaient oculaires, d’intensité légère et aucun n’était
grave. Les effets indésirables très fréquents (≥1/10) ; fréquents (≥1/100 à <1/10) ; peu fréquents (≥1/1 000 à <1/100) ; rares (≥1/10 000 à <1/1 000) ; très rares (<1/10 000) sont classés dans le tableau 1conformément aux classes de systèmes d’organes.
Au sein de chaque fréquence de groupe, les effets indésirables sont présentés par ordre décroissant de gravité : Troubles du système nerveux : peu fréquents - Céphalées. Troubles oculaires : très fréquent - Hyperhémie conjonctivale ; fréquent - kératite ponctuée
superficielle, irritation oculaire, prurit oculaire, croissance des cils ; peu fréquent - Asthénopie, troubles de la vision, troubles conjonctivaux, œdème conjonctival, hyperpigmentation de l’iris, madarose. Troubles gastro-intestinaux : peu fréquents - nausées. Troubles
dermatologiques et des tissus sous-cutanés : fréquents - Erythème de la paupière, prurit de la paupière, hyperpigmentation des tissus, hypertrichose ; peu fréquents - sécheresse cutanée, croûtes au bord de la paupière, prurit. Troubles généraux et anomalies au
site d’administration : fréquents - Irritation du site d’instillation. Dans les études cliniques, plus de 1 800 patients ont été traités par LUMIGAN 0,3 mg/ml. En regroupant les données des études cliniques de phase III de LUMIGAN 0,3 mg/ml en monothérapie ou
en association, les événements indésirables liés au traitement les plus fréquents étaient : croissance des cils jusqu’à 45 % la première année avec une incidence de nouveaux cas réduite à 7 % à 2 ans et 2 % à 3 ans, hyperhémie conjonctivale (la plupart du temps
minime à légère et considérée comme étant de nature non inflammatoire) jusqu’à 44 % des patients la première année avec une incidence de nouveaux cas réduite à 13 % à 2 ans et 12 % à 3 ans et prurit oculaire jusqu’à 14 % des patients la première année
avec une incidence de nouveaux cas réduite à 3 % à 2 ans et 0 % à 3 ans. Moins de 9 % des patients ont dû arrêter le traitement en raison d’un événement indésirable la première année, avec une incidence d’arrêts supplémentaires de 3 % la deuxième et la
troisième année. D’autres effets indésirables rapportés pendant les essais cliniques sur LUMIGAN 0.3 mg/ml sont présentés au Tableau 2. Ce tableau comprend aussi des effets indésirables survenus avec les deux formulations mais avec des fréquences différentes.
La plupart de ces effets sont oculaires, légers à modérés, et aucun n’a été grave: pour chaque fréquence, les effets indésirables sont présentés par ordre décroissant de gravité : Troubles du système nerveux : fréquent - Céphalées ; peu fréquent - Sensations de
vertige. Troubles oculaires : très fréquent - prurit oculaire, croissance des cils ; fréquent - érosion de la cornée, brûlure oculaire, conjonctivite allergique, blépharite, baisse de l’acuité visuelle, asthénopie, œdème conjonctival, sensation de corps étranger, sécheresse
oculaire, douleur oculaire, photophobie, larmoiements, écoulement oculaire, trouble visuel, augmentation de la pigmentation de l’iris, assombrissement des cils ; peu fréquent - Hémorragie rétinienne, uvéite, oedème maculaire cystoïde,, iritis, blépharospasme,
rétraction de la paupière ; non renseignés - énophthalmie. Troubles vasculaires : fréquents - hypertension. Troubles dermatologiques et des tissus sous-cutanés : fréquents - pigmentation des tissus péri oculaires ; peu fréquents - hirsutisme. Troubles généraux et
anomalies au site d’administration : peu fréquents - asthénie. Effets sur les constantes biologiques : fréquents - Anomalies des tests de l’exploration fonctionnelle hépatique. 6.1 LISTE DES EXCIPIENTS Chlorure de benzalkonium, Chlorure de sodium, Phosphate
disodique heptahydraté, Acide citrique monohydraté, Acide chlorhydrique ou hydroxyde de sodium (pour ajuster le pH), Eau purifiée. 7. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHÉ Allergan Pharmaceuticals Ireland, Castlebar Road, Westport,
Co. Mayo, Irlande. 8. NUMÉRO D’AUTORISATION DE MISE SUR LE MARCHÉ EU/1/02/205/003-004.
Code BE/0162/2012
Date of preparation: Oktober 2012
Allergan N.V.
Terhulpsesteenweg 6D - 1560 Hoeilaart
year an
ersary
niv
Annual Congress of the Belgian Ophthalmological Societies
Ophthalmologica Belgica
Brussels Expo
November 28 - 30, 2012
www.ophthalmologia.be
Ta
of
ble
ts
en
ont
c
Message from the President _______________________________________________ 4 - 5
Organizing committee_______________________________________________________ 7
Organizing societies_________________________________________________________ 8
Scientific committee ________________________________________________________ 9
General information _______________________________________________________ 10
Convention center _________________________________________________________ 11
Exhibition ________________________________________________________________ 12
Exhibitors ________________________________________________________________ 13
Guidelines for speakers __________________________________________________ 14-15
Guidelines for poster presentation____________________________________________ 16
Programme overview:
28-11-2012 ________________________________________ 17
29-11-2012 ________________________________________ 18
30-11-2012 ________________________________________ 19
Programme by day:
Wednesday, November 28
OBAO _____________________________________________ 23
BSOPRS ____________________________________________ 24
FAB _______________________________________________ 25
NOC ______________________________________________ 26
Poster session ____________________________________ 27-31
BSA _______________________________________________ 32
BIO _______________________________________________ 33
AOB Free Papers ____________________________________ 35
Thursday, November 29
BGS _______________________________________________ 38
BOG and SBO _______________________________________ 39
PED & LOW ________________________________________ 41
ISC _____________________________________________ 42-43
BBO-UPBMO _______________________________________ 44
AOB - Academic session 20 years OB ___________________ 45
Eye in the sky _______________________________________ 47
Friday, November 30
BSCRS __________________________________________ 50-51
BSONT NL __________________________________________ 52
BSONT FR __________________________________________ 53
BOV-ABO __________________________________________ 55
Award ceremony _________________________________ 56-57
BVVB-OBPC ________________________________________ 58
2
| OB 2012 | PROGRAMME
of
e
l
b
Ta
c
Interactive Clinical Courses - ICC:
Wetlabs:
28-11-2012 _________________________ 60-62
29-11-2012 _________________________ 63-64
30-11-2012 _________________________ 65-67
28-11-2012 __________________________________________________ 70
29-11-2012 __________________________________________________ 71
30-11-2012 __________________________________________________ 73
Abstracts ______________________________________________________________ 76-84
Abstract poster session __________________________________________________ 86-95
Accreditation _____________________________________________________________ 97
Future OB congresses ______________________________________________________ 99
First author index _________________________________________________________112
Advertisements
ALCON _________________________________________________________ Azarga (106)
_______________________________________________ Acrysof Advantage (102)
___________________________________________________ Acrysof IQ Toric (48)
_______________________________________________ Duotrav / Travatan (108)
ALLERGAN __________________________________________________ Lumigan 0,1 (C2)
BAUSCH + LOMB_____________________________________________enVistaTORIC (98)
___________________________________________ Artelac® Splash (74)
DE CEUNYNCK MEDICAL __________________________________________ Gamme (68)
DORC ______________________________________________________________EVA (96)
HOSPITERA LENSITA _____________________________________________ Gamme (100)
JOHNSON & JOHNSON MEDICAL ________________________________UV-Blocking (C3)
REVOGAN __________________________________________ Visio-MAX · Visio-MEGA (6)
THEA __________________________________________________________ Aprokam (20)
TRUSETAL ____________________________________________ Ortolux & Ortolux Air (36)
PROGRAMME | OB 2012 |
3
ts
en
t
n
o
p
r
ef
sag
Mes
he
om t
nt
ide
s
e
r
Chers Confrères, Chers amis,
C’est avec grand plaisir que je vous convie au congrès Ophtalmologica Belgica 2012 qui promet d’être exceptionnel ! En effet,cette année, nous fêtons le vingtième anniversaire de notre
réunion ophtalmologique annuelle.
A cette occasion, nous avons prévu quelques modifications dans le programme habituel. Tout
d’abord, nous avons réorganisé les plages horaires des free papers. Ils ne seront plus intégrés
dans les programmes des différentes sociétés. Le comité d’OB 2012 sélectionnera 10 papiers
originaux qui seront présentés, tous sujets confondus, lors d’une session dédiée le mercredi
après-midi. Le meilleur papier sera récompensé par un prix. Les autres papiers seront acceptés
sous la forme d’un poster.
En cette année anniversaire, les sociétés BOG et SBO vont se grouper pour une session commune
intitulée “CONTROVERSES” à propos de différents sujets très actuels.
Enfin, pour fêter dignement l’événement, nous avons réservé la fin d’après-midi du jeudi,
29 novembre, pour une SESSION SCIENTIFIQUE et ETHIQUE PLENIERE suivie d’un DINER SPECTACLE de haut vol sur le site du congrès. Cette soirée extraordinaire pour les 20 ans d'OB
sera ouverte à tous les participants ainsi qu’aux représentants des firmes (la traditionnelle
soirée “faculty meets industry” n’aura donc pas lieu). Une soirée dansante, animée par un D.J.
de renom, sera organisée après le dîner avec l’aide du comité directeur de l’OBAO et rassemblera, nous l’espérons, un large public.
Nous comptons beaucoup sur la participation enthousiaste d’un maximum d’entre vous à
cette fin de journée exceptionnelle qui nous permettra de nous rencontrer plus longuement
dans une atmosphère très agréable.
Je me réjouis de vous voir très nombreux au Brussels EXPO,
Sabine Bonnet
Président OB 2012
4
p
r
ef
g
a
s
Mes
he
t
m
o
nt
ide
s
e
r
Beste collega’s, Beste vrienden,
Het is me een waar genoegen u uit te nodigen op het congres Ophthalmologica Belgica 2012.
Het belooft dit jaar een bijzonder evenement te worden want we vieren de 20ste verjaardag
van ons jaarlijks oogheelkundecongres!
We hebben voor de gelegenheid enkele wijzigingen voorzien in het traditionele programma.
Allereerst hebben we de tijdsblokken van de free papers gewijzigd. Ze worden niet meer opgenomen in de programma’s van de verschillende organisaties. Het OB 2012 bestuur zal de 10
beste papers selecteren en deze zullen worden voorgesteld tijdens een free paper session op
woensdagnamiddag. De beste paper zal beloond worden met een prijs en de andere papers
worden geaccepteerd als poster.
Ook zullen de verenigingen BOG en SBO samenwerken aan een gemeenschappelijke sessie,
genaamd “CONTROVERSE”. Daarin zullen verschillende actuele onderwerpen aan bod komen.
Op donderdag 29 november, in de late namiddag, voorzien we een PLENAIRE WETENSCHAPPELIJKE ETHIEK SESSIE gevolgd door een uitzonderlijk SPEKTAKEL-DINER om 20 jaar OB te
vieren. Deze uitzonderlijke avond zal plaats vinden in Brussels EXPO en wordt afgesloten met
een dansavond georganiseerd door het OBAO bestuur. Zowel de deelnemers als de vertegenwoordigers van de firma’s worden op deze unieke en buitengewone avond uitgenodigd. (Dit
jaar dus geen traditionele “faculty meets industry”- avond).
We hopen dat u in groten getale en met veel enthousiasme zal deelnemen aan dit unieke
evenement. Het zal voor velen de ideale gelegenheid zijn om elkaar beter te leren kennen in
een aangename sfeer.
Ik verheug mij erop u op Brussels EXPO te mogen verwelkomen,
Sabine Bonnet
Voorzitter OB 2012
5
VISIO
oogveroudering
vieillissement oculaire
rode en branderige ogen
yeux rouges et brûlants
drog e e n v er m o e i d e o g e n
yeux secs et fatigués
AOX (Vaccinium myrtillus extr. sicc., Se, Zn, vit C, vit E)
10 mg LUTEINE + 400 µg ZEAXANTHINE
VITAMINES B
AOX (Vaccinium myrtillus extr. sicc., Se, Zn, vit C, vit E)
10 mg LUTEINE + 400 µg ZEAXANTHINE
VITAMINES B
OMEGA 3 (375 mg DHA)
1 tablet per dag bij voorkeur nuchter
1 comprimé par jour de préférence à jeun
1 tablet + 1 capsule per dag bij de maaltijd
1 comprimé + 1 capsule par jour pendant le repas
www.revogan.be
modulo.be - 022410
M A X MEGA
ing
z
i
n
a
c
Org
Sabine Bonnet
President
Bart Leroy
Past / Vice-president
Programme Secretary
Werner Spileers
Treasurer
Patrick De Potter
ICC
Antonella Boschi
Free papers / Posters
Bernard Heintz
Wetlab - ISC
Joachim Van Calster
Audio-visual
Marlene Verlaeckt
Organization
7
ee
itt
m
m
o
ing
z
i
n
a
s
tie
ocie
s
Org
AOB
Academia Ophthalmologica Belgica
BBO-UPBMO
Belgische Beroepsvereniging van Oogheelkundigen
Union Professionnelle Belge des Médecins Spécialistes en
Ophtalmologie et Chirurgie Oculaire
BGS
Belgian Glaucoma Society
BIO
Belgian Immuno Ophthalmology Club
BOG
Belgisch Oftalmologisch Gezelschap
BOV-ABO
Belgische Orthoptische Vereniging
Association Belge d’Orthoptie
BSA
Belgian Strabismological Association
BSCRS
Belgian Societies of Cataract and Refractive Surgery
BSONT
Belgian Society of Ophthalmic Nurses & Technicians
BSOPRS
Belgian Society of Oculoplastic and Reconstructive Surgery
BVVB-OBPC
Belgische Vereniging ter Voorkoming van Blindheid
Organisation Belge pour la Prévention de la Cécité
FAB
Fluorescein Angiography Club Belgium
NOC
Neuro Ophthalmology Club
OBAO
Organisatie van Belgische Assistenten in Oftalmologie
Organisation Belge des Assistants en Ophtalmologie
PED & LOW
Pediatric Ophthalmology & Low Vision Rehabilitation
SBO
Société Belge d’Ophtalmologie
8
ee
itt
m
m
o
cc
fi
i
t
ien
Sc
Programme secretary
Bart Leroy
AOB
Patrick De Potter - Werner Spileers
BBO-UPBMO
Peter Van Bladel - Philippe Huyghe
BGS
Adèle Ehongo - Marc Goethals
BIO
Philippe Kestelyn
BOG
Joachim Van Calster - Bart Leroy
BOV-ABO
Hilde Janssens - Alain Bauwens
BSA
Sandrine de Temmerman - Lieve Van Eeckhoutte
BSCRS
Guy Sallet - Ed Tackoen
BSONT
Caroline Timmerman - Anne De Pryck
BSOPRS
Veva De Groot - Paul Jonckheere
BVVB-OBPC
Philippe Kestelyn - Marie-José Tassignon
FAB
Anne Dewachter
NOC
Monique Cordonnier
OBAO
Luc Van Os
PED & LOW
Hilde Deconinck - Ingele Casteels
SBO
Minh-Tri Hua - Sabine Bonnet
OB Free papers / Posters
Antonella Boschi
Wetlabs
Interactive Surgical Course
Bernard Heintz
Bernard Heintz
Interactive Clinical Courses
Patrick De Potter
Audio-Visual
Joachim Van Calster
9
f
l in
era
Gen
ion
at
orm
OB Office
AOB vzw - asbl
OB 2012: Werkgroep - Groupe de travail
Kapucijnenvoer 33, 3000 Leuven
OB2012@ophthalmologia.be
BE 0862.155.596
Venue and dates
The congress will take place from
Wednesday 28 to Friday 30, November 2012
at Brussels EXPO, Pal. 10
Place de Belgique - Belgiëplein
1020 Brussels
Exhibition
The exhibition will be open during the
congress from 09:00 to 18:00.
Registration
All participants will receive their congress material at the registration desk. The registration
desk will be open from 08:00 to 18:00.
Entitlements
Payment of the registration fee entitles delegates to participate at the entire congress
programme. The final programme will be sent
to the preregistered participants in order of
payments before November 16, 2012.
The others will receive their documents at the
registration desk.
Badges
Please remember to wear your badge
throughout the congress.
Audiovisual support room
Will be open on Tuesday from 17:00 to 20:00
and from Wednesday to Friday from 07:30 to
17:30.
Bring your presentation at least two hours
prior to your session to the audiovisual
support room.
Internet
Internet access is available at the internet
corner, located in the Foyer.
Accreditation
The OB 2012 congress has been awarded 15CP.
- Wednesday, 6 CP,
- Thursday AM 3 CP
- Thursday PM 3 CP (Ethics and Economics)
- Friday 6 CP
All accreditation certificates will be available
online from December 1 on.
Cancellation and refunds
Refunds up to 75% of the advance registration fee will be granted for cancellation received in writing prior to November 15, 2012.
Refund will not be granted for later cancellations or no-shows.
Catering
Coffee during the whole congress and sandwiches during lunchtime are included in the
registration fee and will be served at the
coffee bar in the foyer and during the poster
session in the poster area.
10
tio
en
onv
C
Brussels EXPO, Hall 10
Place de Belgique - Belgiëplein - 1020 Brussels
20 Years OB
Eye in the Sky
OB 2012 PARKING
METRO
Brussels Expo, located in the heart of Europe, has the major advantage of being
centrally located. The site is easily reached by car, train or airplane.
For more info: www.bruexpo.be
11
er
nt
e
c
n
on
iti
b
i
h
x
E
Entrance
51
1
50
OB2012
Vestiaire
Hall B-C-D-E-F
Hall A
Registration
2
3
43
47
4
4
Internet
AV Support
Room
45
5
Hall 10
6
46
49
Foyer
7
33
32
8
31
36
35
34
30
29
10
28
Exit
27
37
11
Fire Exit
42 / 28
12
26
38
39
25
13
23
24
Fire Exit
23
40
22
14
48
41
15
16
17
18
Wetlab
Eyelid
surgery
12
19
Posters
20
rs
ito
xhib
E
By company
ALCON
42
LEICA MICROSISTEMAS
46
PHYSIOL
13
ALLERGAN
40
LENSONLINE
49
PULSION
24
BAUSCH + LOMB
36
30
45
LENS OPTICAL
TECHNOLOGY
REVOGAN
BRAILLELIGA
27
ROCKMED
35
CARL ZEISS
20
MEDA Pharma
19
RODENSTOCK Benelux
47
CORILUS
10
MEDICAL WORKSHOP
31
SIMOVISION
41
DE CEUNYNCK & Co
6
DE CEUNYNCK Medical
37
DORC
39
ERGRA-ENGELEN
16
ESSILOR
18
FABRILENS & SONKES
4
HOSPITHERA / LENSITA
33
HOYA LENS BELGIUM
1
MERCK SHARP & DOHME 22
STORY - SCIENTIA
3
MMI Informatique
Médicale
32
TECHNOP
2
MORIA
14
NOOTENS
29
NOVARTIS Pharma
THEA Pharma
34
TRB CHEMEDICA
12
28
TRUSETAL
VERBANDSTOFFWERK
26
5
URSAPHARM Benelux
8
7
OBOS
OPHTALMO SERVICE
25
VAASSEN
OPHTEC
15
23
43
48
OPS Eyewear
38
VAN HOPPLYNUS
Ophtalm
KRYS
17
OPTELEC
50
Z-PROJECTS
LABO RX
11
PFIZER
51
JOHNSON & JOHNSON
Medical
By booth number
1 HOYA LENS BELGIUM
20 CARL ZEISS
36 BAUSCH + LOMB
2 TECHNOP
22 MERCK SHARP & DOHME
37 DE CEUNYNCK Medical
3 STORY - SCIENTIA
23 VAN HOPPLYNUS
Ophtalm
38 OPS Eyewear
4 FABRILENS & SONKES
5 OBOS
24 PULSION
40 ALLERGAN
6 DE CEUNYNCK & Co
25 OPHTALMO SERVICE
41 SIMOVISION
7 VAASSEN
26 TRUSETAL
VERBANDSTOFFWERK
42 ALCON
27 LENS OPTICAL
TECHNOLOGY
45 BRAILLELIGA
8 URSAPHARM Benelux
10 CORILUS
11 LABO RX
12 TRB CHEMEDICA
13 PHYSIOL
14 MORIA
15 OPHTEC
39 DORC
43 Z-PROJECTS
46 LEICA MICROSISTEMAS
28 NOVARTIS Pharma
47 RODENSTOCK Benelux
29 NOOTENS
48 JOHNSON & JOHNSON
Medical
30 REVOGAN
31 MEDICAL WORKSHOP
16 ERGRA-ENGELEN
32 MMI Informatique
Médicale
17 KRYS
33 HOSPITHERA / LENSITA
18 ESSILOR
34 THEA Pharma
19 MEDA Pharma
35 ROCKMED
49 LENSONLINE
50 OPTELEC
51 PFIZER
13
es
lin
e
d
i
u
G
Guidelines for speakers
Language
All audiovisual material should be presented in English (slides, movies, ...). For
oral presentations either one of the three Belgian national languages (French,
Dutch and German) or English are acceptable.
However, the Organising Committee of OB 2012 strongly recommends English
for oral presentations, in order to maximize the international appeal of the
meeting.
Technical instructions
Speakers are kindly requested to strictly respect the allocated time to guarantee
smooth running of the sessions.
•
An integrated computerized network running both Windows and
Mac operating systems will be used to manage all slide projections. All
presentations will be sent to the assigned Meeting Room from the central
server at the Slide Room, by the technical staff. This procedure ensures
efficient management and higher quality of projection. The use of personal
laptops for presentations is actively discouraged.
•
Speakers are invited to prepare their presentations in Microsoft PowerPoint
either for Windows or Macintosh/Apple.
•
PowerPoint or Keynote presentations on disk, CD Rom or USB memory stick
must be delivered at the Slide Room at least one hour before the start of the
session. Preview facilities will be available at the Slide Room.
•
Presentations loaded on a personal laptop must be downloaded and copied
at the Slide Room at least two hours before the beginning of the session.
•
Should this be the case, please inform the Meeting Administrator’s Desk
about any particular requests well in advance.
14
es
lin
e
d
i
u
G
Guidelines for speakers
Some suggestions to make a PowerPoint presentation:
•
Write the title of the presentation and the speaker’s name on the first slide
indicating any possible conflict of interest (please specify any consultancy
relation to pharmaceutical companies, industries, etc..).
•
Save the presentation with the speaker’s name embedded in the file name + the
date in order to avoid that all presentations are called OB 2012 or Brussels 2012.
•
Any video/film/image file must be in the same folder of the PowerPoint
presentation and must be copied in the folder before being included in the
presentation. Alternatively, use the option “Pack and go” or “Package to
CD/DVD/USB” in the PowerPoint software.
•
It is recommended that embedded movies start automatically after slide
transmission rather than by mouse click.
•
We suggest putting a maximum of one movie per slide.
•
Reduce the size of your presentation by choosing the option “Reduce File Size...”
and then “Best for viewing on screen” under the “File” dropdown menu in
PowerPoint. Images with either “.png” or “.jpg” extensions are recommended
in order to obtain a smaller size presentation (other kinds of cross-platform
extensions - recognizable by PowerPoint, such as tiff – are also acceptable).
Procedure: All presenters must read the following instructions
Slide Room opening hours
•
The Slide Room is open on November 27 between 17:00 - 20:00 and during
the congress between 7:30 - 17:30.
•
The OB 2012 Organising Committee ensures that all presentations are erased
from computers used by the audiovisual team. In addition, no one other than
the presenter will be allowed to copy PowerPoint files from the AV system.
Session Moderators
Session moderators should ensure that speakers remain within the allocated
time for their presentation, and that the session finishes within the allocated
timeframe. It is actively discouraged to switch the order of talks, as meeting
participants may have planned their itinerary in advance, and may move
between Meeting Rooms during the Sessions to attend specific talks.
15
es
lin
e
d
i
u
G
Guidelines for poster presentation
•
The image area of poster boards is 190 cm wide and 100 cm high
(landscape format)
•
Posters must be mounted on the assigned poster board on Tuesday
27 November 2012, from 16:00hrs onwards through 19:00hrs, or at
the latest on Wednesday morning 28 November 2012 from 7:30hrs and
before 8:30hrs.
•
Poster boards are located in the poster area in Hall 10 in Brussels EXPO
Convention Centre and all carry a unique number.
•
Posters must remain on display until Friday, November 30, 15:30hrs.
Posters not removed by Friday, November 30, 19:00hrs will be removed
and discarded.
•
Material for mounting will be available at the registration desk. Poster
presenters are required to stand beside their poster during the poster
sessions on Wednesday 12:30 - 14:00 in poster area, sandwiches will be
served. During this time the jury will be circulating for the poster award.
•
All posters are eligible for a Poster Award.
•
Best case: 300 EUR
•
AOB best resident’s poster prize: 500 EUR Travel grant EVER 2013 congress
•
An independent panel appointed by the Board of OB 2012 decides on the
Poster Awards through voting. Their decision is final.
The poster awards ceremony will be held on Friday 30 November 2012 at 12:30 to
13:30 in Hall A. In order to receive the prize the presence of poster presenters who
are awarded a poster prize is mandatory.
16
iew
rv
Ove
Wednesday, 28 November 2012
Hall A
Hall B
Hall C
Hall D
Hall E - ICC Hall F-Wetlab Hall G-Eyelid
09:00
10:30
11:00
OBAO
BSOPRS
FAB
ICC-W1
Wetlab-1
ICC-W2
Wetlab-2
NOC
12:30
OB Poster session > in O’Bistro
14:00
FAB
AOB
Free papers
ICC-W3
Wetlab-3
WetlabEyelid NL
BIO
ICC-W5
ICC-W4
Wetlab-4
WetlabEyelid FR
OBAO
15:30
BSA
16:00
17:30
17
iew
rv
Ove
Thursday, 29 November 2012
Hall A
Hall B
Hall D
Hall E - ICC
Hall F-Wetlab
ICC-T6
Wetlab-5
ICC-T7
Wetlab-6
ICC-T8
Wetlab-7
09:00
10:30
11:00
BOG
SBO
BGS
PED & LOW
12:30
14:00
BBO - UPBMO
Ethiek / Ethique
15:30
16:00
Academic session
20 years OB
Ethiek / Ethique
17:30
Eye in the Sky: 20 th Anniversary of OB in Brussels Expo
Reception, walking dinner and music
Free entrance for all registered delegates and industry partners
22:00
18
iew
rv
Ove
Friday, 30 November 2012
Hall A
Hall B
Hall C
Hall D
Hall E - ICC
Hall F-Wetlab
ICC-F10
Wetlab-8
ICC-F11
Wetlab-9
BVVB-OBPC
ICC-F12
Wetlab-10
ICC-F14
ICC-F13
09:00
10:30
11:00
BSCRS
BSONT
BSONT
BOV-ABO
12:30
Award Ceremony - in Hall A
13:30
14:00
BSONT
15:30
BSONT
BSCRS
16:00
17:30
19
antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery*
easy to reconstitute in only one step
high level
of scientific
prophyl axis
l
entific evidence in antibiotic
antibio
single use only
require simplicit y
Aprokam 50 mg poudre pour solution injectable. COMPOSITION QUALITATIVE ET QUANTITATIVE: Chaque flacon contient 50 mg de céfuroxime (52,6 mg sous forme de
céfuroxime sodique). Après reconstitution avec 5 ml de solvant, 0,1 ml de solution contient 1 mg de céfuroxime. FORME PHARMACEUTIQUE: Poudre pour solution injectable.
Poudre pour injection. Poudre blanche à presque blanche. INDICATIONS THERAPEUTIQUES: Antibioprophylaxie des endophtalmies post-opératoires après une chirurgie
de la cataracte. Il convient de tenir compte des recommandations officielles concernant l’utilisation appropriée des antibactériens, incluant celles sur l’antibioprophylaxie
en chirurgie oculaire. POSOLOGIE ET MODE D’ADMINISTRATION: Voie intra-camérulaire. Un flacon pour usage unique seulement. Posologie: Adultes: La posologie
recommandée est de 0,1 ml de solution reconstituée, c’est-à-dire de 1 mg de céfuroxime. NE PAS INJECTER UNE DOSE SUPERIEURE A CELLE RECOMMANDEE. Population
pédiatrique: La posologie optimale et la sécurité d’Aprokam n’ont pas été établies pour la population pédiatrique. Sujets âgés L’adaptation de la posologie n’est pas nécessaire.
Insuffisants rénaux et hépatiques: Considérant la faible dose et le passage systémique négligeable attendu de céfuroxime après utilisation d’Aprokam, l’adaptation de la
posologie n’est pas nécessaire. Mode d’administration: Aprokam doit être administré après reconstitution, par injection intra-oculaire dans la chambre antérieure de l’œil
(voie intra-camérulaire), par un chirurgien ophtalmologiste, dans les conditions recommandées d’asepsie de la chirurgie de la cataracte. Après reconstitution, Aprokam doit
être contrôlé visuellement afin de rechercher la présence de particules ou d’une coloration anormale avant administration. Injecter lentement 0,1 ml de solution reconstituée
dans la chambre antérieure de l’œil en fin de chirurgie de la cataracte. CONTRE-INDICATIONS: Hypersensibilité à la substance active (céfuroxime) ou à l’un des antibiotiques
du groupe des céphalosporines. MISES EN GARDE SPECIALES ET PRECAUTIONS D’EMPLOI : Aprokam doit être utilisé uniquement par voie intra-camérulaire. En raison
d’un possible risque de réaction allergique croisée, une précaution particulière doit être prise chez les patients ayant des antécédents de réactions allergiques à la pénicilline
ou aux autres bêta-lactamines. Chez les patients à risque d’infections avec des souches résistantes, par exemple les patients ayant eu une infection ou colonisation au SARM
(Staphylococcus aureus résistant à la méticilline), un traitement alternatif antibioprophylactique doit être envisagé. En l’absence de données chez des groupes de patients
particuliers (patients avec un risque sévère d’infection, patients avec des cataractes compliquées, patients ayant des opérations combinées à la chirurgie de la cataracte,
patients avec une maladie sévère de la thyroïde, patients avec moins de 2000 cellules endothéliales cornéennes), Aprokam doit être seulement utilisé après une évaluation
prudente de la balance bénéfice/risque. L’utilisation de la céfuroxime ne doit pas être considérée comme une mesure isolée ; car d’autres précautions sont tout aussi
importantes comme le traitement prophylactique antiseptique. La toxicité pour l’endothélium cornéen n’a pas été signalée à la concentration recommandée de céfuroxime,
néanmoins, ce risque ne peut être exclu. Dans la surveillance postopératoire, les médecins doivent garder à l’esprit ce risque potentiel. EFFETS INDESIRABLES: Aucun effet
indésirable particulier n’a été rapportée dans la littérature quand la céfuroxime est administrée par injection intra-oculaire sauf le suivant : Troubles du système immunitaire:
Très rare (<1/10 000): réaction anaphylactique. TITULAIRE DE L’AUTORISATION DE MISE SUR LE MARCHE: Laboratoires Théa, 12 rue Louis Blériot, 63017 ClermontFerrand Cedex 2, France. NUMERO(S) D’AUTORISATION DE MISE SUR LE MARCHE: BE422457. DATE DE PREMIERE AUTORISATION/DE RENOUVELLEMENT DE
L’AUTORISATION: 15.06.2012 / 25.04.2017. DATE DE MISE A JOUR DU TEXTE: Date d’approbation du texte : 06/2012.
BE/031/09/2012
Apro
Aprokam
prokam
kam 50 mg
m poeder voor opl
oplossing
op
ossing voor injectie. KWALITATIEVE EN KWANTITATIEVE SAMENSTELLING: Elke injectieflacon bevat 50 mg cefuroxim (als 52,6
,6 mg
cefuroxim
c
cefu
uroxi
roxim
m natriu
natrium).
na
trium). Na reconstitutie
recon
onstit
stitutie
uti met 5 ml oplosmiddel bevat 0,1 ml op
oplossing 1 mg cefuroxim. FARMACEUTISCHE VORM: Poeder voor oplossing voor injectie. Poederr voor
injectie. Wit tot bijna wit poeder. THERAPEUTISCHE INDICATIES: Antibiotica profylaxe van postoperatieve endophthalmitis na cataractchirurgie. De officiële richtlijnen over
het juiste gebruik van antibacteriële middelen moeten in acht worden genomen, inclusief de richtlijnen over antibiotica profylaxe bij oogchirurgie. DOSERING EN WIJZE VAN
TOEDIENING: Intracameraal gebruik. Één injectieflacon uitsluitend voor eenmalig gebruik. Dosering: Volwassenen: De aanbevolen dosis is 0,1 ml van de gereconstitueerde
oplossing, d.w.z. 1 mg cefuroxim. INJECTEER NIET MEER DAN DE AANBEVOLEN DOSIS. Pediatrische patiënten: De optimale dosis en de veiligheid van Aprokam bij
kinderen zijn niet vastgesteld. Ouderen: Er is geen dosisaanpassing nodig. Patiënten met lever- en nierfunctiestoornis. Rekening houdend met de lage dosis en de verwachte
verwaarloosbare systemische blootstelling aan cefuroxim bij gebruik van Aprokam, is er geen dosisaanpassing nodig. Wijze van toediening: Aprokam moet toegediend
worden na reconstitutie door intra-oculaire injectie in de voorste oogkamer (intracameraal gebruik), door een oogchirurg, onder de aanbevolen aseptische omstandigheden van
cataractchirurgie. Na reconstitutie moet Aprokam visueel geïnspecteerd worden op partikels en verkleuring vóór toediening. Injecteer langzaam 0,1 ml van de gereconstitueerde
oplossing in de voorste oogkamer aan het einde van de cataractoperatie. CONTRA-INDICATIES: Overgevoeligheid voor het werkzame bestanddeel (cefuroxim) of voor
antibiotica van de cefalosporine groep. BIJZONDERE WAARSCHUWINGEN EN VOORZORGEN BIJ GEBRUIK: De behandeling met Aprokam is uitsluitend bestemd voor
intracameraal gebruik. Bijzondere voorzichtigheid is aangewezen bij patiënten die een allergische reactie vertoonden op penicillines of op andere bèta-lactam antibiotica
aangezien kruisreacties kunnen optreden. Bij patiënten die een risico hebben op infecties met resistente stammen, bijv. patiënten met een bekende vroegere infectie of
kolonisatie met MRSA (methicilline-resistente Staphylococcus aureus), moet een alternatief profylactisch antibioticum overwogen worden. Omdat gegevens ontbreken voor
speciale patiëntengroepen (patiënten met ernstig risico op infectie, patiënten met gecompliceerd cataract, patiënten die gecombineerde operaties met cataractchirurgie
ondergaan, patiënten met een ernstige schildklieraandoening, patiënten met minder dan 2000 corneale endotheelcellen), mag Aprokam alleen gebruikt worden na zorgvuldige
evaluatie van de risico’s/voordelen. Het gebruik van cefuroxim mag niet beschouwd worden als een geïsoleerde maatregel maar andere condities zijn ook van belang zoals
een profylactische antiseptische behandeling. Cornea-endotheel toxiciteit werd niet gemeld bij de aanbevolen concentratie van cefuroxim, toch kan dit risico niet worden
uitgesloten. Bij de postchirurgische surveillance moeten artsen rekening houden met dit potentieel risico. BIJWERKINGEN: Er werden geen bijzondere bijwerkingen gemeld
in de literatuur als cefuroxim wordt toegediend als intra-oculaire injectie behalve de volgende: Immuunsysteemaandoeningen: Zeer zelden (<1/10.000): anafylactische
reactie. HOUDER VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN: Laboratoires Théa, 12 rue Louis Blériot, 63017 Clermont-Ferrand Cedex 2, Frankrijk.
NUMMER(S) VAN DE VERGUNNING VOOR HET IN DE HANDEL BRENGEN: BE422457. DATUM VAN EERSTE VERLENING VAN DE VERGUNNING/HERNIEUWING VAN
DE VERGUNNING: 15.06.2012 / 25.04.2017. DATUM VAN HERZIENING VAN DE TEKST: Datum van goedkeuring van de tekst: 06/2012
es
n
Wed
o
,N
day
r
be
m
e
v
2
01
2
,
8
2
We
lA
Hal
09:00
ay
sd
dne
:00 0 / 14
- 12:3
16:20
O
OBA
ORGANISATIE VAN BELGISCHE ASSISTENTEN IN OFTALMOLOGIE
ORGANISATION BELGE DES ASSISTANTS EN OPHTALMOLOGIE
Moderator:
Luc VAN OS
Trauma in ophthalmology
09:00
Ocular burns
1001
DUCHESNE B - Liège
09:20
Corneal ulcers after trauma
1002
CLAERHOUT I - Gent
09:35
Up or down? Posttraumatic intra-ocular pressure
1003
KESTELYN P - Gent
10:05
Blunt ocular trauma
1004
STALMANS P, STALMANS I - Leuven
10:35
Break
11:05
Intra-ocular foreign body
1005
STALMANS P - Leuven
11:20
Penetrating trauma to the anterior segment
1006
RAKIC JM, VAN CAUWENBERGHE F - Liège
11:40
Penetrating trauma to the posterior segment
1007
RAKIC JM, VAN CAUWENBERGHE F - Liège
12:00
Diplopia and motility disorders in ocular trauma
1008
GOMEZ DE LIANO R - Madrid
12:20
Lunch break
14:00
Post-traumatic optic neuropathy
1026
BOSCHI A - Bruxelles
14:20
The glass eye and beyond: ocular prosthesis
1027
NOUVET L - Bruxelles
14:35
Traumatic caroticocavernous fistulae
1028
DE KEIZER R - Antwerpen
14:50
Break
15:20
Orbital trauma and reconstruction
1029
DE GROOT V, DOM I - Antwerpen
15:50
Trauma to the eyelids and lacrimal drainage system
1030
DECOCK C - Gent
16:20
End of session
23
ay
sd
dne
We
l
Hal
09:00
S
PR
O
S
B
Entropion & ectropion surgery
09:00
A good clinical examination tells you which type of surgery to choose
1009
DE GROOT V - Antwerpen
09:15
Temporary measures can be necessary
1010
LEYSEN I - Antwerpen
09:30
Temporal pentagonal wedge resection
1011
DE LEPELEIRE K - Asse
09:45
Temporal resection
1012
DECOCK C - Gent
10:00
Tarsal strip procedure
1013
XHAUFLAIRE G - Liège
10:15
Reattaching the retractors
1014
VANDELANOTTE S - Brugge
10:30
Break
11:00
Medial ectropion
1015
JONCKHEERE P - Deurne
11:15
Cicatricial ectropion
1016
RAUS P - Mol
11:30
Cicatricial entropion
1017
BEACONSFIELD M - London
12:15
Congenital entropion
1018
LEMAGNE JM - Brussels
12:30
End of session
24
0
- 12:3
BELGIAN SOCIETY OF OCULOPLASTIC AND RECONSTRUCTIVE SURGERY
Moderators:
Veva DE GROOT, Sylvie VANDELANOTTE, Michele BEACONSFIELD
B
We
lC
Hal
09:00
ay
sd
dne
:00 0 / 14
- 12:3
15:30
FAB
FLUORESCEIN ANGIOGRAPHY CLUB BELGIUM
Moderator:
Anne DEWACHTER
Retinal tumoral disease
09:00
Challenging cases presented by FAB members
10:00
Ocular manifestations of radiotherapy, chemotherapy
1019
LEYS A - Leuven
10:30
Break
11:00
Case reports
11:30
Keynote Lecture: The role of imaging studies in evaluating intraocular tumors
and simulating lesions
1020
DE POTTER P - Brussels
12:30
Lunch break
Case reports
14:00
Case reports
15:30
End of session
25
ay
sd
dne
We
l
Hal
09:00
NOC
NEURO OPHTHALMOLOGY CLUB
Moderator:
Monique CORDONNIER
Genetics and optic neuropathies
09:30
Power, Sex, Suicide: Mitochondria and the meaning of life:
discoveries commented by CORDONNIER M, GERARD P
1021
LANE N - London
10:00
Leber Optic Neuropathy: up to date and new therapeutic options
1022
GERARD P, CORRAL M - Bruxelles, Paris
10:40
Dominant Optic neuropathy : which work-up, why and how?
1023
DEPASSE F - Bruxelles
11:00
Break
11:30
Non syndromic recessive optic neuropathy : new findings
1024
CORDONNIER M, DESIR J - Bruxelles
12:10
Genetic influence on toxic and nutritional optic neuropathies
1025
DEPASSE F, CORDONNIER M - Bruxelles
12:30
End of session
26
D
0
- 12:3
ay
sd
dne
We
o
tr
s
O’Bi
12:30
0
- 14:0
te
Pos
on
ssi
e
s
r
Each poster is exhibited in the poster area during the all congress. All posters should be
erected before Wednesday 9:00. Poster presenters are required to stand beside their
poster during the poster session on Wednesday from 12:30 to 14:00 (sandwiches
will be served). During this time, the jury will be voting for the poster prizes.
Poster overview on page 28-31. Poster abstracts on pages 86 - 95.
Poster jury:
Monique CORDONNIER, Patrick DE POTTER, Philippe KESTELYN, Jean - Marie RAKIC,
Werner SPILEERS, Marie-José TASSIGNON, François WILLERMAIN
ay
sd
dne
We
te
Pos
on
ssi
e
s
r
ro
t
s
i
O’B
00
12:30
- 14:
12:30
From paediatrics to reversible presbyopia surgery to silicone oiled eyes:
the wonderful world of supplemental IOL use
P101
CLAOUE DE GOHR CMP - London
12:30
P102
La dégénérescence astéroïde du vitré chez les patients Congolais
12:30
P103
Syndromic Congenital Aplasia of Iris Sphincter
12:30
Additional Loop suspension over anteroposition or recession of the inferior
oblique muscle to resolve vertical incomitence in V pattern strabismus.
P104
SELLIER J, PUTTEMEN A, VAN DAELE O - Bruxelles
12:30
Spectral domain optical coherence tomography findings in posterior scleritis
associated chorioretinal folds : report of 3 cases
P105
ROSAPELLY B, WILLERMAIN F, CASPERS L, EL OUARDIGHI H, DAGUZAN M,
POSTELMANS L - Bruxelles
12:30
Visual acuity and factors influencing automobile driving status in
1000 patients age 60 and older
P106
MARINESCU C, LEVECQ L, DE POTTER P, JAMART J - Bruxelles, Yvoir
12:30
P107
Ophtalmological analysis of a nephropathic cystinosis with Confocal Microscopy
12:30
Clinical outcome of hypertensive uveitis: a comparaison of viral and non viral
causes
P108
LEWKOWICZ D, WILLERMAIN F, JUDICE L, MAKHOUL D, JANSSENS S, JANSSENS X,
CASPERS L - Brussels
12:30
P109
clinical features in diabetic macular edema
12:30
P110
Long Follow Up of Juvenile Idiopathic Arthritis Associated Uveitis
KAIMBO WA KAIMBO D - Kinshasa
ROULEZ FM, FAES F, VERHEULPEN D, WERMENBOL V, DE ZAEYTIJD J, DEPASSE F,
DELBEKE P, COUCKE PJ, MEIRE FM - Brussels, Sierre, Ghent
SILBERBERG D, VANDERPERREN B, KALLAY O, SCHROOYEN M - Bruxelles, La Louvière
RABEUX E, GUAGNINI AP - Bruxelles, Bruxelles
LEYS E, BALIKOVA I, VAN BOL L, JANSSENS X, PASTEELS B, CARION T, WILLERMAIN F,
FERSTER A, LÊ PQ, CASPERS L - Brussels, Verviers
28
ay
sd
dne
We
o
tr
s
O’Bi
12:30
0
- 14:0
te
Pos
12:30
Cryptic chromosomal deletions and duplications as a cause of congenital eye
malformations
P111
BALIKOVA I, DE RAVEL T, AYUSO C, CASTEELS I, FRYNS JP, VERMEESCH JR - Brussels,
Leuven, Madrid, Spain
12:30
Reduction of macular cysts after treatment with topical Dorzolamide in
X-Linked Retinoschisis: A case report
P112
VAN BOL L, DEPASSE F, CORDONNIER M - Bruxelles
12:30
Retrospective study of syphilitic uveitis in a cohort of patients from CHU
Saint-Pierre, Brussels
P113
LHOIR S, MAKHOUL D, LIBOIS A, CASPERS L, WILLERMAIN F - Bruxelles
12:30
Monofocale centrale chorioretinopathie bij Churg-Strauss syndroom:
een case report
P114
OEHRENS AM, GOETHAELS S, VAN CALSTER J - Leuven
12:30
P115
Retinal oxygen metabolism in healthy subjects and glaucoma patients
12:30
P117
Flanders and The Netherlands: two different worlds
12:30
Impact of a switch to preservative free Dorzolamide-Timolol on ocular
surface disease symptoms
P118
STALMANS I, BERDEAUX G, BOONS S, VANDEWALLE E - Leuven, Vilvoorde
12:30
Case report: A patient with eyelid and anterior orbital Myeloproliferative
hypereosinophilic syndrome
P119
AL-SABAI N, DE KEIZER RJW, BAL T, DE GROOT V - Brussel, Antwerpen
12:30
P120
A new and standardised method to sample and analyse vitreous samples
12:30
P121
Distance Esotropia in the Elderly
VANDEWALLE E, OLAFSDOTTIR OB, PINTO LA, STALMANS P, VAN CALSTER J,
ZEYEN T, STEFáNSSON E, STALMANS I - Leuven, Reykjavik, Lisbon
MISSOTTEN G, SPILEERS W, DE KEIZER RJW - Leuven, Antwerpen
VAN GINDERDEUREN R, VAN CALSTER J - Leuven
GODTS DJM - Edegem
29
on
ssi
e
s
r
ay
sd
dne
We
te
Pos
on
ssi
e
s
r
ro
t
s
i
O’B
00
12:30
- 14:
12:30
Outcome improvement of glaucoma filtration surgery through the effect
of local rock-inhibition on wound healing
P122
SIJNAVE D, HOLLANDERS K, VAN BERGEN T, VAN DE VELDE S, VANDEWALLE E,
MOONS L, LEYSEN D, STALMANS I - Leuven, Diepenbeek
12:30
P123
Intravitreal bevacizumab induced uveitis: report of 2 cases
12:30
Nd:YAG Laser Hyaloidotomy for Premacular Subhyaloid Haemorrhages:
A Case Series
P124
VANDEKERCKHOVE G, PLATTEAU E, VANWYNSBERGHE D, DE ZAEYTIJD J, LEROY BP Ghent
12:30
Hidden information about the macular anatomy in the interferrometric
biometry spikes.
P125
BOECKAERT J, BLANCKAERT J - Leuven, Ieper
12:30
Vitrectomy with heavy oil tamponade and peripapillary laser for serous
maculopathy secondary to optic pit: a case series
P126
JANSEN J, VAN CALSTER J, STALMANS P - Leuven
12:30
P127
Acute welder’s maculopathy
12:30
The effect of a local ROCK-inhibitor (AMA0076) combined with Benzalkonium
chloride on the intraocular pressure
P128
HOLLANDERS K, SIJNAVE D, VAN BERGEN T, VAN DE VELDE S, VANDEWALLE E,
12:30
P129
Glaucoma from eye to brain: are matrix metalloproteinases (MMPs) involved?
12:30
P130
Is it a conjunctival naevus or melanoma or is it something else?
12:30
The effect of AMA0076, a locally acting rho kinase (ROCK) inhibitor, on IOP
in Dutch Belted Rabbits
P131
VAN DE VELDE S, VAN BERGEN T, SIJNAVE D, HOLLANDERS K, VANDEWALLE E,
VANDEWEYER E, SMETS RME - Edegem
DEWILDE J, DEWILDE E, STALMANS P - Leuven
DE GROEF L, DEKEYSTER E, GAUBLOMME D, MOONS L - Leuven
WEYNS M, DE GROOT V, DE KEIZER R - Antwerp, Leiden
30
ay
sd
dne
We
o
tr
s
O’Bi
12:30
0
- 14:0
te
Pos
12:30
Macular scleral band for degenerative high myopia: overview of the surgical
technique and short term results
P132
VANDENBROUCKE S, BREEMERSCH M, WARD B, STALMANS P - Leuven,
Campbell, USA
12:30
Pseudoxanthoma elasticum confirmed by genetic analysis but not by skin
biopsy
P133
VAN LOEY S, LEYS A - Leuven
12:30
Therapeutic potential of placental growth factor (PlGF) inhibition in scar
formation after glaucoma filtration surgery
P134
VAN BERGEN T, JONCKX B, HOLLANDERS K, SIJNAVE D, VAN DE VELDE S,
VANDEWALLE E, MOONS L, STASSEN JM, STALMANS I - Leuven, Heverlee
12:30
Let this be lattice? Dendritiform erosion in lattice dystrophy type I,
a source of confusion
P135
VANLERBERGHE V, KESTELYN PH-A, CLAERHOUT I, KESTELYN P - Ghent
12:30
Lasik for myopia and astigmatism with ZEISS MEL 80 excimer and
visumax femtosecond laser
P136
DEBROUWERE V, JACOB J, HUYGENS M - Leuven, Drongen
12:30
P137
Visual Function after Gene Therapy for RPE65-Related LCA
12:30
P138
Definition of an absolute scotoma in the central visual field for driver license
UVIJLS A, MAGUIRE AM, HIGH KA, WRIGHT JF, PIERCE EA, DE BAERE E,
MARSHALL KA, CHUNG DC, SUN J, MCDONNELL J, BENNETT J, LEROY BP Ghent, Philadelphia
STEVENS AM, ZEYEN T, BELGIAN GLAUCOMA SOCIETY - Gent
31
on
ssi
e
s
r
ay
sd
dne
We
l
Hal
14:00
BSA
BELGIAN STRABISMOLOGICAL ASSOCIATION
Moderator:
Carl GOBIN
Doctor I don’t see 3D
14:00
Introduction by Carl Gobin, President
14:10
3-D neuronal networks
1031
YUKSEL D - Brussels
14:30
1032
Stereopsis tests in clinical setting
14:50
1033
3-D movies and binocularity
GOMEZ DE LIANO R - Madrid
15:20
Discussion
15:30
Break
16:00
3-D videogames and binocular vision: orthoptic evaluation
1034
DECONINCK H - Brussel
16:20
3-D movie: a live-experience
1035
YUKSEL D - Brussels
17:00
Frequently asked questions
1036
DE NIJS E - Gent
17:10
End of session
VAN LAMMEREN M - Leuven
32
B
0
- 17:1
lC
Hal
16:00
ay
sd
dne
We
0
- 17:3
BIO
BELGIAN IMMUNO OPHTHALMOLOGY CLUB
Moderator:
Philippe KESTELYN
Case reports
33
We
lD
Hal
14:00
ay
sd
dne
0
- 15:3
e
Fr
B
O
A
ACADEMIA OPHTHALMOLOGICA BELGICA
Moderators:
Antonella BOSCHI, Bart Peter LEROY
14:00
Epiretinal membrane ( ERM ) and congenital hamartoma of the retina and
retinal pigment epithelium (CHRRPE) in very young children with and without NF2
1037
ROULEZ F, POSTOLACHE L, ZIERIESEN F, CLAES K, MEIRE F - Brussels, Sierre, Ghent
14:10
Relaxing retinectomy in the management of retinal detachment complicated
by proliferative vitreoretinopathy
1038
MARINESCU C, NOEL A, GRIBOMONT AC - Bruxelles
14:20
Long-term results of low-fluence photodynamic therapy in chronic central
serous chorioretinopahy
1039
LEYS E, TUTTLE S, RASQUIN F, NEU F, POSTELMANS L - Brussels
14:30
1040
Long-term follow-up of “bag-in-the-lens” pediatric cataract surgery
14:40
A retrospective data collection study in patients receiving two or more
OZURDEX® injections for macular edema secondary to retinal vein
occlusion (RVO)
1041
VAN CALSTER J, ON BEHALF OF THE BELGIAN OZURDEX MEDICAL NEED PROGRAM
INVESTIGATORS - Leuven
14:50
Recovery of visual acuity following a single ocriplasmin injection for
symptomatic vitreomacular adhesion - Results of Phase 3 Trials
1042
STALMANS P - Leuven
15:00
Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda,
Central Africa: a randomised, double-masked, controlled clinical trial
1043
DE SMEDT SK, NKURIKIYE J, FONTEYNE Y, TUFT S, DE BACQUER D, GILBERT C,
KESTELYN P - Gent, Kigali, Muhanga, London
15:10
Subretinal tissue plasminogen activator injection to treat submacular
hemorrhages in age-related macular degeneration
1044
DEWILDE E, DELAERE L, VANINBROUKX I, VAN CALSTER J, STALMANS P - Leuven
15:20
1045
The EVRS Macular Edema Study
15:30
End of session
VAN LOOVEREN J, BAKKER E, GODTS D, DE VEUSTER I, TASSIGNON MJ - Antwerpen
PINXTEN I, VAN CALSTER J, DUCOURNAU D, STALMANS P - Leuven, Nantes
35
rs
pe
a
p
e
TR U SETAL VERB A N DST O FF WERK G M B H
&
Sterile, ergonomically contoured eye bandage with transparent, unbreakable chamber. Hypoallergenic due to very gentle
adhesive (hot-melt adhesive). Especially suitable for maintaining a moisture chamber in cases of Lagophthalmus and after
care for LASIK surgeries. The bandage enables a wide visual field.
Available in two different sizes:
Ortolux ® large
Ortolux ® large
Ortolux ® small
Ortolux ® small
Qty: 1
Stock code: 70105
Qty: 20
Stock code: 70106
Total size:
approx. 96 mm x 67 mm
NEW! Chamber size: approx. 47 mm x 30 mm
Total size:
Chamber size:
Qty: 1
Stock code: 70107
Qty: 20
Stock code: 70108
Sterile, ergonomically contoured eye bandage with peripheral perforation for a comfortable aeration of the eye
area, without visual field limitation.
Especially suitable for post-operative use after cataract
operations and for protective care of the eye.
(e.g. LASIK surgery)
Available in two different sizes:
Ortolux ® Air small
Ortolux ® Air small
A70136-BE/A3/03-2012
Qty: 1 Stock code: 70135
Total size:
NEW! Chamber size: approx. 47 mm x 30 mm
Ortolux ® Air large
Ortolux ® Air large
Total size:
Chamber size:
For free samples please call:
Eastb eco PG m b H
Phone:
Fax:
087-55 44 91
087-55 52 72
info@eastbeco.com
www.eastbeco.com . www.tshs.eu
Onlineshop:
www.eyesfirst.eu
12
mb
e
v
o
e
Thu
r
,N
y
a
sd
, 20
9
2
r
ay
sd
hur
T
lA
Hal
09:00
BGS
BELGIAN GLAUCOMA SOCIETY
Moderators:
Philippe KESTELYN, Michèle DETRY, Veva DE GROOT
Myths and misconceptions in glaucoma
09:00
Welcome P. Kestelyn
09:05
NTG is a rare disease
2001
KESTELYN P - Gent
09:20
Misconception about IOP
2002
POURJAVAN S - Brussels
09:35
Misconception about functional & structural changes
2003
STALMANS I - Leuven
09:50
Misconception about medical treatment of glaucoma
2004
EHONGO A - Brussels
10:05
Break
10:45
Misconception about risks of glaucoma surgery
2005
DE GROOT V - Antwerpen
11:00
Misconception about glaucoma blindness
2006
HONDEGHEM K - Antwerpen
11:15
Generics are identical and less expensive
2007
STEVENS A - Gent
11:30
Clinical cases: M. Goethals, A.Hoste, N.Collignon, M.Detry
12:30
End of session
38
0
- 12:3
lB
Hal
09:00
ay
sd
hur
T
0
- 12:3
O
BELGISCH OFTALMOLOGISCH GEZELSCHAP
SOCIÉTÉ BELGE D’OPHTALMOLOGIE
BOG
SB
d
n
a
Moderators:
Joachim VAN CALSTER, Minh-Tri HUA
Controversies in ophthalmology
09:00
Multifocal IOL’s:
pro (Goes) and contra (Claerhout)
2008
GOES F JR, CLAERHOUT I - Antwerpen, Gent
09:45
Vitrectomy for floaters:
pro (Stalmans) and contra (Veckeneer)
2009
STALMANS P, VECKNEEER M - Leuven, Rotterdam
10:30
Break
11:00
Non arteritic anterior ischemic neuropathy: corticosteroids or not?
pro (Borruat), contra (Boschi)
2010
BORRUAT F, BOSCHI A - Lausanne, Brussels
11:45
Femtosecond laser cataract surgery: true or false progress?
pro (Gerten), contra (Tassignon)
2011
GERTEN G, TASSIGNON MJ - Cologne, Antwerp
12:30
End of session
39
T
lD
Hal
09:00
ay
sd
hur
0
- 12:3
w
Lo
&
d
e
P
PEDIATRIC OPHTHALMOLOGY
& LOW VISION REHABILITATION
Moderators:
Ingele CASTEELS, Hilde DECONINCK
Pediatric Ophthalmology and
metabolic disorders
09:30
Pediatrische aspecten van metabole aandoeningen
2012
MEIRLEIR L - Brussel
09:50
Treatment of metabolic disorders in children
2013
ZEEVAERT R - Leuven
10:10
2014
Ocular manifestations in metabolic disorders
10:30
Discussion
10:50
Break
11:20
Oftalmologische en algemene aspecten van ceroid lipofuscinosis
2015
WALRAEDT S, STANDAERT L - Gent, Brugge
11:40
Contactpunt NCL
2016
MATTHEEUWS S - Mol
12:00
Discussion
12:30
End of session
CASSIMAN C, MEIRE F - Leuven, Brussel
41
r
Inte
a
eS
v
i
t
c
u
se
r
u
Co
lA
l
l
a
a
c
H
rgi
ay
0
sd
r
Thu
12:30
- 14:0
T
lA
Hal
12:30
ay
sd
hur
0
- 14:0
ISC
INTERACTIVE SURGICAL COURSE
Moderators:
Werner SPILEERS, Bernard HEINTZ
12:30
2023
Is ‘Relex Smile’ pushing the boundaries in refractive corneal surgery?
12:45
Case discussion
12:50
2024
Is femtosecond laser pushing the boundaries in refractive lens surgery?
13:05
Case discussion
13:10
Are new lens technologies pushing the boundaries in presbyopic surgery?
2025
BLANCKAERT J - Ieper
13:25
Case discussion
13:30
Are intracorneal rings pushing the boundaries in keratoconus treatment?
2026
CHAVES A - Waterloo
13:45
Case discussion
13:50
Questions & Answers
14:00
End of session
GOES Fjr - Antwerp
MERTENS ELJG, SCHRAEPEN PS - Antwerpen
43
ay
sd
hur
T
O
PBM
14:00
U
BBO
lA
Hal
0
- 17:3
ique
Eth
iek /
Eth
BELGISCHE BEROEPSVERENIGING VAN OOGHEELKUNDIGEN
UNION PROFESSIONNELLE BELGE DES MÉDECINS SPÉCIALISTES EN
OPHTALMOLOGIE ET CHIRURGIE OCULAIRE
Moderators:
Philippe HUYGHE, Peter VAN BLADEL
Medico-legale items in de Oogheelkunde
Sujets medico-légaux en ophtalmologie
14:00
Les problèmes potentiels des dossiers électroniques vus d’un point de
vue juridique
2017
GENICOT G
14:45
De potentiële problemen van electronische dossiers vanuit technisch standpunt
2018
SAELENS S
15:30
Break
44
T
lA
Hal
14:00
ay
sd
hur
0
- 17:3
AOB
Eth
ACADEMIA OPHTHALMOLOGICA BELGICA
Moderator:
Bart Peter LEROY
Academic session 20 years OB
Ethiek en Economie
16:00
Introduction
16:05
What you see may not be what you get; structure and function in
retinal disease
2019
HOLDER G - London
16:25
Shining the light on diabetic retinopathy
2020
ARDEN G - London
16:45
Access to new treatments will not be available anymore for all?
Are there selection criteria and who will set them?
2021
CASSIMAN JJ - Leuven
17:05
Femtolaser technology from the cornea to the lens, what next
2022
PALLIKARIS I - Heraklion
17:25
20 year OB congresses
17:30
Start of the celebration evening, EYE in the SKY in Pal 6
45
e
hiqu
Et
iek /
OB Congress Dinner
Belga Queen
Thursday
19:30 - 23:00
y
k
s
e of OB
h
t
y
n
i
sar
r
e
e
nniv
a
Ey
20
9
er 2
b
m
ove - 22:00
N
,
y
a
rsd
17:30 EXPO
Thu
s
ssel
u
r
B
th
usic
m
d
n
er a
n
n
i
d
lking
a
red
e
w
t
,
s
i
n
g
o
i
e
all r
r
o
Recept
f
ers
e
n
c
t
r
n
a
a
r
p
t
y
Free en and industr
tes
a
g
e
l
e
d
CONFIDENCE
Thank you.
One million times over.
Thank you for treating astigmatism at the time of cataract surgery
with the AcrySof ® IQ Toric IOL in more than one million eyes.
© 2011 Novartis
12/11
TOR11420MS / MA2012-204
o
F
y, N
a
d
i
r
r
be
m
e
v
2
1
0
2
,
30
ay
Frid
S
R
BSC
09:00
lA
Hal
4:00
:30 / 1
- 12
0
- 16:3
BELGIAN SOCIETIES OF CATARACT AND REFRACTIVE SURGERY
Moderators:
Carina KOPPEN, Ingrid HOUTTEQUIET, Edmond TACKOEN, Guy SALLET
Management of corneal diseases in daily practice
09:00
Introduction by Jérôme Vryghem
09:05
CORNEA & CONTACTLENSES
Moderators: KOPPEN C, HOUTTEQUIET I
• Correction of irregular astigmatism with contactlenses
3001
KOPPEN C - Antwerpen
• Therapeutic contact lenses for corneal and ocular surface disease
3002
AL-SABAI N - Brussels
• Non-infectious complications of contact lenses: differential diagnosis and
treatment
3003
BEIRNAERT V - Maldegem
• Lens-related infectious ulcerations of the cornea
3004
CLAERHOUT I - Gent
• How to avoid contact lens complications
3005
SANTOS A - Deurne
10:30
Break
11:00
HOT TOPICS IN CORNEA AND EXTERNAL DISEASE
Moderators: TACKOEN E, SALLET G
EXPERT PANEL: P. MAUDGAL, M. SCHROOYEN, P. KESTELYN, L. CAPSERS, C. KOPPEN
Interactive discussion with university experts with regard to management and
treatment of corneal and external diseases and disorders
12:30
Lunchbreak
50
ay
Frid
lB
Hal
09:00
:00 0 / 14
- 12:3
16:30
S
R
BSC
BELGIAN SOCIETIES OF CATARACT AND REFRACTIVE SURGERY
Moderators:
Carina KOPPEN, Ingrid HOUTTEQUIET, Edmond TACKOEN, Guy SALLET
Management of corneal diseases in daily practice
14:00
SURGICAL TREATMENT OF CORNEAL DISEASES
Moderators: TACKOEN E, LEMAGNE JM
• Pre-operative management of ocular surface disease:
- blefaritis & dry eye
3020
LEYSEN I - Antwerpen
- prevention of recurrence of herpetic disease
3021
CLAERHOUT I - Gent
• Post-operative corneal healing:
- persistent & recurrent erosions
3022
VAN CLEYNENBREUGEL H - Heverlee
• Surgical treatment of corneal diseases:
- ectasia: corneal cross linking
3023
KOPPEN C - Antwerpen
- ectasia: intra-corneal ring / phakic iol / excimerlaser
3024
VRYGHEM J - Brussels
15:00
Break
15:30
SURGICAL TREATMENT OF CORNEAL DISEASES
Moderators: SALLET G, VRYGHEM J
- Lamellar graft techniques:
- DALK vs PKP
3025
VAN CLEYNENBREUGEL H - Heverlee
- DSAEK vs DMEK vs PKP
3026
BLEYEN I - Rotterdam
- Pterygium surgery
3027
LEMAGNE JM - Brussels
- Limbal stemm cells and amniotic membranes
3028
TASSIGNON MJ - Antwerpen
- Bandkeratopathy + anterior stromal dystrophies
3029
16:30
TRAU R - Antwerpen
End of session
51
ay
Frid
T
N
BSO
08:30
l
Hal
4:00
:30 / 1
- 12
Moderator:
Peter VAN ELDEREN
IV injectie / Implantlenzen
Inschrijvingen
09:15
Welkom door Dr. Sabine Bonnet, voorzitter OB 2012 en
Dr. Patrick Brabant, peter BSONT 2012
09:30
Werkingsmechanismen en indicaties voor torische lenzen
BLANCKAERT J, KESTELYN Pjr - Ieper, Gent
•
•
•
•
•
•
bouw van het oog en definitie brekingsafwijking en astigmatisme
vooronderzoeken
cataractoperatie “monofacale en multifocale torische kunstlens”
refractieve chirurgie
verloop chirurgie: film en toelichting
resultaten
11:00
Pauze
11:30
Communicatie door C. Klint
12:30
Lunch break
14:00
Intravitreale injecties
• 14:00 Pathologie: medische retina
DIRVEN W - Turnhout
• 14:15 Medicatie
DEPLA J - Antwerpen
• 14:40 Procedure intravitreale injectie
VAN CALSTER J - Leuven
• 15:00 Esprit: Increased patient satisfaction without big waiting times
BAEYER S
15:45
Einde
52
5
- 15:4
BELGIAN SOCIETY OF OPHTHALMIC NURSES & TECHNICIANS
08:30
B
ay
lC
Hal
08:30
Frid
:15 5 / 13
- 12:1
15:45
T
N
BSO
BELGIAN SOCIETY OF OPHTHALMIC NURSES & TECHNICIANS
Moderator:
Carine VERBIEST
L’enfant et la vision / Strabisme
08:30
Inscriptions
09:30
Mot d’accueil par le Dr. Sabine Bonnet, Président OB 2012
et le Dr. Julie Sellier, marraine du BSONT 2012
Le strabisme: du dépistage au traitement
• 09:45 Evolution de la vision et de la réfraction - défauts de réfraction
et amblyopie
ROULEZ F - Bruxelles
• 10:30 Dépistage des troubles visuels, moyens techniques lors d’une
consultation
VAN DAELE O - Bruxelles
11:00
Pause café
• 11:30 Pathologies fréquentes en ophtalmologie pédiatrique
MEIRE F - Bruxelles
12:15
Lunch break
• 13:15 DMLA pratique Q_Perior (S.Bayer) exposé satellite
• 14:00 Le Strabisme; anatomie, sortes, pronostics, traitement par caches
SELLIER J - Bruxelles
• 14:45 La chirurgie du strabisme en ambulatoire
YUKSEL D - Bruxelles
• 15:15 Post-op et suivis
SELLIER J - Bruxelles
15:45
Clôture
53
ay
Frid
lD
Hal
09:00
0
- 12:3
O
-AB
V
O
B
BELGISCHE ORTHOPTISCHE VERENIGING
ASSOCIATION BELGE D’ORTHOPTIE
Visual field defects and their consequences
09:00
Welcome
Moderators: Hilde DECONINCK, Daisy GODTS
09:05
3010
Methods of assessement
09:20
3011
Etiology
09:35
Visual field defects and orthoptics: Case report
3012
VERHELLE V, VAN BELLINGHEN V - Genk, Leuven
09:45
3013
Strabismus and hemianopia
10:15
3014
Visual field defects and fusion
VAN LAMMEREN M - Leuven
10:30
Break
BUYCK A - Antwerpen
BOSCHI A - Bruxelles
VAN WAVEREN - Tübingen
Moderators: Inge JONIAU, Kristl DE SMEDT
11:00
3015
Rehabilitation in hemianopia
11:20
Cerebral tumor and visual field deficit; orthoptics as a
tool- case report
3016
FRITZ L - Mons
11:40
Visual field defects and low vision: Case reports
3017
DIERICKX L, LAMONT L - Antwerpen
11:55
Complementarity of the neuropsychologic and the orthoptic
approach to visual field defects
3018
LEPUITS G, STREEL C - Liège
12:15
Case reports
3019
STREEL C, LEPUITS G - Liège
12:30
End of session
COECKELBERGH T - Edegem
55
ay
Frid
d ce
r
Awa
y
on
m
e
r
lA
Hal
12:30
0
- 13:3
Moderator:
Werner SPILEERS
Poster Awards
All posters are eligible for a Poster Award.
• Best case report: 300 EUR
• AOB best resident’s poster prize: 500 EUR – Travel grant EVER 2013
An independent panel appointed by the Board of OB 2012 decides on the Poster Awards through
voting. Their decision is final.
FRO awards
Prizes of the Société Royale de Philanthropie
Stichting Brailleliga / Ligue Braille Foundation
EBO Diploma
MATAR Vincent Wassim
PIENS Isabelle
RENIER Steven
TEK Arzu
TERMOTE Karolien
VAN GRASDORFF Sigi
VERSCHOOTEN Roel
BARBRY Julie
CALUWAERTS Evi
COULIER Julie
CREVECOEUR Laurent
DELAHAUT Audrey
DEVRESSE Laure
ELMALEH Valérie
LUCAS Rajkumar
56
ay
lA
Hal
12:30
Frid
0
- 13:3
dC
r
Awa
ny
mo
e
r
e
ay
Frid
C
OBP
14:00
-
B
BVV
l
Hal
D
BELGISCHE VERENIGING TER VOORKOMING VAN BLINDHEID
ORGANISATION BELGE POUR LA PRÉVENTION DE LA CÉCITÉ
Moderator:
Hilde DECONINCK
Hopefully, people with low vision are not
helpless!
14:00
3036
Depression among visually impaired older adults: an underestimated problem
14:20
Multidisciplinary reeducation : an open door on everyday
life reality
3037
JOURDAN C
14:40
Therapeutic intervention on Activities of Daily Living :
effects on quality of life
3038
HAMAIDE S, DEMARTIN S
15:00
3039
Apprehension of the place of life by the elderly person after a fall of vision
15:15
Questions and answers
15:30
End of session
VAN NISPEN RMA
HOENRAET D, GOLINVAUX D
58
0
- 15:3
al
Int
ct
a
r
e
iv
inic
l
C
e
es
rs
u
o
C
ive
ct
era
Int
al
ic
Clin
es
rs
Cou
WEDNESDAY, 28 NOVEMBER 2012
09:00 - 10:30
ICC - W1 | INTERMEDIATE
Hall E
Astigmatism correction during phaco-emulsification
Benoît GOLENVAUX, Guy SALLET, Emmanuel VAN ACKER
This course will provide pragmatic information on surgical correction
of astigmatism for the phaco surgeon. The course will cover selection
of candidates, determination of axis and surgical correction of astigmatism, either by incisional surgery or with toric IOL’s. Toric IOL’s on
the market will be presented, together with their calculating method
and alignement process. Finally, several clinical cases and videos on
astigmatism management will be presented for discussion with the
audience. This ICC is a prerequisite to the WETLAB organized on the
same subject.
11:00 - 12:30
Hall E
Oogscreening van de allerjongsten door K&G
Ingele CASTEELS, Mirjam van LAMMEREN, Erwin VAN KERSCHAVER
Tijdens deze ICC wordt enerzijds het nieuwe screeningsprogramma
van K&G toegelicht: de K&G-oogscreener, het onderzoeksprotocol, de
verwijscriteria en de eerste resultaten. Na een aantal valideringsstudies
en pilootprojecten is dit programma al in een aantal Vlaamse regio’s
geïmplementeerd, de andere regio’s volgen binnen afzienbare tijd.
Anderzijds zal stilgestaan worden bij de uitdagingen die dit project met
zich meebrengt voor de oogartsen die nu frequenter jonge tot zeer
jonge kinderen op consultatie zien.
Aan de hand van praktische voorbeelden wordt een voorstel van standaardonderzoek en het mogelijke beleid bij deze kinderen besproken.
60
ive
ct
a
r
e
Int
al
ic
n
i
l
C
es
rs
u
o
C
14:00 - 15:30
Hall E
La gonioscopie: un examen irremplaçable.
Gonioscopie is onmisbaar
Sayeh POURJAVAN, Michèle DETRY
La gonioscopie représente la pièce clé du puzzle que constitue le bilan
d’un suspect de glaucome ou d’un glaucome confirmé.En son absence,
le clinicien s’expose à poser des diagnostics erronés et à instaurer des
traitements inappropriés. Après un rappel théorique, plusieurs cas cliniques exposés en français et néerlandais seront discutés avec les particpants pour illustrer l’importance de la gonioscopie. De gonioscopie
is een onmisbaar onderdeel van het globale onderzoek van mogelijke
glaucoompatiënten en patiënten waarbij effectief glaucoom werd
vastgesteld.Het niet uitvoeren van dit onderzoek is één van de meest
voorkomende oorzaken van verkeerde diagnoses en niet geschikte behandelingen. Na een korte theoretische uiteenzetting van de gonioscopie, worden acht klinische casussen die om beurt worden uiteengezet
in het Frans en in het Nederlands en die het belang van de gonioscopie
onderstrepen, besproken met de deelnemers.
61
ive
ct
era
Int
al
ic
Clin
es
rs
Cou
16:00 - 17:30
ICC - W4 | BASIC
Hall E
Visual fields and structural measurements for
glaucoma into clinical practice
Ingeborg STALMANS, Tania BARLET
The course is based on the educational program “Save Sight Years II”
which was developed by the renown glaucoma specialists Prof Dr
Fancisco Goni and Prof Dr Luca Rossetti with the support of Allergan.
This program is developed to illustrate the importance of measuring
both structural and functional rate of progression, in order to identify
patients at risk of visual impairment as early as possible. Combining information from structure and function can significantly improve detection and assessment of glaucoma progression. The program will include
a practical workshop to illustrate how function (visual fields) and structural measurements can be implemented in clinical practice. Moreover,
the latest data showing that effective IOP reduction can substantially
impact the rate of glaucoma progression and have an outcome on
saving sight years and quality of life will be discussed.
16:00 - 17:30
Hall D
Indicatiestelling en follow-up bij vitreoretinale
chirurgie
Eric FERON, Jozef DEPLA
Indicaties voor vitreoretinale chirurgie evolueren voortdurend.Vooral
de recente verbeteringen in diagnostische methoden (zoals de OCT)
hebben geleid tot een betere inschatting van de juiste indicaties voor
vitreoretinale chirurgie.Evoluties in het instrumentarium hebben ook
bijgedragen tot beter voorspelbare resultaten met minder complicaties. Hierdoor is er een tendens om de indicaties op te schuiven naar
de eerdere stadia van de aandoeningen, met betere visuele resultaten
als gevolg.
62
ive
ct
a
r
e
Int
al
ic
n
i
l
C
es
rs
u
o
C
THURSDAY, 29 NOVEMBER 2012
09:00 - 10:30
ICC - T6 | BASIC
Hall E
Les uvéites postérieures illustrées: les reconnaitre
par le FO, l’angiographie et l’OCT
Alexandra KOZYREFF, Dorine MAKHOUL, Nacima KISMA, Pierre LEFEBVRE
L’objectif est de reconnaître les uvéites postérieures les plus fréquentes,
infectieuses et non infectieuses, en faisant la distinction entre les
atteintes inflammatoires rétiniennes et choroïdiennes.
Les pathologies inflammatoires seront présentées, expliquées et illustrées par les clichés du fond d’oeil, l’OCT la fluoangiographie et l’ICG.
11:00 - 12:30
ICC - T7 | BASIC-INTERMEDIATE
Hall E
Oedèmes maculaires :
a) aspects cliniques et thérapeutiques
b) dans les thromboses veineuses
Ann - Pascale GUAGNINI, Alexandra KOZYREFF, Fabrice KORCZEWSKI,
Gwendoline LEPIECE
Analysis of macular edema and adapted treatment in retinal diseases.
L’oedème maculaire est observé dans un certain nombre de pathologies
oculaires englobant les thromboses veineuses, les uvéites, les syndromes
de traction vitréo-rétinienne, la DMLA, les dystrophies rétiniennes, les
traumatismes et la chirurgie intra-oculaire. La baisse d’acuité visuelle
observée est liée à la présence de l’oedème maculaire. Nous vous proposons de revoir la physiopathologie de l’oedème maculaire secondaire
aux thromboses veineuses et de rappeler l’apport de l’angiographie à
la fluorescéine et de l’OCT autant dans le diagnostic que dans le suivi
de cette pathologie et de ses complications.Nous verrons les différents
traitements disponibles ainsi que la séquence thérapeutique à suivre.
Finalement, nous reprendrons en revue les différentes causes d’oedème
maculaire et les pièges diagnostiques que ces situations peuvent engender.
63
ive
ct
era
Int
al
ic
Clin
es
rs
Cou
14:00 - 15:30
ICC - T8 | INTERMEDIATE
Hall E
Retinopathy of prematurity
Ingele CASTEELS, Joachim VAN CALSTER, Catherine CASSIMAN
Retinopathy of prematurity (ROP) is a retinal vascular disorder associated with preterm birth; it has become one of the leading causes
in childhood blindness. Over the last decades, clinical characteristics,
classification of ROP and treatment modalities have changed.
In this ICC, classification of ROP, indications for treatment and
treatment modalities will be discussed. Special attention is paid to the
necessity for everyone caring for premature babies to have a well
defined screening and treatment protocol, with written responsibilities.
64
ive
ct
a
r
e
Int
al
ic
n
i
l
C
es
rs
u
o
C
FRIDAY, 30 NOVEMBER 2012
09:00 - 10:30
ICC - F10 | ADVANCED
Hall E
Interpretatie van de vitreomaculaire interface
Peter STALMANS
SD-OCT heeft nieuwe inzichten opgeleverd in de aandoeningen van
de vitreo-maculaire interface. Binnenkort komt het eerste geneesmiddel op de markt voor enzymatische vitreolyse ter behandeling van
symptomatische vitreomaculaire adhesie. Hiervoor is een correcte
indicatiestelling op basis van OCT-beeldvorming vereist. Tijdens deze
cursus wordt een overzicht getoond van de verschillende aandoeningen
van de vitreo-maculaire interface gevolgd door een interactieve quiz
aan de hand van OCT-beelden.
11:00 - 12:30
ICC - F11 | INTERMEDIATE
Hall E
Les nouveautés dans la chirurgie du glaucome :
quels impacts ont-elles en pratique ?
Nathalie COLLIGNON, Géraldine DUPONT
Le traitement chirurgical du glaucome a évolué ces dernières années
grâce à de nouvelles techniques destinées à augmenter son profil
de sécurité. Cet ICC se propose d’exposer, grâce à une importante
iconographie, les nouvelles chirurgies du glaucome, d’envisager les
mécanismes d’action et leurs résultats au travers de l’analyse de la
littérature publiée à ce sujet. Enfin, nous discuterons de l’impact que
ces nouveautés chirurgicales ont sur la prise en charge globale du
glaucome.
65
ive
ct
era
Int
al
ic
Clin
es
rs
Cou
14:00 - 15:30
ICC - F12 | BASIC
Hall E
New concepts and review of retinal vein occlusion
Julie DE ZAEYTIJD, Joachim VAN CALSTER, Elise PLATTEAU
Retinal vein occlusions (RVOs) are the second most common type of
retinal vascular disorder after diabetic retinal disease and are a major
cause of vision loss. We provide an overview of the clinical features,
pathophysiology, natural history, work-up for modifiable risk factors,
identification of complications and establishment of a treatment and
follow-up plan for both branch and central retinal vein occlusion.
Management of RVOs should be directed at the underlying etiology
and the resulting sequelae. Several recent multicenter randomized
clinical trials have been completed which have changed the approach
to this disorder. Traditional laser photocoagulation and effective
new treatment options including intravitreal pharmacotherapy and
sustained drug delivery devices will be discussed.
16:00 - 17:30
ICC - F13 | BASIC
Hall E
Les désordres inter et supranucléaires une fois
pour toutes
Tania BARLET
Comment examiner correctement les ophtalmoplégies monoculaires
et binoculaires? Au cours de cet ICC, nous passerons en revue les
atteintes du III, du IV et du VI. Nous aborderons ensuite d’une manière
claire et interactive les schémas des voies inter et supranucléaires afin
de mieux les comprendre et les reconnaitre dans notre pratique de
tous les jours. Vous en ferez des connaissances acquises une fois pour
toutes.
66
ive
ct
a
r
e
Int
al
ic
n
i
l
C
es
rs
u
o
C
16:00 - 17:30
ICC - F14 | BASIC
Hall D
Le traitement de l’amblyopie
Monique CORDONNIER, Thipaine SOYER
Les aspects pratiques, diagnostiques et thérapeutiques de l’amblyopie
strabique et non strabique seront abordés, avec démonstration de cas
cliniques reprenant les différentes étapes du traitement.
67
AMO T
E
Preloa CNIS iTec
ded S
ystem
We invite you to visit
our booth 37 and discover our
OB 2012
SUPER PROMOTIONS
Action only valid
from 28/11/’12 until 30/11/’12
Topc
Non C on Aladdin
ontac
t Biom
eter
Topco
n
DRI O
CT-1
DE CEUNYNCK MEDICAL nv/sa
Kontichsesteenweg 36
B-2630 Aartselaar - Belgium
Tel +32 (0)3 870 37 63
Fax +32 (0)3 887 27 06
info@dcmedical.be
www.dcmedical.be
bs
la
t
e
W
s
lab
t
e
W
09:00 - 10:30
Wetlab 1 (ENG)
Hall F
Phakic iol’s
Bernard MATHYS
11:00 - 12:30
Wetlab 2 (ENG)
Hall F
Astigmatism correction during phaco
ICC - W1 is a prerequisite to the WETLAB 2 organized
on the same subject.
Registration of ICC - W1 is mandatory to register for WETLAB 2
Benoît GOLENVAUX
14:00 - 15:30
Wetlab 3 (NL)
Hall F
Cataractchirurgie: phaco voor beginners
Ivo NIJS, Huib LODEWIJKS
16:00 - 17:30
Wetlab 4 (ENG)
Hall F
Small incision manual cataract surgery
Piet NOË
14:00 - 15:30
Wetlab eyelid surgery (NL)
Hall G
Wetlab ooglidchirurgie
Paul JONCKHEERE, Philippe BETZ
16:00 - 17:30
Wetlab eyelid surgery (FR)
Wetlab chirurgie des paupières
Paul JONCKHEERE, Philippe BETZ
70
Hall G
s
lab
t
e
W
09:00 - 10:30
Wetlab 5 (ENG)
Hall F
Small incision manual cataract surgery
Piet NOË
11:00 - 12:30
Wetlab 6 (ENG)
Hall F
Learning phaco-chop
Ann HAUSTERMANS
14:00 - 15:30
Wetlab 7 (ENG)
Hall F
Trabeculectomy
Ingeborg STALMANS
71
s
lab
t
e
W
09:00 - 10:30
Wetlab 8 (ENG)
Hall F
Glaucoma surgery with tubes
Philippe KESTELYN
11:00 - 12:30
Wetlab 9 (FR)
Hall F
Sutures en ophtalmologie:
(1) sutures du segment antérieur
Minh HUA
(2) de la conjonctive et des muscles
Caroline FRESON
(3) des paupières
Philippe BETZ
14:00 - 15:30
Wetlab 10 (FR)
Hall F
Chirurgie de la cataracte: phaco pour débutants (FR)
Vincent WERY, Alessandra CHAVES
73
Suffering from irritated, tired, dry eyes ?
provides instant relief
whenever needed
0,24 % sodium
hyaluronate
BE(e) ART SPL DLI 2 2 2012
NEW
ControlGrip™
ts
Ab
ac
str
s
act
r
t
bs
BSA
A
1032
Stereopsis tests in clinical setting
VAN LAMMEREN M
Leuven
Clinicians have a wide gamma of tests at their disposal for the quantitative
and qualitative assessment of stereo-acuity. In many instances, the resulting
degree of stereo-acuity not only depends upon the binocular status but also
on the characteristics of the test.A selection of the most useful tests will be
discussed, with practical tips for the choice of the appropriate tests, for the
execution of the tests and for the interpretation of the results.
76
cts
a
r
st
ers
Ab
p
e pa
re
OB F
A
1037
1038
Epiretinal membrane ( ERM ) and congenital
hamartoma of the retina and retinal pigment
epithelium (CHRRPE) in very young children with
and without NF2
Relaxing retinectomy in the management of
retinal detachment complicated by proliferative
vitreoretinopathy
ROULEZ F (1), POSTOLACHE L (2), ZIERIESEN F (3), CLAES K (4), MEIRE F (1)
(1) Department of pediatric ophthalmology, HUDERF,
ULB, Brussels/Sierre
(2) Department of pediatric ophthalmology, HUDERF,
ULB, Brussels
(3) Department of radiology, HUDERF, ULB, Brussels
(4) Department of genetics, UZ Ghent , Ghent
purpose NF2 is a tumor suppressor gene that encode for Merlin.
Manifestations are explained by the loss of function of Merlin through NF2
mutation and allelic loss of heterozygosity. Absence of Merlin provides
dysplastic Müller cells that proliferate as an epiretinal membrane through
breaks in internal limiting membrane (ILM) of the retina.
methods We report 2 unrelated very young children with ERM and CHRRPE
as first manifestation of NF2. The children carry respectively a non sense
mutation and a non reported deletion in NF2 gene.In a third child, with
unilateral CHRRPE NF2 was excluded.
results OCT of those hamartoma is pathognomonic.
conclusion Therefore the recognition by paediatric ophthalmologist
of those hamartoma as a hallmark of NF2 leads to an appropriate
multidisciplinary follow up. Prognosis of NF2 is adversely affected by early
age at onset.
MARINESCU C, NOEL A, GRIBOMONT AC
Université Catholique de Louvain, 1200 Bruxelles
purpose To review the anatomical and functional results of relaxing
retinectomies in non-traumatic retinal detachment (RD) complicated by
proliferative vitreoretinopathy (PVR).
methods In this retrospective study, we reviewed the outcome of 39
consecutive eyes that underwent relaxing retinectomies for RD complicated
by PVR between 2002 and 2010 and with a minimum follow-up of 6
months.
results The 39 patients underwent a mean number of 2,15 vitreoretinal
surgeries before retinectomy was performed (range 0-4). Mean
preoperative visual acuity (VA) was 0,12. One patient had LP only.
Prominent features of the surgery included membrane peeling, use of
perfluorocarbon liquid (76,92%), relaxing retinectomy (mean size : 141,67°)
and intraocular tamponade with silicone oil (94,88%), C3F8 (2,56%) or
SF6 gaz (2,56%). Complete retinal reattachment was achieved in 100%
of cases at the end of the procedure. Recurrent RD was documented in 18
patients (46,15%). Retina could be reattached by one additional surgery
in 5 of these patients. Final success rate was 66,67%. Mean VA at the
end of follow-up was 0,088, with a mean follow-up time of 35,15 months
(range 6-92). Two patients had a final VA of LP and one other underwent
an enucleation. Complications included ocular hypertension (17,95%),
corneal decompensation (7,69%) and epimacular membrane development
(15,38%). Three patients developed neovascular glaucoma due to chronic
RD, and one of them had to be enucleated.
conclusion RDs complicated by PVR and in need of a relaxing retinectomy
still carry a fair functional and anatomical prognosis.
1039
1040
Long-term results of low-fluence photodynamic
therapy in chronic central serous chorioretinopahy
Long-term follow-up of “bag-in-the-lens” pediatric
cataract surgery
LEYS E (1), TUTTLE S (2), RASQUIN F (3), NEU F (3), POSTELMANS L (2)
(1) CHU Brugmann - CHU Saint-Pierre, Brussels
(2) CHU Brugmann, Brussels
(3) Erasme, Brussels
purpose To evaluate long-term results of low-fluence photodynamic
therapy (PDT) with verteporfin in the treatment of Chronic Central Serous
Chorioretinopathy (CCSC).
methods Retrospective medical record review of 42 eyes (39 patients)
who received low-fluence PDT for the treatment of CCSC. Visual acuity,
fundus biomicroscopy, fluorescein angiography (FA), indocyanine green
angiography (ICG) and optical coherence tomography (OCT) were analysed.
results Forty two eyes (39 patients) with CCSC received low fluence PDT.
Mean follow-up after PDT was longer than 3 years (39,43 months; range,
12-96 months; median, 36 months). Mean logMar best corrected visual
acuity (BCVA) improved significantly from 0,32 (0,48 Snellen visual acuity)
to 0,1 (0,80 Snellen visual acuity) at the last follow up which corresponds to
a gain of 2,2 lines in logMar scale. Complete resolution of central subretinal
fluid on OCT was achieved 6 months after 1 PDT in 41 eyes and after 2 PDTs
in 1 eye (treated at 3 months after first PDT). No treatment-related side
effects were observed.
conclusion Low fluence PDT for CCSC is efficient and safe at long term.
VAN LOOVEREN J, BAKKER E, GODTS D, DE VEUSTER I, TASSIGNON MJ
UZA
purpose To evaluate the long-term follow-up of the bag-in-the-lens
intraocular lens (BIL IOL) in pediatric cataract surgery.
methods All pediatric cataract surgeries using the BIL IOL that completed
a follow-up period of more than 5 years in our department were included
in the study. Type of cataract, age at time of surgery, ocular and systemic
pathology were recorded. Follow-up examination included best corrected
visual acuity (BCVA), refraction, anterior and posterior segment evaluation,
axial length measurement and orthoptic examination.
results Between July 1999 and September 2007 133 eyes of 107 children
were operated using the BIL IOL. Of this group 46 eyes of 33 children
completed a follow-up of at least 5 years. Follow-up ranged from 60 to
157 months (mean: 78). Age at time of surgery ranged from 2 months
to 14 years and 11 eyes of 7 children were below the age of 1 year at
time of surgery. BCVA improved postoperatively in all cases except one.
Of the bilateral cases nearly all recovered up to normal visual acuity. Of
the unilateral cases none fully recovered. All patients had acceptable
postoperative refraction. Spherical equivalents were distributed around
emmetropia, with a tendency towards light myopia.
The visual axis
remained clear in nearly all cases.
In 4 eyes, where proper BIL IOL
implantation was not feasable, visual axis reopacification (VAR) occurred
and secondary surgery was needed.
conclusion The “bag-in-the-lens” implantation in babies and children
gives very promising results. When properly implanted, it prevents the
occurrence of VAR, allowing early intensive visual rehabilitation. However,
despite this major advantage the unilateral cataracts still have the worst
prognosis regarding visual recovery.
77
s
act
r
t
s
bs
per
A
e pa
re
OB F
A
1041
1042
A retrospective data collection study in patients
receiving two or more OZURDEX® injections for
macular edema secondary to retinal vein occlusion
(RVO)
Recovery of visual acuity following a single
ocriplasmin injection for symptomatic
vitreomacular adhesion - Results of Phase 3 Trials
VAN CALSTER J, ON BEHALF OF THE BELGIAN OZURDEX MEDICAL NEED
PROGRAM INVESTIGATORS
University Hospitals Leuven, Leuven
purpose This retrospective observational study was designed to investigate
the re-injection interval, efficacy and safety of OZURDEX® in routine clinical
practice in the Belgian RVO population.
methods This analysis contains data from 26 patients from 7 sites in
Belgium who had received at least 2 OZURDEX® injections. Data was
collected from the time of the first injection until 6 months following the
latest OZURDEX® injection in each patient. Analysis was performed for the
full analysis set, i.e. 26 patients with RVO, and for the sub-population with
central retinal vein occlusion (CRVO, n=23).
results The mean time to OZURDEX® re-injection between 1st and 2nd
treatments was 144 days (5.14 months). In the overall population, a mean
LogMAR BCVA improvement compared to baseline from 0.65 to 0.52 was
recorded 7-12 weeks following the last OZURDEX® injection. For CRVO,
the mean improvement was from 0.67 to 0.52. Following the 1st injection,
50% of patients showed an improvement of 2 lines compared to baseline.
42% showed an improvement of 3 lines. Following the 2nd injection, 2
and 3 line improvements compared to baseline were shown by 38% and
35% of patients respectively. Reductions in central retinal thickness were
also observed.Intraocular pressure measurements over 25mmHg were
reported in 5 patients (19%). No glaucoma surgeries were reported. 4
patients underwent cataract surgery during the course of the study, all of
whom presented with lens opacity prior to receiving OZURDEX®.
STALMANS P
Dept. Ophthalmology UZLeuven, Leuven
purpose To examine the impact on visual acuity (VA) and function for
6 months after a single intravitreal ocriplasmin injection in patients with
vitreomacular traction (VMT) or macular hole.
methods VA testing (ETDRS) and visual function assessment (VFQ-25) at
baseline and 6 months after treatment were done on patients from 2 phase
3 trials receiving intravitreal ocriplasmin 125µg, n= 464 vs placebo, n=188.
results At 6 months, best corrected visual acuity improved 2 lines in 28% of
all ocriplasmin-treated eyes vs 17.1% of all placebo eyes (p= 0.003) and 3
lines in 12.3% vs 6.4% (p= 0.024). Among patients with baseline 20/50,
25.1% ocriplasmin-treated eyes gained 3 lines vs 11.4% of placebo
(p<0.001). In macular hole patients, 76.7% (n=33) of ocriplasmin-treated
eyes with hole closure at month 6 gained 2 lines, and 51.2% (n=22) gained
3 lines. In VMT patients, 41.1% (n=23) of ocriplasmin-treated eyes gained
2 lines following resolution, and 14.3% (n=8) gained 3 lines. Ocriplasmin
patients also improved on VFQ-25 composite scale by 3.4 vs 0.7 for placebo
(p= 0.004) and 6/11 subscales. Median time to onset for a majority of
adverse drug reactions (ADRs) occurred within the first 7 days of treatment,
with ADRs Day 8 to end of study mirroring the placebo group.
conclusion Patients receiving ocriplasmin reported significant
improvements in VA and visual function over placebo. Ocriplasmin may
provide a minimally invasive pharmacologic approach to treat patients with
symptomatic vitreomacular adhesion and restore VA.
conclusion In this observational study, OZURDEX® was found to be safe
and effective with repeat treatments. The mean re-injection interval for
RVO patients was 5.14 months.
1044
1043
Topical ciclosporin in the treatment of vernal
keratoconjunctivitis in Rwanda, Central Africa: a
randomised, double-masked, controlled clinical
trial
DE SMEDT SK (1), NKURIKIYE J (2), FONTEYNE Y (3), TUFT S (4), DE
BACQUER D (5), GILBERT C (6), KESTELYN P (1)
(1) Ophthalmology Department, Ghent University Hospital, Gent
(2) Ophthalmology Department, King Faisal Hospital, Kigali, Rwanda
(3) Kabgayi Hospital, Muhanga, Rwanda
(4) Moorfields Eye Hospital NHS Foundation Trust, London, UK
(5) Public Health Department, Ghent University Hospital, Gent
(6) International Centre for Eye Health, London, UK
purpose To compare the short-term efficacy and safety of topical
ciclosporin A (CsA) 2% with dexamethasone 0.1% in the treatment of
predominantly limbal VKC in Rwanda.
methods Consecutive patients with VKC were randomised in a prospective,
double-masked, clinical trial to receive either topical CsA 2% dissolved in
olive oil vehicle or dexamethasone 0.1% drops for 4 weeks. Both groups
then received sodium chromoglycate 2% drops for maintenance therapy
for a further 4 weeks. The primary outcome was the reduction in composite
score for VKC-related symptoms and signs at 4 weeks. Secondary outcomes
included side effects, comfort rating of the trial drops during 4 weeks test
medication, and relapse rate thereafter.
results The 366 participants recruited had the limbal (91.5%) or mixed form
of VKC. At the end of the 4 week treatment period the composite score
had significantly (p<0.001) reduced from baseline without a significant
difference between CsA and dexamethasone (p= 0.20).There were no
severe adverse reactions but CsA drops caused more stinging than the
oil placebo and dexamethasone (p<0.001). The relapse rate following
cessation of the trial treatments was similar (p= 0.84) in both groups.
Subretinal tissue plasminogen activator injection
to treat submacular hemorrhages in age-related
macular degeneration.
DEWILDE E, DELAERE L, VANINBROUKX I, VAN CALSTER J, STALMANS P
Afdeling Oogheelkunde UZLeuven, Leuven
purpose To determine the efficacy and safety of 23G transconjunctival
sutureless vitrectomy (TSV), subretinal tissue plasminogen activator
injection (tPA) and pneumatic displacement with air/SF6 gas to treat
submacular hemorrhages secondary to AMD.
methods Retrospective analysis of 74 patients (mean age 79.3 years),
surgically treated for submacular hemorrhage caused by neovascular AMD
between November 2008 and July 2012 at the University Hospitals Leuven.
Main outcome measures: Short-term, best and final postoperative visual
acuity, displacement of subretinal hemorrhage, and surgical complications.
results The submacular hemorrhage was successfully displaced in 86% of
the patients. After the surgery, the visual acuity improved by 0.34 logMAR
unit after two months and by 0.06 logMAR unit at the final visit (mean
follow up 241 days). The best postoperative visual acuity increased by 0.46
logMAR unit. Complications consisted of 9 cases of recurrent hemorrhage,
2 vitreous hemorrhages, 7 cases of retinal detachment, and 2 subchoroidal
hemorrhages during the follow-up period.
conclusion This study indicates that a surgical approach with 23G TSV, tPA
and pneumatic displacement may be an effective procedure for submacular
hemorrhage displacement in patients with AMD. The procedure induced
an improved visual recovery. However, visual outcome is limited by the
underlying macular pathology. Larger multicenter randomized controlled
studies are warranted to determine the therapeutic effect of this surgical
approach.
conclusion There is no significant difference between the efficacy of
topical CsA 2% and dexamethasone 0.1% for the management of acute
VKC in Central Africa, but tolerance needs to be improved.
78
cts
a
r
st
ers
Ab
A
1045
The EVRS Macular Edema Study
PINXTEN I (1), VAN CALSTER J (1), DUCOURNAU D (2), STALMANS P (1)
(1) UZ Leuven, Leuven
(2) Clinique Sourdille, Nantes
purpose To determine the efficacy of different treatment options in macular
edema (ME) of numerous etiologies.
methods A retrospective multicenter study including 2603 patients with ME
treated between January 2008 and December 2011 with a minimal follow
up of 6 months. Due to the numerous etiologies and treatment complexity
only the 4 major etiologies were analyzed (2159 patients): diabetic macular
edema (DME), idiopathic epiretinal membrane (ERM), branch retinal vein
occlusion (BRVO) and central retinal vein occlusion (CRVO). CRVO and
BRVO were combined (RVO) to obtain larger populations for the statistical
analysis. The data were analyzed by presentation with trend lines based on
averages containing a minimum of three cases. The visual improvement was
considered according to pretreatment vision level.
results In idiopathic ERM, 62.5% were treated by vitrectomy with ILM
peeling, 10 times more than by anti-VEGF or triamcinolone alone. ME
following all RVO was treated by anti-VEGF alone in 33.6% of cases.
Combined treatment was chosen in 40% of cases. The single treatment
population was large enough to justify a separate analysis. In DME the
treatment distribution is more equally divided: 26.6% were treated by
anti-VEGF alone, 18.5% were treated by threshold grid laser, in 25.4%
combined treatment was chosen. Further treatment groups contained ILM
peeling, triamcinolone alone and sub-threshold grid laser.
conclusion In all ME etiologies, ILM peeling provides the most visual
improvement without resulting in more complications than the other
treatments. Second best results are achieved by intravitreal anti-VEGF
injection, followed by ILM peeling combined with intravitreal triamcinolone
injection.
79
p
e pa
re
OB F
cts
ra
bst
A
&
Ped
Low
2014
Ocular manifestations in metabolic disorders
CASSIMAN C (1), MEIRE F (2)
(1) Leuven
(2) Brussel
conclusion Metabolic diseases are inborn errors in metabolism. The
expression ‘You are what you eat’ suits perfectly to explain the clinical
picture of each entity. Ophthalmologists can play an important role in
diagnosis and follow up of these patients. The speakers will highlight a few
disease entities with ocular manifestation and discuss on their therapeutic
options and visual aids.
80
ts
ac
str
Ab
ISC
2023
2024
Is ‘Relex Smile’ pushing the boundaries in
refractive corneal surgery?
Is femtosecond laser pushing the boundaries in
refractive lens surgery?
GOES Fjr
Goes Eye Centre, Antwerp
MERTENS ELJG, SCHRAEPEN PS
Medipolis, Antwerpen
purpose To report the 3-month results of the first ten patients who
underwent Small Incision Lenticule Extraction (SMILE) in the correction of
myopia and myopic astigmatism.
purpose Evaluation of the different femtosecond procedures and clinical
outcomes on a single laser platform.
methods Eightteen eyes of ten patients with myopia or myopic astigmatism
underwent SMILE by cutting a lenticule of intrastromal corneal tissue
using the Visumax 500 kHz femtosecond laser. The lenticule was manually
dissected and removed from the stroma through a 3.5 mm incision
using 0.12 forceps. All patients completed 3 months of follow-up. The
uncorrected visual acuity the best spectacle-corrected visual acuity after 3
months, corneal topography, objective and manifest refractions, and side
effects are reported.
results The patients’ mean age was 26.9 years. The preoperative mean
spherical equivalent (SE) was -5.73 ±1.26 diopters (D). Three months
postoperatively, the mean SE was +0.27±0.19 D. Stability was achieved
within 6 weeks. No complications were noted in any of the cases, no eyes
lost any lines of BSCVA.
conclusion These preliminary results show that Relex SMILE, a flapless
minimally invasive technique, appears to be a safe and effective new
refractive procedure correcting myopia and myopic astigmatism.
methods The Victus femtosecond laser (Bausch+Lomb/Technolas Perfect
Vision, Munich, Germany) has been designed to perform the key steps in the
cataract surgery procedure (lens emulsification, capsulotomy and corneal
incision), an intrastromal procedure for presbyopia, LASIK flaps, corneal
procedures penetrating keratoplasty (PKP) and lamellar keratoplasty (LKP),
femtosecond-laser assisted endothelial keratoplasty (FLEK), tunnels for
corneal ring implantation along with arcuate cuts for astigmatic keratotomy.
The clinical outcomes of performing the different procedures with the
femtosecond laser will be assessed.
results Experience with this femtosecond laser system has demonstrated
that it is capable of delivering a wide range of procedures including
predictable LASIK flap making capabilities and the intrastromal treatment of
presbyopia. Early clinical experience using the new laser refractive cataract
surgery procedure indicates the laser produced more predictable, circular
and reproducible capsulotomies than manual. The phaco energy may also
be reduced when fragmentation is done with the femtosecond laser versus
manually.
conclusion This single femtosecond laser platform is able to safely perform
multiple procedures, with the potential to provide more accurate and
reproducible clinical outcomes. Financial Disclosure:
81
s
act
r
t
bs
ABO
A
-
BOV
3010
3011
Methods of assessement
Etiology
BUYCK A
Visuele revalidatie De Markgrave, Antwerpen
BOSCHI A
Cliniques Universitaires St Luc, Bruxelles
The choice of visual field examination depend on the patient and the
purpose of the examination. Every visual field test require the cooperation
of the patient. The most primitive test is the confrontation field test. The
Amsler grid is often used in daily practice and evaluates quickly the central
10° of vision. The Goldmann perimeter is an important tool in the low vision
clinic. The results of the kinetic perimetry translate the quality of functional
vision: V/4,V/1,III/1,II/1. Each isopter has its significance. Finally we focus on
automated static, computer-assisted perimetry that allow detailed analysis
of the visual field.
purpose Review the different types of visual field defect and the different
methods of visual field evaluation. The clinical features allowing localization
of the visual field defect along the visual pathway will be described. The
different etiology will be discussed.
methods Presentations of clinical cases
results In general, the visual abnormalities caused by lesions anterior to
and including the chiasm cause acuity loss, color deficits, and visual field
defects (abnormal central and peripheral vision). Unilateral retrochiasmal
(posterior to the chiasm) lesions present primarily with homonymous visual
field defects without visual loss. But, interpretation of visual images might
also be disturbed, when extrastriate association cortex and induce object
recognition, color perception, motion detection, and visual attention
conclusion Visual field testing is the corner stone of the clinical evaluation
in any patient with visual complains.Adequate interpretation of the visual
field defects and visual complains is essential for management of patient
with visual abnormalities
3013
3014
Strabismus and hemianopia
Visual field defects and fusion
VAN WAVEREN
Department for Ophthalmology, University Clinic Tübingen, Department
for Strabismus, Periocular Surg, Tuebingen
VAN LAMMEREN M
Leuven
purpose Homonymous hemianopia leads to a severe disturbance of
visual orientation under binocular conditions. In contrast patients with
bitemporal hemianopia binocularity show a normal visual orientation except
a hemifield-slide phenomenon is present.
methods Visual field defects and strabismus can prove to be a difficult
combination. In some cases binocular visual fields can possibly be enlarged
or reduced by the squint.A simulation of different visual field defects will
show the effects of strabismus (eso-, exotropia). The simulation will also
show the effect of eye muscle surgery in these cases.
results Although expecting that a visual field loss and an additional
strabismus will lead to a more pronounced disturbance of vision, rarely
a strabismus may even compensate the visual field defect. In these cases
strabismus surgery is not recommendable.
In patients with visual field defects, the defective function of specific
retinal areas may compromise the fusional potential. The relative impact
upon binocular functions will depend upon the presence or absence of
“overlap” of the functioning retinal areas in each eye.The best known and
most extreme examples are- homonymous hemianopia, with a more or less
full “overlap” of the functional areas, resulting in a fairly stable binocular
status; - bitemporal hemianopia, where preciously few if any corresponding
retinal cells are preserved.Binocular complaints may vary and are not always
easy to interpret. Permanent or intermittent diplopia may occur, but many
patients have other complaints, for instance confusion, unstable vision,
...Orthoptic examination can be challenging: the presence of visual field
defects - in some instances associated with diminished visual acuity in one
or both eyes - and the various and sometimes atypical complaints ask for a
creative approach. We present clinical examples to illustrate these problems
and discuss some treatment options for these difficult to manage patients.
conclusion Before a strabotomy it is necessary to know if there is a visual
field defect.
82
ts
ac
str
Ab
O
-AB
BOV
3015
3016
Rehabilitation in hemianopia
Cerebral tumor and visual field deficit; orthoptics
as a tool- case report
COECKELBERGH T
Universitair Ziekenhuis Antwerpen, i.s.m. Vlaams Oogpunt Antwerpen,
Edegem
purpose A saccadic compensation training program (Tant et al., 2002;
Pizzamiglio et al., 1992) was developed to improve the visual scanning
pattern in hemianopic patients.
methods The program aims at making large and fast eye movements into
the blind hemifield in order to create a quick overview of the entire visual
field. They should be frequent in order to anticipate new events. The
program uses a fixed stimulus presentation to allow patients to program
their saccades accurately. Predictability is gradually decreased.
results Four out of seven patients who completed the program subsequently
passed an on-road driving test. Two patients failed the driving test and one
subject was referred for a second evaluation.
conclusion The program seems to be a promising tool to train compensatory
viewing strategies in patients with hemianpia. Further research is needed.
FRITZ L
Amis des Aveugles et Malvoyants, Mons
purpose To describe the functional impact of a deficit of the peripheral
field of vision. 2) To demonstrate the consequences of the visual handicap
which shouldn’t be underestimated. 3) To underline the importance of the
rehabilitation with outcome results regarding quality of life and autonomy.
methods Presentation of a clinical case, illustrating the orthoptic
re-education in the Center of Functional Re-education. The orthoptic
re-education is a visual training to optimize the functional visual capacities
by the optimal use of the residual field of vision.
results At the end of the orthoptic examination, the project of re-education
which is defined together with the patient, determines the various
fields of action of the orthoptic re-education. In the presented case, the
objective was to be autonomous in a supermarket. We demonstrate how
a programmed perceptual-motor rehabilitation restored gaze control and
prepared the intervention of the other therapists (instructors in locomotion,
occupational therapists...).
conclusion By the objectification of the consequences of the deficit on
functional vision, the orthoptist often helps in the recognition of the visual
handicap which is too often underestimated. Besides, by the use of the
residual potential and the optimization of the visual efficiency, he favors the
autonomy and the quality of life of the visual deficient person, limits the
negative impact of the severe low vision to daily life (risks of falls, disorders
of equilibrium) and favors the well-being of the persons who restore selfconfidence in their visual capacity.
3018
Complementarity of the neuropsychologic and the
orthoptic approach to visual field defects
LEPUITS G (1), STREEL C (2)
(1) Centre de la mémoire et de l’attention, Liège
(2) Centre de rééducation fonctionnelle, Liège
Cognitive impairements – attentionnal, executive and memory deficits – can
hinder the set up of compensation strategies for visual deficits learned in
the orthoptic approach. Visual perception in case of visual field defects is
expensive in terms of attentionnal ressources, which are no more available
for complex treatment of visual information. Executive deficits – inhibition,
planning, anosognosia – reduce the awareness of deficits and hold up the
spontaneous use of compensation strategies. Identifying these cognitive
impairements, evaluating them through a neuropsychologic assessment
and rehabilitating them with the neuropsychologic approach allow a
cognitive improvement, with better learning capacities of the compensation
strategies as learned in the orthoptic approach, and a shift of such strategies
in everyday life.
83
s
act
r
t
bs
BPC
A
B-O
BVV
3036
3037
Depression among visually impaired older adults:
an underestimated problem
Multidisciplinary reeducation: an open door on
everyday life reality
VAN NISPEN RMA
Licht en Liefde
JOURDAN C
La Lumière
purpose Depression in visually impaired older adults is still an
underestimated problem which may lead to undesirable rehabilitation
outcomes. The aim was to investigate prevalence, severity and associated
factors for depression.
The patients taking in care within our functional reeducation center
aims at the autonomy and at an adapted response to the needs of
the visually impaired persons. The acquisition of autonomy enables an
integration in the everyday, family, social, scholastic and professionnal life.
The multipluridisciplinary intervention, which is our functional rehabilitation
center specialty, is adapted according to each individual particularities, his/
her own pathology, his/her age, capacities and needs.It is by the means of
a clinical case that we propose to you to discover our « technicity » and
professional approaches. We will enter upon the evaluation and research of
optical aids, orthoptie, colored filters tests, the lighting improvements and
place of residence arrangements, the technical aids, computing, mobility
and orientation work, Braille, and the social and psychological support.
Our goal is to bring the visually impaired person to reinvest in the world
of the seeing persons, to enable him /her to live his/her handicap the most
harmoniously possible, remaining nethertheless aware of all the difficulties
he/she will come up against.
methods In a cross-sectional design, older adults who enrolled in outpatient
Belgian and Dutch rehabilitation centres (Blindenzorg Licht en Liefde, Royal
Dutch Visio, Bartiméus) participated in semi-structured interviews in their
own homes. Besides depression (CES-D; diagnostic interview: CIDI), other
health indicators and socio-demographic variables were investigated.
Results were formally discussed with psychologists and social workers to find
possibilities for improvement in care and referral pathways.
results Clinically significant depressive symptoms were found in 29%,
and 7% was diagnosed with a depressive disorder according to DSM-IV
(N=274). Women experienced more depressive symptoms. More problems
with activities of daily living, mobility, adaptation to vision loss and
coping resulted in a less favourable CES-D score. An integrated approach,
screening, offering support groups, and monitoring were suggested as
possibilities to improve care.
conclusion In outpatient centres, there is a large group of visually impaired
older adults with severe psychosocial problems. Since having symptoms
is the most important predictor of developing a full-blown disorder, we
recommend outpatient centres to increase their focus on this topic. A
depression protocol may prevent clients with mild symptoms to develop
a depressive disorder, and will enable adequate referral of clients with
disorders. In a new international study (starting 2012) with Blindenzorg
Licht en Liefde, Visio and Bartiméus we will develop and test a steppedcare protocol.
3038
3039
Therapeutic intervention on Activities of Daily
Living : effects on quality of life
Apprehension of the place of life by the elderly
person after a fall of vision
HAMAIDE S, DEMARTIN S
Amis des Aveugles et Malvoyants
HOENRAET D, GOLINVAUX D
Oeuvre Nationale des Aveugles
purpose The aim is to illustrate the actions of reeducation, in the field of
the Activities of Daily Living and their impact on the quality of life of visually
impaired persons for whom no improvement of the ophthalmological
situation is possible from a medical point of view.
The study of the life day labourer of the elderly people reached of one
deficient vision is articulated on the general problems of the management
of the loss of autonomy and the deconstruction/rebuilding of an identity
disturbed by the appearance or the stressing of a visual deficiency.The
universe of the people reached of this affection lets appear a total system of
assumption of responsibility made up of the medical community, specialists
in the low vision and professionals of the assumption of responsibility
of the elderly people. Lived of the people reached follows a route which
can be cut out in three great social processes, psychic and material.The
first process describes the medical course of the people cantered on the
therapeutic practices of search for recourse. The second rebuilt the psychic
way according to lived more intimate of the person. The third recalls the
transformation of the management of the daily newspaper on the relational
and material level because of loss of vision.The talk that we propose, recalls
in the broad outlines the difficulties encountered by the elderly people
reached of one deficient vision, as well as the solutions which we could
bring within the framework of our service of social accompaniment: that of
the ONA.The testimony of our assistant to the life day labourer opens real
practical solutions in order to reduce the weight of the visual handicap and
to open the person with the maintenance of her autonomy in residence.
methods The therapeutic interventions to improve the autonomy of
the persons in diverse activities such as personal hygiene and grooming,
dressing, self-feeding, housework, shopping, meal preparation, medication
taking, money managing, access to leisure activities, will be illustrated
through case studies. At the same time, the results of a questionnaire
specifically created to estimate the quality of life in connection with the
functional reeducation will be presented.
results The obtained results demonstrate that the reeducation activities
allow to decrease the impact of a low vision pathology on the Activities of
Daily Living and to increase the level of quality of life.
conclusion When a severe visual pathology settles down and when the
medical profession is helpless, the functional re-education turns out to
be a solution allowing to limit the functional consequences of the visual
handicap and, so, to improve the autonomy and the quality of life of blind
and partially-sighted persons.
84
ac
tr
s
b
A
te
os
P
s
t
on
ssi
e
s
r
s
act
r
t
bs
sion
A
es
er s
t
Pos
P101
P102
From paediatrics to reversible presbyopia surgery
to silicone oiled eyes: the wonderful world of
supplemental IOL use
La dégénérescence astéroïde du vitré chez les
patients Congolais
CLAOUE DE GOHR CMP
Ophtalmology, Queen’s Hospital, London
purpose To educate the audience about the scope of supplemental IOL use.
methods Classification os surgery into primary vs. secondary, permanent
vs. temporary allows the practitioner to understand the situations where
supplemental IOLs can be used to help patients.
results Modern supplemental IOLs are not just “piggy back IOLs” but a
radical new platform. This safer technology opens a variety of uses that have
not previously been recognised.
conclusion An understanding of the IOL platform of modern supplemental
IOLs together with a conceptual classification of surgery allows
ophthalmologists to appreciate the wide range of situations where
supplemental IOLs may help patients.
KAIMBO WA KAIMBO D
Université de Kinshasa, Kinshasa
purpose Déterminer la fréquence relative ainsi que les caractéristiques
cliniques de la dégénérescence astéroïde(DA) chez les patients Congolais.
methods Une étude transversale et descriptive des patients avec le
diagnostic de la DA du vitré a été réalisée dans une clinique d’ophtalmologie
générale de janvier 2005 à août 2012. Tous les patients d’âge ≥ 40 ans
ont été inclus et chaque patient a subi un examen ophtalmologique de
routin. Le diagnostic de la DA a été basé sur l’examen biomicroscopique et
l’ophtalmoscopie indirecte.
results Durant la période d’étude, 7721 patients âgés de ≥ 40 ans ont
été examinés et 18 patients (20 yeux) avaient un diagnostic de DA, ce qui
donne une fréquence relative de 0,23%. L’âge moyen des patients a été
de 61,33 ans±10. La répartition en fonction du sexe a été la suivante : 15
hommes (83%) et 3 femmes (17%). La fréquence de la DA a montré une
tendance à augmenter avec l’âge passant de 0,09% dans le groupe de 40
à 49 ans à 0,45% dans celui de plus de 70 ans (P < 0.05). La fréquence
de la DA a été plus élevée chez l’homme (0,35%) que chez la femme
(0,09%). L’atteinte unilatérale a été la plus fréquente (80%). Le diabète
sucré, l’hypertension artérielle, la goutte et le cancer de la prostate ont été
retrouvés respectivement chez 33,3%, 33,3%, 5,6% et 5,6% des patients.
La cataracte et le glaucome ont été retrouvés respectivement chez 44,4%
et 22,2% des patients.
conclusion La fréquence relative de la DA rapportée dans cette étude
de 0,23% est inférieure à celle rapportée dans des études antérieures et
confirme la rareté relative de cette pathologie.
P103
P104
Syndromic Congenital Aplasia of Iris Sphincter
Additional Loop suspension over anteroposition
or recession of the inferior oblique muscle
to resolve vertical incomitence in V pattern
strabismus.
ROULEZ FM (1), FAES F (2), VERHEULPEN D (3), WERMENBOL V (3),
DE ZAEYTIJD J (4), DEPASSE F (5), DELBEKE P (4), COUCKE PJ (6),
MEIRE FM (7)
(1) Department of pediatric ophthalmology, HUDERF, ULB , Brussels / Sierre
(2) Department of neuropediatry, Ghent University , Ghent
(3) Department of neuropediatry Erasme, ULB , Brussels
(4) Department of ophthalmology, Ghent University , Ghent
(5) Department of ophthalmology, Erasme ULB, Brussels
(6) Department of medical genetics, Ghent University, Ghent
(7) Department of pediatric ophthalmology, HUDERF, ULB , Brussels
purpose Congenital mydriasis, sometimes referred as fixed dilated pupils,
is characterized by aplasia of the iris sphincter muscle. Iris morphology
is pathognomonic, with absence of iris between collarette and pupillary
border resulting in a scalloped pupillary margin. This developmental
anomaly has sometimes been misdiagnosed as aniridia.
methods We describe ophthalmological manifestations in 2 patients
with congenital mydriasis and multisystemic smooth muscle dysfunction
associated with R179H mutation in the ACTA2 gene.
results Congenital mydriasis has been reported in a multisystemic smooth
muscle dysfunction syndrome with congenital patent ductus arteriosus,
cerebrovascular disease (Moya-moya,) coronary artery disease and thoracic
aorta aneurysm and dysfunction of smooth muscle cells in organs
throughout the body. All reported affected individuals carry a R179H
heterozygous mutation in the ACTA2 gene.
conclusion Congenital mydriasis is a rare condition whose presence should
alert pediatric ophthalmologists to the possibility of the co-existence of
systemic life treating disorder.
86
SSELLIER J, PUTTEMEN A, VAN DAELE O
CHU Saint-Pierre, Bruxelles
purpose The current techniques to correct the V pattern strabismus remain
unsatisfactory when the inferior oblique overaction (IOOA) is significant.
We share a novel technique to resolve vertical incomitence by adding a
loop suspension to either anteriortransposition or recession of the inferior
oblique muscle, in order to correct vertical incomitnece while avoiding
recession of the contralateral inferior rectus.
methods We present patients with asymetrical lateral gaze incomitences
.The IOOA was quantified by measuring the amount of hypertropia in
lateral gaze. The surgical technique consisted of a 5 mm loop suspension
to the recession or the anteriortransposition of the inferior oblique muscle
on the side where the upshoot is more important, compared to the classic
recession or anteriortransposition to the other eye, when necessary.
results
The patient satisfaction was ranked high at 6 months
postoperatively. No complications were reported in this series.
conclusion The additional 5 mm loop Suspension to either the
anteriortransposition or recession of the inferior oblique muscle in V
pattern Strabismus is a reliable technique to weaken the IOOA. It insures a
satisfactory result with a considerable gain on lateral gaze, circumventing
surgery to the other muscles. It has nonetheless little benefits for primary
gaze with a net gain of only 0 to 2 degrees
cts
a
r
st
on
Ab
essi
s
ster
po
P105
P106
Spectral domain optical coherence tomography
findings in posterior scleritis associated
chorioretinal folds : report of 3 cases
Visual acuity and factors influencing automobile
driving status in 1000 patients age 60 and older
ROSAPELLY B (1), WILLERMAIN F (1), CASPERS L (1), EL OUARDIGHI H (1),
DAGUZAN M (1), POSTELMANS L (2)
(1) CHU Saint Pierre, Bruxelles
(2) CHU Brugmann, Bruxelles
purpose To describe the Spectral Domain Optical Coherence Tomography
(SD-OCT) findings in posterior scleritis associated chorioretinal folds
methods Case reports of three eyes of three patients who came
in emergency in University hospitals (CHU St Pierre, CHU Brugmann,
Brussels Belgium). Fundus examination of the three eyes showed papillary
edema, retinal folds and choroidal folds. A diagnosis of posterior scleritis
was confirmed by B mode echography. A standard systemic work up
was initiated and fluorescein angiography and SD-OCT were performed
(Spectralis , Heidelberg in case 1) (RTVue, Optovue in cases 2 and 3).
results The first case was compatible with an incomplete connectivitis,
the other cases were idiopathic. SD-OCT findings were similar in the three
cases and revealed the presence of 2 types of folds: one at the level of the
nerve fiber layer of the retina and one at the level of the Bruch’s membrane.
These folds are different because the first has a small wavelength and the
second has a bigger wavelength. In the three eyes, symptoms and signs
dramatically improved after oral steroids treatment and SD-OCT images
returned to normal.
conclusion SD-OCT has allowed us to provide details on the pathology of
posterior scleritis associated chorioretinal folds. Pictures appear relatively
distinct from folds of other origin, because they involve 2 structures with
different wavelengths between the 2 folds. SD-OCT thus can be useful for
the diagnosis and the follow up of mild posterior scleritis.
MARINESCU C (1), LEVECQ L (1), DE POTTER P (2), JAMART J (1)
(1) CHU Mont-Godinne, Yvoir
(2) CHU St-Luc, Bruxelles
purpose To evaluate the number of people driving in accordance with
common legal standards, measured through far binocular visual acuity and
to identify variables associated with non-legal driving habits.
methods Subjects aged of 60 years and older were recruited at a tertiary
referral center.We measured visual acuity on each eye and far binocular visual
acuity. Driving criterias were defined as far binocular visual acuity equal or
better than 20/40, according to the European legal driving requirements.
Socioeconomic informations were obtained by questionnaires.
results 1000 subjects were enrolled in the study during seven months
(mean age: 71.3 years), of whom 810 were current drivers. Among the
810 current drivers, 732 (90.4%) had a far binocular visual acuity equal
or better than 20/40, and 78 (9.6%) did not. Among the 190 non-drivers,
94 (49.5%) never drove; 47 (24.7%) had stopped driving because of their
impaired vision; and 49 (25.8%) had stopped driving for other reasons.
A logistic regression was performed to identify the variables statistically
associated with the practice of driving without minimal visual requirements
among licensed drivers, which revealed that a non-recent ophthalmological
examination (p<0.001), the subject’s non-perception of impaired vision
(p= 0.001) and non-access to stores without a car (p<0.001) were
influencing factors.
conclusion 81% of our subjects aged 60 years and older were still driving,
of whom 10% did not meet the European legal driving requirements set
at equal or better than 20/40. The variables associated with driving status
were the time of last examination, non-perception of visual impairment and
limited access to stores without a car.
P107
P108
Ophtalmological analysis of a nephropathic
cystinosis with Confocal Microscopy
Clinical outcome of hypertensive uveitis: a
comparaison of viral and non viral causes.
SILBERBERG D (1), VANDERPERREN B (2), KALLAY O (1), SCHROOYEN M (1)
(1) Hôpital ULB Erasme, Bruxelles
(2) hôpital de Jolimont, La Louvière
LEWKOWICZ D (1,2), WILLERMAIN F (2), JUDICE L (2),
MAKHOUL D (2), JANSSENS S (1), JANSSENS X (1), CASPERS L (1)
(1) CHU saint-Pierre
purpose To document the interest of using Confocal Microscopy for the
diagnosis and for the follow up of patients with nephropathic cystinosis
methods Cystinosis is a genetic disorder that typically follows an autosomal
recessive inheritance pattern. It is a lysosomal storage disease characterized
by the abnormal accumulation of the amino acid cystin within cells, forming
crystals than can damage the cells.These crystals have a negative impact
on many systems in the body, especially on the kidneys and the eyes.A
15-year-old boy was referred to our department for evaluation of an
asymptomatic bilateral corneal anomaly. This patient seemed to have a lateonset nephropathic cystinosis, which is a rare presentation of the disease.
It was diagnosed upon observation of typical crystals in his corneas and a
story of albuminuria. He didn’t have any sign of renal failure at this time.We
studied the ophtalmological presentation of this disease and we analysed
the corneal deposits of cystin with anterior segment pictures and the use
of Confocal Microscopy
results Disseminated punctuate deposits were visible bilaterally with Slitlamp examination. Confocal microscopy demonstrated randomly oriented
crystals in many corneal layers which could be quantified and localised in
the depth of the corneas.
conclusion Late-onset nephropathic cystinosis is a rare presentation of the
disease. Confocal microscopy is a very useful tool to diagnose and make the
follow-up of patients with nephropathic cystinosis.
purpose To review the clinical outcome of our series of patients with
hypertensive uveitis.
methods We performed a systematic database search of patients with
uveitis who presented at least one intraocular pressure (IOP) > 25 mmHg.
Each patient was classified according to clinical presentation, etiology,
first IOP at presentation of uveitis, first elevated IOP, maximal IOP, IOP
at 3 months, 1 year and at last visit; time before first elevated IOP, need
of surgery and apparition of glaucoma. The categories of etiologies are
composed as such: viral and non-viral causes.
results 65 patients met the inclusion criteria. Different infectious and non
infectious causes were found and were grouped in viral (N= 24/36.9%)
and non viral uveitis (N= 41/63.1%). We found that patients with viral
uveitis have a significant higher maximal IOP (40.63 mmHg) than patients
in non viral group (34.37 mm Hg) (p= 0, 012). IOP at other times were not
significantly different. Viral hypertensive uveitis were always unilateral as
compared to non viral uveitis, 0(0%) vs 11(25%), and this difference was
statistically significant (p= 0.005).IOP could be successfully lowered in most
of the patients (95.1% & 95.8%) in both groups. The incidence of glaucoma
was higher in non viral group, 13(32.5%) vs 4(16%) in the viral group.
However this difference was no reaching significance (p= 0,237).
conclusion We found that patients with a viral hypertensive uveitis have
a higher maximal IOP and were more frequently unilateral compared to
non viral causes. IOP could be lowered in most of patients in both groups.
However glaucoma develops in a significant proportion in both groups.
87
s
act
r
t
bs
sion
A
es
er s
t
Pos
P109
P110
Clinical features in diabetic macular edema
Long Follow Up of Juvenile Idiopathic Arthritis
Associated Uveitis
RABEUX E, GUAGNINI AP
Université Catholique de Louvain, Bruxelles
purpose To evaluate the clinical signs of diabetic macular edema (DME)
in patients with rapid glycemic control (RGC) compared to other patients
presenting DME (no RGC).
methods Retrospective non randomized study of 25 diabetic patients
presenting with DME. Color photographs and fluorescein angiographies
were reviewed. Spectral domein OCT (HRA) was analyzed with subanalysis
of macular thickness and mearements of the inner and outer plexiform
layers.
results The mean age of patients was 58.4 y-o in the RGC group and 63.8
y-o in the non RGC group. The mean glycated hemoglobin’s value was
significantly more important in the RGC group (p<0.00044). The mean
foveolar and overall macular thickness were significantly more important in
the RGC group (p<0.017 to p<0.038). The central and nasal thickness of
the internal plexiform layer were significantly more important in the RGC
group (p<0.26). The central thickness of the external plexiform layer was
significantly more impotant in the no RGC group (p<0.02). Concerning the
presence of subretinal fluid and other fundus clinical signs, there were no
statistical differences between the 2 groups but there seems to be more
association wtih subretinal fluid in the RGC group and more association
with important hard exsudates in the no RGC group.
conclusion Diabetic patients with rapid glycemic control seem to be
younger. They have an increased overall macular thickness associated with
a more important swelling in the central and nasal internal plexiform layer.
LEYS E (1), BALIKOVA I (2), VAN BOL L (3), JANSSENS X (1), PASTEELS B (4),
CARION T (5), WILLERMAIN F (1), FERSTER A (6), LÊ PQ (6), CASPERS L (1)
(1) CHU Saint-Pierre, Brussels
(2) CHU Saint-Pierre - HUDERF, Brussels
(3) Erasme, Brussels
(5) Verviers
(6) HUDERF, Brussels
purpose To evaluate treatment and outcome of patients with juvenile
idiopathic arthritis (JIA)-associated uveitis.
methods Retrospective chart review of 18 cases (aged between 1 and 16
years at diagnosis) of JIA associated uveitis. Collected data was: gender,
age at diagnosis (uveitis and arthritis), follow up duration, arthritis subtype,
ANA positivity, treatment, complications and visual acuity (initial and final).
results Eighteen patients (14 F) were included, 11 with oligoarticular
subtype, 12 positive for ANA. Mean age of JIA related arthritis, uveitis and
at end follow up were respectively 3.13, 3.9 and 19 years. Mean follow
up duration was 10.6 years. All had systemic steroids. Fifteen patients
took immunomodulatory drugs, 11 took anti-TNF alpha. Eight patients
had a final VA <20/40 at least in 1 eye. Cataract was noted in all but 2
patients. Elevated IOP occurred in 14 and hypotony in 7 cases. Retina
detached in 4 patients. Inactivity was noted in 10 patients with ongoing
immunomodulatory drugs and in 3 with only topical steroids at the last
follow up. Steroid side effects were potentially reversible.
conclusion JIA associated uveitis treatment remains challenging, ocular
morbidity lasting well into adulthood. Drug associations were useful to
decrease dosage and severe drug-related side effects.
P111
P112
Cryptic chromosomal deletions and duplications as
a cause of congenital eye malformations
Reduction of macular cysts after treatment with
topical Dorzolamide in X-Linked Retinoschisis:
A case report
BALIKOVA I (1), DE RAVEL T (2), AYUSO C (3), CASTEELS I (4), FRYNS JP (2),
VERMEESCH JR (2)
(1) Departement of Ophthalmology CHU St Pierre, Brussels
(2) Centre for Human Genetics, Leuven
(3) Fundación Jyménes Díaz, Madrid, Spain
(4) Department of Ophthalmology, Leuven
purpose Congenital ocular malformations (COM) are a frequent cause of
childhood blindness. Mutations in a variety of genes known to be involved
in the development of the eye can underlie COM. However, a large number
of patients remains without a molecular diagnosis. Large chromosomal
aberrations such as trisomies 13 and 18 are known to cause a variety of eye
anomalies, such as microphtalmia, anophtalmia and coloboma. Such large
aberrations are cytogenetically detectable using metaphase chromosome
spreads. The purpose of the current study was to investigate the role of
smaller chromosomal deletions and duplications in the etiology of COM.
methods We applied Agilent 244K oligoarray copy number profiling
platform for the analysis of patients with various idiopathic COM. The
resolution of this platform is 100-fold higher than what can be achieved
using metaphase spreads.
results We analyzed 38 patients and identified causal deletions in 5 patients
(13%). Most of these deletions affected known genes (OTX2, PAX6, FOXC1
and COH1) but were found in patients with atypical presentations, thus
broadening the phenotypic spectrum associated with mutations in these
genes. Deletions were not enriched in any class of COM.
VAN BOL L, DEPASSE F, CORDONNIER M
Erasme, Bruxelles
purpose To document the effects of Dorzolamide treatment on a 4 year
old boy with X-linked retinoschisis (XLRS) by optical coherence tomography.
methods XLRS is an inherited retinal disease which affects young boys.
It is characterized by bilateral cystoid macular changes and a peripheriral
retinoschisis in 50% of patients. During a number of decades, the ERG was
the best diagnostic tool, showing a marked decrease in amplitude of the
b-wave with a normal a-wave on scotopic and photopic testings. However,
the recent use of the optical coherence tomography has allowed an easier
follow-up of maculopathy. Overall, molecular research of mutations
provides the final confirmation.
results We report a significant reduction of macular cysts after a few
months of local instillation of Dorzolamide.
conclusion XLRS is one of the most frequent cause of early-onset macular
degeneration in males. No successful treatment has yet been reported and
the ophthalmologist was for a long time limited to the prescription of low
vision aids and surgical management of complications such as vitreous
hemorrhage and retinal detachement. Although gene therapy in mice led
to promising results by restoring retinal function, further studies are still
required. Nevertheless, recent studies show a significant reduction of the
macular schisis when applying carbonic anhydrase inhibitor locally. Our case
report illustrates this statement.
conclusion Our findings clearly demonstrate that hitherto cryptic
deletions and duplications contribute to the etiology of a variety of ocular
developmental defects, and that diagnostic methods allowing high
resolution analysis of chromosomal copy number changes improve the
diagnosis of the patients with congenital eye anomalies.
88
cts
a
r
st
on
Ab
essi
s
ster
po
P113
P114
Retrospective study of syphilitic uveitis in a cohort
of patients from CHU Saint-Pierre, Brussels
Monofocale centrale chorioretinopathie bij ChurgStrauss syndroom : een case report
LHOIR S (1), MAKHOUL D (2), LIBOIS A (3), CASPERS L (3), WILLERMAIN F (1)
(1) CHU Saint Pierre/ Brugmann, ULB, Bruxelles
(2) CHU Saint Pierre/ Brugmann, Bruxelles
(3) CHU Saint Pierre, Bruxelles
OEHRENS AM (1), GOETHAELS S (2), VAN CALSTER J (2)
(1) Prive praktijk , Korbeek-Lo
purpose Description of the clinical presentation and outcome of patients
with syphilitic uveitis.
methods Retrospective study of 11 patients with ocular syphilis seen in our
centre between 2003 and 2012. The diagnosis of syphilitic uveitis was based
on clinical evidence of intraocular inflammation not attributable to other
causes and positive serology for syphilis (treponemal and non treponemal
tests). Following data were recorded: age, gender, HIV status, CD4 cell
count in AIDS patients, ocular manifestations, serum and cerebrospinal fluid
(CSF) analysis, treatment and ocular sequelae.
results 15 eyes of 11 patients (10 men, 1woman) were included. Mean
age at diagnosis was 36 year. Risk factors were identified in 7 cases:
homosexuality in 6, drug abuse in 1. 45% were seropositive for HIV-1 with
a mean CD4 cell counts of 567.6 cells/mm³. We found 8 posterior uveitis,
3 papillitis, 4 panuveitis. Ten patients had CSF analysis and 7 of them had
pleiocytosis. All were treated with IV antibiotics. Final ocular presentations
were normalization (4/11), retinal atrophy (5/11), salt and pepper retina
(3/11), epiretinal membrane (1/11), cystoid macular oedema (1/11) and
diffuse capillaropathy (1/11).
conclusion In our series, syphilitic uveitis was found in healthy patients
and HIV homosexual men with an over all good CD4 cell count. Clinical
presentation was not specific but more than 50% had posterior uveitis. CSF
analysis was negative in 33% of cases, suggesting that uveitis is not always
concomitant with a neurosyphilis. IV treatment is effective but sequelae can
occur in some patients.
purpose Case rapportering van centrale chorioretinopathie bij en patient
met antecedenten van Churg-Strauss syndroom
methods Onderzoek van de oogmanifestaties bij Churg-Strauss syndroom
en beschrijving van de klinische bevindingen en behandeling bij deze casus.
results Een vrouw van 40 jaar consulteerde wegens visus daling en
metamorfopsiën aan het rechter oog. Zij was gekend met ChurgStrauss syndroom sinds meer dan 10 jaar .Op fundus was een centrale
chorioretinopathie zonder tekens van lekkage bij de fluoangiografie.
De patiënte werd gedurende 3 maanden opgevolgd met oogfundus
onderzoek, fluoangiografie en OCT. Na 3 maanden was de visus scherpte
gedaald van 0.7 tot 0.1. Op fundus en fluoangiografie was er een discrete
toename van het letsel, met minimale laattijdige lekkage. De OCT toonde
een verdikking van de externe retinale lagen. Na drie intravitreale injecties
van bevacizumab met telkens één maand interval was er een gedeeltelijke
visus recuperatie.
conclusion Deze oogcomplicatie, kan een ongewone presentatie zijn in
het kader van een Churg-Strauss syndroom (allergische granulomateuze
angiitis). Choroïdale neovascularisatie is
aangetoond met OCT.
Anatomopathologisch onderzoek is hier niet mogelijk.
Anti-VEGF
intravitreale injecties (bevacizumab) was doeltreffend voor de behandeling.
P115
P117
Retinal oxygen metabolism in healthy subjects
and glaucoma patients
Flanders and The Netherlands: two different
worlds.
VANDEWALLE E (1), OLAFSDOTTIR OB (2), PINTO LA (3), STALMANS P (1),
VAN CALSTER J (1), ZEYEN T (1), STEFáNSSON E (2), STALMANS I (1)
(1) UZLeuven, Leuven
(2) University of Iceland, Reykjavik
(3) Lisbon University, Lisbon
purpose To study the role of ischemia/hypoxia in the pathophysiology of
glaucoma in a prospective, clinical trial.
methods This was a 2 centre study where retinal vessel oxygen saturation
was measured in glaucoma patients and healthy individuals with a noninvasive spectrophotometric retinal oximeter. Visual fields were obtained in
the glaucoma patients. Statistical analysis was performed using a Student’s
t-test.
results No statistical difference was found in retinal oxygen saturation
in arterioles (p= 0.16), in venules (p= 0.12) and arteriovenous difference
(AV) (p= 0.39) whenglaucoma patients (n=74) were compared to healthy
individuals (n=89). However, when patients with advanced glaucoma
(visual field mean defect (MD -10dB, n=21) were compared to healthy
individuals, the oxygen saturation in venules was higher (58%±5% vs.
54%±6%; p= 0.005, mean ± standard deviation (SD)) and the AV difference
was lower (36±5% vs. 40%±6%; p= 0.02). In glaucoma patients with mild
glaucoma (MD -5dB, n=33), compared to healthy individuals, no statistical
differences were found in retinal oxygen saturation (p= 0.26-0.99).
MISSOTTEN G (1), SPILEERS W (1), DE KEIZER RJW (2)
(1) Katholieke Universiteit Leuven, Leuven
(2) Universiteit Antwerpen, Antwerpen
purpose To investigate the correlation between iris color and the incidence
of conjunctival melanoma. In skin and uveal melanoma there are some
reports on a correlation between skin type, iris color and melanoma. This
study investigate the correlation between iris color and melanoma of the
conjunctiva.
methods The iris color of 62 conjunctival melanoma patients diagnosed
at Leiden University and of 5 conjunctival melanoma patients of Antwerp
University were compared with 500 control persons in Leiden and 100
control persons of Antwerp and Leuven University.
results The iris color differs between the Flemish and Dutch population.
There was no correlation between iris color and the incidence of conjunctival
melanoma.
conclusion This study started from the clinical observation in The
Netherlands that conjunctival melanomas mostly occur from eyes with a
blue or grey iris. In comparing with a Flemish population we can conclude
that there is no significant correlation between iris color and melanoma of
the conjunctiva, but there is a significant difference in iris color between
Flemish and Dutch people.
conclusion Glaucoma patients with severe glaucoma have higher oxygen
saturation in venules and lower AV difference in oxygen saturation
compared to healthy individuals. No difference is found between healthy
individuals and glaucoma patients with mild visual field defects. The
decreased AV difference in severe glaucoma may be related to lower oxygen
consumption resulting from tissue atrophy in the retina.
89
s
act
r
t
bs
sion
A
es
er s
t
Pos
P118
P119
Impact of a switch to preservative free
Dorzolamide-Timolol on ocular surface disease
symptoms
Case report: A patient with eyelid and anterior
orbital Myeloproliferative hypereosinophilic
syndrome
STALMANS I (1), BERDEAUX G (2), BOONS S (1), VANDEWALLE E (1)
(2) IMS HEOR, Vilvoorde
AL-SABAI N (1), DE KEIZER RJW (2), BAL T (2), DE GROOT V (2)
(1) UZ Antwerpen/ UZ Brussel, Brussel
(2) UZ Antwerpen, antwerpen
purpose To study the impact of a switch from a preserved to preservative
free dorzolamide-timolol fixed combination (Cosopt® unit dose) on ocular
surface symptoms self-reported by patients.
purpose The aim of the study is to evaluate the clinical- and histopathological
discrepancy of the inflamed eyelid/anterior orbital mass features.
methods An 8-week multi-centre, prospective, observational study
including glaucoma patients who were switched from a preserved glaucoma
eye drop drug to unpreserved dorzolamide-timolol. The Glaucoma Symptom
Scale items (GSS functional, symptom and total scores; 0 to 100, the higher
the better) were completed by patients at baseline, week 4 and 8. Pairwise
t-tests were used for changes from baseline in this interim analysis.
results The clinical picture revealed an erythemaous eyelid-skin inflamed
mass without effect on local and general antibiotic treatments. The
histopathological “diagnose was made as “chalazion material”. However
the mass was superior located from the tarsus pre- and intraseptal with
a lot of eosinophilic cell in the pathological material; where the patient
already was known with a pulmonal myoblastic hypereosinophilic disease
and treated with hydrea with the extra feature of a red face.
results 77 patients were included (66.5 years; 36% male) and 55 reached
week 8 at the time of the interim analysis. GSS total score improved from
65.1 (baseline), to 76.8 (week 4) and 79.9 (week 8; P<0.0001). Respective
baseline, week 4 and 8 average scores were 60.0, 74.6 and 78.7 (P<0.0001)
for the GSS symptom score and 72.9, 80.3 and 81.6 (P<0.006) for the GSS
functional score. All the OSD symptoms had a decrease in prevalence:
burning from 72.7% to 50.9%, tearing from 49.4% to 34.6%, dryness
feeling from 63.6% to 34.6%, itching from 54.6% to 21.8%, soreness
from 50.7% to 41.8% and foreign body sensation from 62.3% to 34.6%.
No other adverse events were spontaneously reported.
methods Case report
conclusion Knowledge of the systemic disease of a patient and the
precise location of a pathologic ophthalmic process is important to make
the definitive diagnosis. In difficult processes it is always necessary that
pathologist and ophthalmologist consulted each other and made together
the end conclusion
conclusion This observational survey demonstrated that, in daily practice,
a switch to preservative free dorzolamide-timolol fixed combination,
improves significantly patient self reported symptoms related to ocular
surface disease. All GSS scores had improved at week 4 and even more
at week 8. A final analysis on the total study patient population will be
available and presented at the OB meeting.
P120
P121
A new and standardised method to sample and
analyse vitreous samples
Distance Esotropia in the Elderly
VAN GINDERDEUREN R, VAN CALSTER J
Oogziekten, Leuven
purpose To investigate and prepare a universal protocol for sampling
and analysing vitreous material. Vitreous biopsies are difficult to handle
because of the paucity of cells, the gelatinous formation and structure
of the vitreous, the low frequency of biopsies and the burden of longduring, delicate handwork by the technician. Vitreous biopsies can be very
useful in uveitis in difficult cases and can differentiate common uveitis
from lymphoma, low-grade infectious diseases and rare causes of vitreal
opacification
methods After a standardised 23gauge vitrectomy, 50 consecutive vitreous
samples were analysed with the Cellient® tissue processor (Hologic). This
machine is a fully automatic processor from a specified container with
PreservCyt® (fixative fluid) with cells to paraffin. Cytology was compared
with fixatives Cytolyt® ( contains a mucolyticum) and Preservcyt®.
results In 96% (48 of 50 cases) sufficient material was found for diagnosis.
Cytolyt® wash was necessary in 15% of cases to prevent clotting of the
delicate tubes in the Cellient®, this procedure causes a loss of cellular
material. Immuno-histochemical stainings were equal in quality with both
preservatives. Labour hours of processing by technician was diminished by
4, compared with former, not-standardised techniques.
GODTS DJM
Universitair Ziekenhuis Antwerpen, Afdeling OOgheelkunde, Edegem
purpose To describe the clinical findings of small esodeviation with
horizontal diplopia on distance fixation, seen in elderly patients and not
associated with lateral rectus underaction or with any currently known
neurological abnormalities.
methods Eighty-five elderly patients, age 62 till 91, with permanent or
intermittent horizontal diplopia at distance were prospectively evaluated
from February 2008. Ocular alignment, fusion amplitudes and horizontal
eye movements were measured at distance and near.
results Distance esodeviation varied from 2 prism dioptres (PD) esotropia
(ET) to 18 PD ET. At near fixation, the deviation ranged from 10 PD
exophoria to 12 PD esophoria. Divergence fusional amplitude at distance
ranged from 0 PD to 10 PD while the divergence fusional amplitude at near
ranged from 2 PD to 18 PD. Horizontal ductions and versions were full in all
patients. All patients were successfully treated with prisms, ranging from 2
PD base out to 16 PD base out.
conclusion Our findings indicate that elderly patients with distance
esotropia may have a slight increase in their distance esodeviation over time,
with slow decrease of fusional divergence amplitude and with normal ocular
motility, being successfully treated with prisms for many years.
conclusion A standardised protocol for sampling and handling viteous
biopsies by a 23G vitrectomy, fixing in PreservCyt® and processing by the
Cellient® gives a superior result in morphology, number of cells, possibility
of immuno-histochemical stainings and technician labour hours. The
diagnosis can be established or confirmed in nearly all cases.
90
cts
a
r
st
on
Ab
essi
s
ster
po
P122
P123
Outcome improvement of glaucoma filtration
surgery through the effect of local rock-inhibition
on wound healing
Intravitreal bevacizumab induced uveitis: report
of 2 cases
SIJNAVE D (1), HOLLANDERS K (1), VAN BERGEN T (1), VAN DE VELDE S (1),
VANDEWALLE E (1), MOONS L (1), LEYSEN D (2), STALMANS I (1)
(1) KU Leuven, Leuven
(2) Amakem NV, Diepenbeek
purpose The aim of this study was to investigate the efficacy of a local
ROCK-inhibitor; AMA0076 (Amakem NV) for improving surgical outcome,
after glaucoma filtration surgery in a rabbit model.
methods The in vivo effects of local ROCK-inhibition were investigated
in a rabbit model of glaucoma filtration surgery (n=5 per histological
analysis group). Topical treatment with AMA0076 (study eye) and
vehicle (control eye) was administered every day 3x/day (9h/13h/17h)
from day 1 after surgery. Treatment outcome was studied by clinical
investigation (IOP; intraocular pressure, bleb area and bleb survival) as well
as immunohistological analyses for inflammation (CD45), angiogenesis
(CD31) and collagen deposition (Sirius Red) at day 3, 8 and 14 after surgery.
results Bleb survival showed no difference between treated and nontreated eyes however, there a trend (p= 0,09) can be distinguished. Topical
treatment of AMA0076 reduced inflammation on day 3 (p= 0.036) and day
8 (p= 0.044) as well as angiogenesis on day 8 (p= 0.04). There were no
differences in collagen deposition.
conclusion Targeting ROCK with a local ROCK inhibitor, AMA0076, is
efficacious in reducing inflammation and angiogenesis on several time
points in a rabbit model of glaucoma surgery. These results render ROCK an
interesting target to increase the success rate of filtration surgery and point
to potential therapeutic benefits of the local ROCK inhibitor, AMA0076.
VANDEWEYER E, SMETS RME
Universitair Ziekenhuis Antwerpen, Edegem
purpose To report 2 cases of intravitreal bevacizumab induced uveitis and
review of the literature.
methods Study of medical records and literature.
results The first patient treated for neovascular age-related macular
degeneration (nAMD), developed anterior uveitis within 12 hours following
the 5th intravitreal injection of bevacizumab (IVB). The second patient
treated for nAMD developed a hypertensive anterior uveitis within 2
hours after the 9th IVB administration. In both cases the uveitis resolved
within a week under topical prednisolone treatment. No recurrences were
noticed after repeated intravitreal ranibizumab injections (case 2).The risk
of developing uveitis after IVB is approximately 0,1%. An immunological
response to the drug or a contaminant is generally believed to be its cause.
Bevacizumab and ranibizumab are molecules with different chemical and
biological properties, between which no immunological cross reactions
have been reported yet.
Uveitis after IVB occurs within 1 day, presenting with ocular pain,
conjunctival injection, corneal edema, anterior chamber and vitreous
cells. Topical prednisolone therapy leads to complete resolution of the
inflammation within 1-2 weeks. In contrast, infectious endophthalmitis
presents 1 to 6 days after intravitreal injection and has a worse prognosis
even after adequate treatment.
conclusion Uveitis after IVB is rare, occuring within 24 hours and
responding to topical prednisolone. Relapses have not been reported after
subsequent intravitreal ranibizumab administration.
P124
P125
Nd:YAG Laser Hyaloidotomy for Premacular
Subhyaloid Haemorrhages: A Case Series
Hidden information about the macular anatomy in
the interferrometric biometry spikes
VANDEKERCKHOVE G (1), PLATTEAU E (2), VANWYNSBERGHE D (3),
DE ZAEYTIJD J (4), LEROY BP (5)
(1) Dept of Ophth, Ghent University Hospital & Ghent University, Ghent
(2) Dept of Ophth, GUH and Maria Middelares Hospital, Ghent
(3) Dept of Ophth, Maria Middelares Hospital, Ghent
(4) Dept of Ophth, GUH and GU, Ghent
(5) Dept of Ophth, GUH and GU, Ctr for Medical Genetics, Ghent
purpose Premacular subhyaloid haemorrhage may occur in retinal vascular
disorders, haematological disorders, Valsalva retinopathy or following
LASIK. Spontaneous resorption may take months and may result in
permanent visual impairment due to macular changes. Nd:YAG laser
hyaloidotomy with consequent drainage of the blood into the vitreous
cavity has been applied as an alternative in a small number of cases.
methods Four patients with unilateral premacular subhyaloid haemorrhages
due either to Valsalva retinopathy or diabetic retinopathy were treated
with Nd:YAG laser hyaloidotomy (intensity 2,5 to 9,5 mJ) focused on the
posterior hyaloid using a Goldmann 3-mirror lens. Patients were treated
within 1 to 4 weeks after first noticing visual loss.
BOECKAERT J (1), BLANCKAERT J (2)
(1) UZ Leuven dep opht, Leuven
(2) Jan Ypermanziekenhuis - UZ Leuven dep opht, Ieper - Leuven
purpose To study the retinal spikes of the interferrometric biometric
waveform in normal eyes and eyes with abnormal macular anatomy.
methods 10 normal patients and 10 patients with macular pathology are
studied. The Lenstar interferrometric biometer was used in all cases. The
retinal spikes are magnified and studied in details to depict normal retinal
spikes and abnormalities. An OCT image of the pathology will be correlated
with the retinal spike form.
results All retinal macular pathology was detected by carefull examining
and studying the retinal spike form of the Lenstar biometer. In detail analysis
will be presented.
conclusion It is possible to detect retinal macular abnormalities in the
waveform of the biometry by interferrometry.
results Two patients experienced significant recovery of vision within
minutes after the treatment. Another noticed improvement 1 week after
treatment. In one case YAG laser hyaloidotomy failed but spontaneous
resolution was achieved 3 months later. None of the 4 patients had any
complications.
conclusion Nd:YAG laser hyaloidotomy is a safe and easy alternative to
either deferral of treatment or prompt vitrectomy with drainage for recent
premacular subhyaloid bleeding. Performed on a simple outpatient basis,
it results in rapid recovery of visual function. Risks and benefits of Nd:YAG
laser treatment should be evaluated on a case by case basis.
91
s
act
r
t
bs
sion
A
es
er s
t
Pos
P126
P127
Vitrectomy with heavy oil tamponade and
peripapillary laser for serous maculopathy
secondary to optic pit: a case series
Acute welder’s maculopathy
JANSEN J, VAN CALSTER J, STALMANS P
University Hospitals Leuven, Leuven
purpose To describe the case of a 28-year-old welder who develops
bilateral phototoxic maculopathy without photokeratitis.
DEWILDE J, DEWILDE E, STALMANS P
Oogheelkunde UZLeuven, Leuven
purpose We present this technique used in our department for the repair
of serous maculopathy, secondary to optic pits. In literature there is still no
consensus regarding the best treatment of this condition.
methods Vitrectomy with heavy oil tamponade and gentle lasercoagulation
at the border of the pit was performed.
results Nine eyes of nine patients were treated, all of which achieved
anatomical success within 1 year after oil removal. Deterioration was
prevented or better visual acuity achieved in 7 of 9 patients. Visual loss
was seen in 2 patients; one related to macular hole formation, another
due to a central artery occlusion in the perioperative period. Two cases
had complications related to silicone oil emulsification;one case was
medically controlled with no glaucomatous repercussion. The other case
was refractory to medical treatment and needed anterior chamber rinsing
for removal of emulsification bubbles and developed minor glaucomatous
damage. We saw 2 late retinal detachments in the one year follow up after
oil removal; these patients needed subsequent vitrectomy, none of these
patients experienced visual loss.
conclusion A high rate of anatomical and visual success was achieved using
this technique. When used, complications of heavy oil usage should be
carefully monitored in view of its high emulsification rate. We experienced
one dramatic case of central artery occlusion. Prevention of intra- and
postoperative pressure spikes should always remain a concern in avoiding
this devastating complication.
methods The patient presented with blurred vision, one day after
performing conventional arc welding with protective gear. Visual acuity is
0.3 in both eyes. Fundus examination reveals central foveal changes with
an oval yellowish lesion. OCT demonstrates hyperreflectivity of the centre
of the fovea with disruption of the RPE and photoreceptor layers, and a
central hypofluorescent foveal lesion is visible on angiography. The patient
shows gradual visual improvement and gradual recovery on OCT starting at
the inner layers during follow-up. Five months later, the OCT image appears
normal except a small persistent RPE disruption in the right eye. Final visual
acuity recovers to 1.0 in both eyes.
results Solar retinopathy from exposure to arc welding is clinically rare
and a review of literature reveals only few similar publications correlating
clinical and OCT findings. The main components of arc welding emission
are ultraviolet (UV) , visible and infrared (IR) light. UV light is absorbed by
the cornea and the lens, visible and IR light penetrate to the retina. In this
particular case, the patient wore a protective mask which blocks UV light
and prevented corneal epithelial injury, but not the dark filter to block the
visible and IR light. In most cases, retinal injuries heal spontaneously without
permanent vision loss. Severe burns of the macula on the other hand may
lead to permanent loss of central vision.
conclusion This case illustrates the importance of wearing protective gear
against a wide spectrum of light exposure during welding, ranging from
IR to UV.
P128
P129
The effect of a local ROCK-inhibitor (AMA0076)
combined with Benzalkonium chloride on the
intraocular pressure
Glaucoma from eye to brain: are matrix
metalloproteinases (MMPs) involved?
HOLLANDERS K (1), SIJNAVE D (1), VAN BERGEN T (1), VAN DE VELDE S (1),
(1) KULeuven, Leuven
purpose To elucidate the effect of Benzalkonium chloride (BAK) on the
intraocular pressure (IOP) lowering efficacy of a local ROCK-inhibitor
AMA0076 (Amakem NV) in the rabbit eye.
methods Topical administration of AMA0076 (0.1%, 0.3% and 0.5%)
was tested in a normotensive New Zealand White rabbit model (5 rabbits/
group). The IOP lowering efficacy of the compound was determined with
or without the addition of 0.01% BAK. The contralateral eye was used as
a control and was treated with vehicle (H2O PEG) in all groups. IOP was
measured at baseline and at 1, 2, 3, 4, 5, 6, 7 and 8h post administration.
Data at individual time points were analyzed using mixed model analysis for
repeated measures. P < 0.05 was considered to be statistically significant.
results Single topical administration of AMA0076 significantly lowered
IOP in a concentration dependent manner compared to the control eye
(p<0.05). Placebo/vehicle administration did not induce significant changes
in IOP. The maximal IOP lowering effect of AMA0076 0.1%, 0.3% and
0.5% containing 0.01% BAK was 38%, 45% and 53%, which was
significantly stronger compared to their BAK-free equivalents: 21%, 28%
and 37% (p= 0.005, p=<0.001; p= 0.008 respectively).
conclusion The local ROCK inhibitor, AMA0076 was significantly more
effective in lowering IOP in the presence of 0.01% BAK.
92
DE GROEF L, DEKEYSTER E, GAUBLOMME D, MOONS L
KU Leuven, Leuven
purpose MMPs are often linked to glaucoma, however a clear definition
of their role is lacking. Moreover, glaucoma is increasingly recognized as
a disorder of ‘visual neurons’ within the eye and brain. Unraveling the
influence of glaucoma on the visual system circuitry, and the role of MMPs
herein, will help to better understand glaucoma. Here, we report on (1)
the pathological changes of the visual system; and (2) the involvement of
MMPs, during glaucoma.
methods As an in vivo mouse model of glaucoma, we used intravitreal
NMDA injections to induce apoptosis of retinal ganglion cells (RGCs).
The impact on the retina and its target areas was examined via
immunohistochemical stainings (IHC). Alterations in MMP expression/
activity were assessed via IHC and zymography.
results Excitotoxic RGC death induces loss of neurons and synaptic
connections in the retinal target areas and is accompanied by extensive glial
reactivity.In the healthy retina, MMP-2, -3, and -14 are expressed by Müller
glia. Strong MMP-14 expression is also found in RGC axons in the nerve fiber
layer, the optic nerve and the primary visual brain targets. Whereas MMP-9
is not detectable in de healthy retina, its expression increases in RGCs as
they undergo apoptosis. However, the most upregulated MMP in excitotoxic
versus healthy retinas, is MMP-3.
conclusion Based on their expression patterns, we hypothesize that MMPs
are involved in RGC death and glial reactivity in the retina. Therefore, we
are currently investigating their in vivo role in specific MMP deficient mice
subjected to the excitotoxicity model. Moreover, the glaucomatous changes
observed in the brain indicate that these retinal target areas should not be
overlooked in future research.
cts
a
r
st
on
Ab
essi
s
ster
po
P130
P131
Is it a conjunctival naevus or melanoma or is it
something else?
The effect of AMA0076, a locally acting rho kinase
(ROCK) inhibitor, on IOP in Dutch Belted Rabbits
WEYNS M (1), DE GROOT V (1), DE KEIZER R (2)
(1) Antwerp University Hospital, Antwerp
(2) Leiden University Medical Center, Leiden
VAN DE VELDE S (1), VAN BERGEN T (2), SIJNAVE D (1), HOLLANDERS K (1),
(1) Universiteit Leuven, Leuven
purpose A 47-year old healthy man was referred by his opthalmologist
to exclude malignancy of a naevus of the nasal conjunctiva present since
20 years. Patient did not notice any change in colour or size of the lesion.
methods On biomicroscopy a cystic poorly pigmented non mobile lesion
was seen. The clinical impression was a small hole in the sclera. In the
medical history no trauma was known. To differentiate the lesion a high
resolution B scan ultrasonography was performed.
results Ultrasonography showed a small scleral perforation without any
protrusion of a mass of the pars plana. Probably a blunt trauma on his
eye, as child, had caused this small scleral opening but the patient did not
remember any eye trauma.
conclusion Conjunctival naevi are typically located in the juxtalimbal region
and are obligatory mobile with the conjunctiva. When not mobile they
need to be distinguished from protrusion in openings in the sclera after
trauma or extraocular extension of a ciliairy body melanoma. Movement of
the conjunctiva by hands and High resolution B scan ultrasonography have
important roles in the differential diagnosis of conjunctival lesions.
purpose To determine the intra ocular pressure (IOP) lowering efficacy of
the local ROCK inhibitor, AMA0076, in Dutch Belted rabbits.
methods Dutch Belted rabbits (5 rabbits/group) received topically a single
dose of AMA0076 in one eye. A concentration range of 0.031 - 0.625%
AMA0076 was tested. The contralateral eye served as control and was
treated with saline. IOP was measured at baseline and 30 min, 1, 2, 3, 4, 5,
6, 7, 8h post topical administration.
results Single topical administration of AMA0076 significantly lowered
IOP in all groups compared to the control eye (p<0.05). Mean baseline IOP
during the experiments was between 20.6 and 21.5 mmHg. Thirty minutes
after topical treatment, a concentration dependent reduction in IOP was
demonstrated with a IOP ranging from 3.9mmHg – 7mmHg compared to
the control eye. Maximal IOP reduction of each concentration following
single dose administration of AMA0076 was observed ±2 hours after
instillation with a IOP ranging from 4.6mmHg and 7.5mmHg. The IOP
lowering effect with the highest concentrations of AMA0076 (0.625% and
0.125%) was sustained during the experiment.
conclusion AMA0076 was effective in rapidly lowering IOP in a dose
depended and sustained manner after a single topical dose in Dutch Belted
rabbits. This new class of local ROCK inhibitors has potential therapeutic
value for the IOP lowering treatment of glaucoma.
P132
P133
Macular scleral band for degenerative high
myopia: overview of the surgical technique and
short term results
Pseudoxanthoma elasticum confirmed by genetic
analysis but not by skin biopsy
VANDENBROUCKE S (1), BREEMERSCH M (1), WARD B (2), STALMANS P (1)
(1) University Hospital of Leuven, Leuven
(2) Retinal Diagnostic Center, Campbell, CA, USA
purpose To describe the used surgical technique and short term results of
the macular buckling procedure in degenerative myopia.
methods Between 30/3/2012 and 7/9/2012, a posterior scleral
reinforcement was performed in our center on 7 high myopic eyes (ranging
from 28.19 to 38.46 mm). A scleral band of 1 cm wide and up to 8 cm long
was prepared from an autologous donor eye and fixated to the sclera nasally
from the superior rectus muscle insertion. After passing the band under the
superior rectus muscle and the lateral rectus muscle, behind the insertion of
the inferior oblique and between the inferior rectus muscle and the globe,
the free end was secured to the sclera in the inferonasal quadrant, whereby
the band was placed over the macular area. To minimize post-operative
swelling and complications, oral NSAIDS, diuretics and steroid drugs were
administered. The axial length of the eyeball was measured by A-scan
ultrasonography or IOL-master before and after treatment, and ultrasound
was performed post-operatively.
results The used technique was effective to place the sclera band in the
required macular position. As expected, the post-operative axial length
was shortened by a variable extent. Temporary postoperative complications
included choroidal effusion, limited motility and intra-ocular pressure
elevation. Except for one eye, with a complex history, there were no
unexpected per- or post-operative complications.
conclusion The used macular buckling technique was effective to place
the donor sclera band in the required macular position with post-operative
shortening of the axial length.
VAN LOEY SVL, LEYS AL
UZ Leuven, Leuven
purpose In patients diagnosed with angioid streaks additional
investigations are useful to identify underlying systemic disease unless age
and short peripapillary streaks are indicative of senile streaks as an isolated
abnormality. In middle-aged or young adults with angioid streaks and no
obvious systemic disease, -thalassemia and pseudoxanthoma elasticum
(PXE) are to be searched for. Fundus changes in -thalassemia and PXE are
fairly similar, but in contrast to -thalassemia, retinal vessel tortuosity is
absent in PXE and comet tail lesions can be observed. This allows making a
presumed clinical diagnosis of PXE based on extensive angioid streaks, peau
d’orange, crystalline bodies and comet tail lesions. The hemoglobulinopathy
in -thalassemia is easily diagnosed with blood screening. For confirmation
of PXE the gold standard is dermatologic examination and skin biopsy, but
since the last decade molecular diagnosis is also available.
methods Case report of a patient with ocular lesions suggestive of PXE and
PXE confirmed by genetic analysis but not by skin biopsy.
results recently, we identified PXE in a 42-year-old patient who presented
with angioid streaks-associated neovascularization, peau d’orange, and
crystalline bodies. Hemoglobinopathy was excluded. He had no PXEassociated skin lesions and a skin biopsy was not indicative of PXE. However,
genetic analysis showed a compound heterozygote mutation in the ABCC
gene (a 3413G>A mutation and a 3389C>T mutation).
conclusion Exceptionally, molecular diagnosis of PXE can be made
in patients with apparently normal skin and negative skin biopsies, as
demonstrated in this case and in another case published in 2011 (GMS
Ophthalmol Cases).
93
s
act
r
t
bs
sion
A
es
er s
t
Pos
P134
P135
Therapeutic potential of placental growth factor
(PlGF) inhibition in scar formation after glaucoma
filtration surgery
Let this be lattice? Dendritiform erosion in lattice
dystrophy type I, a source of confusion
VAN BERGEN T (1), JONCKX B (2), HOLLANDERS K (1), SIJNAVE D (1),
VAN DE VELDE S (1), VANDEWALLE E (1), MOONS L (1), STASSEN JM (2),
STALMANS I (1)
(1) KUL, Leuven
(2) ThromboGenics , Heverlee
purpose We checked the hypothesis that placental growth factor (PlGF)
may be a target for improvement of the outcome of glaucoma filtration
surgery (GFS).
methods The effect of the anti-murine PlGF-antibody (5D11D4) was
investigated in a mouse model of GFS. Immediately after surgery 5D11D4
(5.2µg) or 1C8, an irrelevant mouse IgG antibody (4.8 µl), was injected in
the anterior chamber (n=10 eyes for both groups). An anti-murine VEGF-R2
antibody (DC101) was used as a positive control (6.2 µg; n=10). Mice were
killed on post-operative day 8. Treatment outcome was studied by clinical
investigation of the bleb and by immunohistological stainings. All antibodies
were kindly provided by ThromboGenics NV.
results Treatment using the anti-PlGF antibody significantly improved
surgical outcome by increasing bleb survival and bleb area with 29%
compared to negative control (1C8). Postoperative inflammation and
angiogenesis was reduced during the first days after surgery and collagen
deposition was decreased at later stages. A single administration of antiVEGF-R2 also significantly improved bleb area with 7% as compared to
1C8, but had no effect on bleb survival. Inhibition of VEGF-R2 only reduced
angiogenesis and collagen deposition, but did not influence inflammation.
VANLERBERGHE V, KESTELYN PH-A, CLAERHOUT I, KESTELYN P
University Hospital, Ghent
purpose Lattice dystrophy type I usually presents with symptoms of
recurrent erosions. As these erosions frequently follow the branching
pattern of the underlying lattice network, they may often mimic dendritic
herpetic keratitis. The purpose of this poster is to differentiate between
a dendritiform erosion in lattice dystrophy type I and a genuine dendritic
ulcer.
methods Biomicroscopy/anterior segment photography
results Lattice dystrophy type I appears in the first decade of life. Corneal
involvement is usually bilateral and symmetric. In the early stages, the
lesions can appear as irregular lines and dots in the anterior axial stroma
with clear intervening stroma. These lines increase in size and number
with time, extend to the periphery, and involve both the deeper and the
superficial stromal tissue. Epithelial erosions occur secondary to involvement
of the subepithelial area and Bowman’s layer. Therefore they follow the
pattern of the lattice network. Decreased corneal sensation occurs in later
stages.Herpes simplex dendrites are fine, branching epithelial defects
which stain brightly with fluorescein. They typically have terminal bulbs and
swollen epithelial borders. A herpetic dendritic ulcer has no predilection for
the central cornea.
conclusion A dendritiform erosion in lattice dystrophy type I typically
follows the branching pattern of the underlying lattice network, is mostly
seen in the central cornea and lacks terminal bulbs and swollen borders.
conclusion Targeting PlGF with an inhibitory monoclonal antibody is
efficacious in improving GFS outcome, possibly even more effectively than
inhibition of VEGF-R2, due to its additional effect on inflammation. These
results render PlGF an appealing target for ocular wound healing and point
to the potential therapeutic benefits of PlGF-inhibition.
P137
P136
Lasik for myopia and astigmatism with ZEISS MEL
80 excimer and visumax femtosecond laser
DEBROUWERE V (1), JACOB J (1), HUYGENS M (2)
(2) BOLC laser centrum, Drongen
purpose To study the efficacy of myopic excimer laser assisted in situ
keratomileusis (LASIK) using the Zeiss MEL 80 excimer laser in association
with the Zeiss Visumax femtosecond laser, with a follow-up up to 12
months.
methods Design: Retrospective case study.Participants: Patients with
different degrees of myopia and astigmatism treated with LASIK.Technique:
The flap was made with the Zeiss Visumax femtosecond laser . Ablations
were performed with the Zeiss MEL 80 excimer laser. Analysis: Data of 1,3,
6 and 12 months follow up were reviewed retrospectively. A questionnaire
was sent to the patients to assess subjective satisfaction and side effects.
Main outcome measures: uncorrected distance visual acuity (UDVA),
remaining refraction error (RE) in spherical equivalent, safety of the
procedure expressed in change in lines of corrected distance visual acuity
(CDVA).
results The preliminary results show a mean RE of -0,04 D, -0,12 D, -0,11
D and -0,1 D after a follow up of 1, 3, 6 and 12 months respectively. The
UDVA was 20/16 or better in 29% of patients, 20/20 or better in 83% of
patients and 20/25 or better in 100% of the cases after a follow up of
12 months. The preliminary safety results show an unchanged CDVA in
54% of patients. None of the patients had a loss of lines in CDVA after a
follow-up of 1 year. 33% gained 1 line and 13% gained 2 lines of CDVA,
resulting in a safety index of 1.13 after 12 months follow up. Other results
of remaining astigmatism, accuracy, predictability, stability and subjective
satisfaction will also be shown for the different follow up periods.
Visual Function after Gene Therapy for
RPE65-Related LCA
UVIJLS A (1), MAGUIRE AM (2), HIGH KA (3), WRIGHT JF (3), PIERCE
EA (2), DE BAERE E (4), MARSHALL KA (3), CHUNG DC (2), SUN J (3),
MCDONNELL J (3), BENNETT J (2), LEROY BP (5)
(1) Dept Ophth, GUH, Ghent
(2) FM Kirby Center for Mol Ophth, Penn, Philadelphia
(3) Ctr Cell Mol Therapeutics, CHOP, Philadelphia
(4) Ctr for Med Genet, GUH, Ghent
(5) Dept Ophth & Ctr Med Genet, GUH, Ghent
purpose To describe changes in visual function after gene therapy for
RPE65-related Leber congenital amaurosis.
methods Two male Belgian patients of 9 and 10 years old at the first
treatment underwent an extensive ophthalmological work-up, including
psychophysical testing. Here, we focused on best-corrected visual acuity
(BCVA), Goldmann visual fields (GVF) and a Low Vision Panel D-15 colour
vision test. Both patients were treated with consecutive vitrectomies with
a subretinal injection of AAV2-hRPE65v2 ((4,8x1010 and 1,5x1010 vector
genomes in 1st and 2nd eyes respectively).
results Both patients showed a significant bilateral improvement of BCVA
after treatment of the first eye, but BCVA did not significantly change after
treatment of the second eye. A clear improvement in GVF of both eyes was
noted after treatment of the first eye, with further improvement of both
GVFs, after the second eye was treated. Colour vision did not improve
significantly following gene therapy.
conclusion Gene therapy with subretinal injection of AAV2-hRPE65v2
is a safe procedure, but also significantly improves retinal sensitivity and
consequently visual function. This is most clearly illustrated by the improved
GVF.
conclusion This study illustrates the accuracy of lasik for myopia and
astigmatism with Zeiss MEL 80 exceimer and visumax femtosecond laser.
94
cts
a
r
st
on
Ab
essi
s
ster
po
P138
Definition of an absolute scotoma in the central
visual field for driver license
STEVENS AM, ZEYEN T, BELGIAN GLAUCOMA SOCIETY
Gent
purpose The latest update of the criteria for driver license stipulate that
the binocular central 20° (Group 1) or the binocular central 30° (Group
2) should be free of an absolute scotoma. However, no definition of an
absolute scotoma is provided.To provide guidelines for the ophthalmologists
for the definition of an absolute scotoma when validating a driver license.
methods A literature search was conducted to look for definitions of an
absolute scotoma in the central visual field in relation to driver licences.
results An absolute scotoma in the central 20° or 30° of the binocular visual
field should be examined with standard automated perimetry using the
Esterman program or any other form of automated perimetry that allows
to integrate the monoculair visual fields . The definition we propose: a
minimum of 3 contiguous test locations, maximum 6° apart with a threshold
of < 10 decibel (dB) in the binocular central visual field.
conclusion Criteria for the definition of absolute scotomas in relation to
a driver license are proposed and will be implemented in collaboration
with CARA.
95
meet
Please visit our DORC booth #39
At the heart of EVA is a revolutionary fluid control system called VacuFlow VTi using
Valve Timing intelligence technology. It just effortlessly delivers the precise flow
and fast vacuum required by you, the surgeon.
Put simply, EVA VacuFlow VTi technology puts you in absolute control, all of the time.
www.evabydorc.com
on
ti
a
t
i
ed
r
Acc
N° agréation
Activiteitsnr.
Date
Datum
Type
Rubriek
Intitulé
Titel
Durée
Duur
CP
Organisateur
Organisator
12009344
28/11/12
3
OB 2012
6 h/u
6
2080 AOB
12009345
29/11/12
3
OB 2012
3 h/u
3
2080 AOB
12016558
29/11/12
6
Medico-legale items in de
Oogheelkunde
Sujets medico-légaux en
ophtalmologie
Ethical Ophthalmology
over the past 20 years
3 h/u
3
2080 AOB
12009346
30/11/12
3
OB 2012
6 h/u
6
2080 AOB
97
s
sse
e
r
g
re
u
Fut
n
o
C
OB
OB 2013 Brussels Expo
Nov 27 - 29, 2013
OB 2014 Brussels Expo
Nov 26 - 28, 2014
99
en
ier
l
u
m
for
l
e
t
es
CANON
B
UFSK
600-XLE
CX-1
CANON
HS100-OCT
CANON
TX20P
LUNEAU
L40P
LUNEAU
L80
JOHN WEISS
DUCKWORTH & KENT
UFSK
SURGITREND
CANON
CR-2 Plus
LENSITA, DIVISION OF HOSPITHERA
100
| OB 2012 |
Rue de la Petite Ile/Klein Eilandstraat 3
1070 Bruxelles/Brussel I Belgium
TEL: + 32 (0)2 535 03 23
FAX: + 32 (0)2 535 03 29
info@lensita.com I WWW.LENSITA.COM
PROGRAMME
es
Not
101
He trained you to be the best
And he chose you to perform his cataract surgery
That’s success story 60 million and one
CONFIDENCE
© 2012 Novartis
1/12
ACR12838JAD / MA2012-205
es
Not
103
104
es
Not
105
AZARGA 3x5ml: € 51,56
Strength
and
comfort
A Novartis company
Nov. 2012
AZARGA®
Naam van het geneesmiddel: AZARGA 10 mg/ml + 5 mg/ml oogdruppels, suspensie
Kwalitatieve en kwantitatieve samenstelling: Eén ml suspensie bevat 10 mg brinzolamide en 5 mg timolol (als timololmaleaat). Lijst van hulpstoffen: benzalkoniumchloride, mannitol (E421), carbopol 974P, tyloxapol,
dinatriumedetaat, natriumchloride, zoutzuur en/of natriumhydroxide (voor het instellen van de pH), gezuiverd water.
Farmaceutische vorm: Oogdruppels, suspensie (oogdruppels). Witte tot gebroken witte egale suspensie, pH 7,2 (bij benadering).
Therapeutische indicaties: Verlaging van de intraoculaire druk (IOD) bij volwassenen met openkamerhoekglaucoom of oculaire hypertensie waarbij monotherapie onvoldoende daling van de intraoculaire druk geeft.
Dosering en wijze van toediening: Gebruik bij volwassenen, inclusief ouderen: De dosis is één druppel AZARGA in de conjunctivale zak van het (de) aangedane oog (ogen) tweemaal daags. De systemische absorptie
wordt verminderd wanneer nasolacrimale occlusie wordt toegepast of wanneer het ooglid 2 minuten wordt gesloten. Hierdoor kunnen systemische bijwerkingen verminderen en kan de lokale werkzaamheid toenemen.
Indien meer dan één topisch oftalmisch geneesmiddel wordt gebruikt, moeten deze geneesmiddelen met een tussenperiode van minimaal 5 minuten worden toegediend. Als een dosis wordt vergeten, dient de behandeling
volgens schema voortgezet te worden met de volgende dosis. De dosis mag niet hoger zijn dan tweemaal daags één druppel in het (de) aangedane oog (ogen). Wanneer een ander oftalmisch antiglaucoommiddel
wordt vervangen door AZARGA, moet het gebruik van het andere middel worden stopgezet en de volgende dag met AZARGA worden begonnen. Pediatrische patiënten: AZARGA wordt niet aanbevolen voor gebruik bij
kinderen jonger dan 18 jaar vanwege een gebrek aan gegevens over veiligheid en werkzaamheid. Gebruik bij lever- en nierfunctiestoornissen: Er is geen onderzoek verricht met AZARGA of timolol 5 mg/ml oogdruppels
bij patiënten met lever of nierfunctiestoornissen. Een dosisaanpassing is niet nodig bij patiënten met leverfunctiestoornissen of bij patiënten met lichte tot matige nierfunctiestoornissen. AZARGA is niet onderzocht bij
patiënten met ernstige nierfunctiestoornissen (creatinineklaring < 30 ml/min) of bij patiënten met hyperchloremische acidose. Aangezien brinzolamide en zijn belangrijkste metabolieten voornamelijk via de nieren worden
uitgescheiden, is AZARGA gecontraïndiceerd bij patiënten met ernstige nierfunctiestoornissen. Wijze van toediening: Voor oculair gebruik. Instrueer patiënten het esje vóór gebruik goed te schudden. Om besmetting
van de druppelteller en de suspensie te voorkomen, moet er op gelet worden dat de druppelteller niet in contact komt met de oogleden, het omringende gedeelte of andere oppervlakken. Instrueer patiënten het esje
goed te sluiten wanneer het niet wordt gebruikt.
Contra-indicaties: Overgevoeligheid voor de werkzame bestanddelen of voor één van de hulpstoffen. Overgevoeligheid voor andere bètablokkers. Overgevoeligheid voor sulfonamiden. Reactieve luchtwegaandoeningen
waaronder astma bronchiale of een anamnese van astma bronchiale, ernstige chronische obstructieve longziekte. Sinus bradycardie, sick-sinus syndroom, sino-atriaal blok, tweede of derdegraads atrioventriculair blok
niet gereguleerd door een pacemaker. Manifest hartfalen, cardiogene shock. Ernstige allergische rhinitis. Hyperchloremische acidose. Ernstige nierfunctiestoornissen.
Bijwerkingen: Samenvatting van het veiligheidspro el: In twee klinische studies van 6 respectievelijk 12 maanden, waarbij 394 patiënten werden behandeld met AZARGA, was de meest gerapporteerde bijwerking
voorbijgaand wazig zicht na indruppeling (3,6%), variërend van een paar seconden tot een paar minuten. Samenvatting van de bijwerkingen: De volgende bijwerkingen zijn gerangschikt volgens de volgende conventie:
zeer vaak ( 1/10), vaak ( 1/100 tot <1/10), soms ( 1/1.000 tot <1/100), zelden ( 1/10.000 tot <1/1000), zeer zelden (<1/10.000), of niet bekend (kan met de beschikbare gegevens niet worden bepaald). Binnen iedere
frequentiegroep worden bijwerkingen gerangschikt naar afnemende ernst. Psychische stoornissen: Soms: insomnia. Niet bekend: depressie. / Zenuwstelsaandoeningen: Vaak: dysgeusia. / Oogaandoeningen: Vaak:
wazig zicht, oogpijn, oogirritatie, corpus alienum gevoel in de ogen. Soms: corneale erosie, keratitis punctate, droog oog, oogafscheiding, pruritus aan het oog, oculaire hyperemie, blefaritis, allergische conjunctivitis,
aandoening van de cornea, are in de voorste oogkamer, conjunctivale hyperemie, korstvorming op de ooglidrand, astenopie, abnormaal gevoel in het oog, pruritis van de oogleden, allergische blefaritis, erytheem aan
het ooglid. / Bloedvataandoeningen: Soms: verlaagde bloeddruk. / Ademhalingsstelsel-, borstkas- en mediastinumaandoeningen: Soms: chronisch obstructieve pulmonaire aandoening, faryngolaryngale pijn, rhinorrhoea,
hoesten. / Huid- en onderhuidaandoeningen: Soms: aandoening van het haar, lichen planus. Beschrijving van geselecteerde bijwerkingen: Dysgeusie (bittere of vreemde smaak in de mond na indruppeling) was een
frequent gerapporteerde systemische bijwerking die in verband werd gebracht met het gebruik van AZARGA tijdens klinische studies. Het wordt waarschijnlijk veroorzaakt door de passage van de oogdruppels in de
nasofarynx via het nasolacrimale kanaal en is toe te schrijven aan brinzolamide. Nasolacrimale occlusie of het zachtjes sluiten van het ooglid na indruppeling kan helpen om de incidentie van dit effect te beperken. AZARGA
bevat brinzolamide, een sulfonamideremmer van koolzuuranhydrase, die systemisch wordt geabsorbeerd. Effecten op het maagdarmstelsel, op het zenuwstelsel en hematologische, renale en metabole effecten worden
gewoonlijk in verband gebracht met systemische koolzuuranhydraseremmers. Gelijksoortige bijwerkingen als die worden toegeschreven aan orale koolzuuranhydraseremmers kunnen voorkomen bij topische toediening.
AZARGA bevat brinzolamide en timolol (als timololmaleaat). Zoals andere topisch toegediende oftalmische geneesmiddelen wordt timolol systemisch geabsorbeerd. Hierdoor kunnen dezelfde bijwerkingen optreden
als bij systemische bètablokkers. De bijwerkingen die hieronder genoemd worden, bevatten de reacties waargenomen binnen de klasse van oftalmische bètablokkers. Bijkomende bijwerkingen die in verband worden
gebracht met het gebruik van de individuele bestanddelen die mogelijk kunnen voorkomen met AZARGA worden hieronder weergegeven. De incidentie van systemische bijwerkingen na topische oftalmische toediening is
lager dan na systemische toediening. Infecties en parasitaire aandoeningen: Brinzolamide 10 mg/ml: nasofaryngitis, faryngitis, sinusitis, rinitis. / Bloed- en lymfestelselaandoeningen: Brinzolamide 10 mg/ml: verminderde
hoeveelheid rode bloedcellen, verhoogde hoeveelheid chloride in het bloed. / Immuunsysteemaandoeningen: Timolol 5 mg/ml: systemische allergische reacties waaronder angio-oedeem, urticaria, gelokaliseerde en
gegeneraliseerde uitslag, pruritus, anafylaxie. / Voedings- en stofwisselingsstoornissen: Timolol 5 mg/ml: hypoglykemie. / Psychische stoornissen: Brinzolamide 10 mg/ml: apathie, depressie, depressieve stemming,
verminderd libido, nachtmerries, nervositeit. Timolol 5 mg/ml: nachtmerries, geheugenverlies. / Zenuwstelselaandoeningen: Brinzolamide 10 mg/ml: slaperigheid, motorische disfunctie, amnesie, geheugenstoornis,
paresthesie, tremor, hypoesthesie, ageusie. Timolol 5 mg/ml: cerebrale ischemie, cerebrovasculair accident, syncope, verergering van de tekenen en symptomen van myasthenia gravis, paresthesie, hoofdpijn,
duizeligheid. / Oogaandoeningen: Brinzolamide 10 mg/ml: keratitis, keratopathie, verhoogde cup/disc ratio van de oogzenuw, defect van het corneaepitheel, aandoening van het corneaepitheel, verhoogde intraoculaire
druk, afzetting op het oog, verkleuring van de cornea, corneaoedeem, conjunctivitis, meibomianitis, diplopie, glare, fotofobie, fotopsie, verminderde gezichtsscherpte, pterygium, oculair ongemak, keratoconjunctivitis
sicca, hypoesthesie van het oog, sclerale pigmentatie, subconjunctivale cyste, toegenomen lacrimatie, visuele stoornissen, zwelling van het oog, oogallergie, madarosis, ooglidstoornis, ooglidoedeem. Timolol 5 mg/
ml: tekenen en symptomen van oculaire irritatie (zoals branden, prikken, jeuken, tranen, roodheid), keratitis, choroïdloslating na ltratiechirurgie, verminderde corneagevoeligheid, ptose, diplopie. / Evenwichtsorgaanen ooraandoeningen: Brinzolamide 10 mg/ml: tinnitus, vertigo. / Hartaandoeningen: Brinzolamide 10 mg/ml: cardiorespiratoire uitputting, angina pectoris, bradycardie, onregelmatige hartslag, arrythmie, palpitaties,
tachycardie, versnelde hartslag. Timolol 5 mg/ml: bradycardie, borstkaspijn, palpitaties, oedeem, arrythmie, congestief hartfalen, atrioventriculair blok, hartstilstand, hartfalen. / Bloedvataandoeningen: Brinzolamide 10
mg/ml: hypertensie. Timolol 5 mg/ml: hypotensie, fenomeen van Raynaud, koude handen en voeten. / Ademhalingsstelsel-, borstkas-, en mediastinumaandoeningen: Brinzolamide 10 mg/ml: dyspneu, astma, bronchiale
hyperactiviteit, epistaxis, irritatie van de keel, nasale congestie, congestie van de bovenste luchtwegen, postnasale drip, niezen, nasale droogte. Timolol 5 mg/ml: bronchospasmen (voornamelijk bij patiënten met een
bestaande bronchospastische aandoening), dyspneu. / Maagdarmstelselaandoeningen: Brinzolamide 10 mg/ml: droge mond, oesofagitis, braken, dyspepsie, abdominaal ongemak, maagklachten, frequente bewegingen
van de darm, gastrointestinale aandoening, orale hypoesthesie, orale paresthesie, atulentie. Timolol 5 mg/ml: misselijkheid, dyspepsie, diarree, droge mond, abdominale pijn, braken. / Lever- en galaandoeningen:
Brinzolamide 10 mg/ml: abnormale leverwaarden. / Huid- en onderhuidaandoeningen: Brinzolamide 10 mg/ml: urticaria, maculo-papulaire uitslag, algemene pruritus, alopecia, strakke huid, dermatitis, erytheem. Timolol
5 mg/ml: alopecia, psoriasisachtige huiduitslag of verergering van psoriasis, huiduitslag. / Skeletspierstelsel- en bindweefselaandoeningen: Brinzolamide 10 mg/ml: rugpijn, spierkrampen, myalgie, arthralgie, pijn in de
extremiteiten. Timolol 5 mg/ml: myalgie. / Nier- en urinewegaandoeningen: Brinzolamide 10 mg/ml: nierpijn, pollakiurie. / Voortplantingsstelsel- en borstaandoeningen: Brinzolamide 10 mg/ml: erectiele disfunctie. Timolol
5 mg/ml: sexuele disfunctie, verminderd libido. / Algemene aandoeningen en toedieningsplaatsstoornissen: Brinzolamide 10 mg/ml: pijn, asthenie, ongemak ter hoogte van de borst, vermoeidheid, abnormaal gevoel,
zenuwachtig gevoel, geïrriteerdheid, pijn op de borst, perifeer oedeem, malaise, medicatieresidu. Timolol 5 mg/ml: asthenie, vermoeidheid. / Letsels, intoxicaties en verrichtingscomplicaties: Brinzolamide 10 mg/ml:
corpus-alienum in het oog. Pediatrische patiënten: AZARGA wordt niet aanbevolen voor gebruik bij kinderen jonger dan 18 jaar vanwege een gebrek aan gegevens over veiligheid en werkzaamheid.
Publieksprijs inclusief BTW: 3 x 5 ml: 51,56 €.
Registratiehouder: Alcon Laboratories (UK) Ltd., Pentagon Park, Boundary Way, Hemel Hempstead, Herts HP2 7UD, Verenigd Koninkrijk.
Fabrikant: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, België.
Registratienummer: EU/1/08/482/002.
A evering: Geneesmiddel op medisch voorschrift.
Datum van herziening van de tekst: 17 februari 2012.
Mei 2012
AZARGA®
Dénomination du médicament: AZARGA 10 mg/ml + 5 mg/ml collyre en suspension
Composition qualitative et quantitative: Un ml de suspension contient 10 mg de brinzolamide et 5 mg de timolol (sous forme de maléate de timolol). Liste des excipients: chlorure de benzalkonium, mannitol (E421),
carbopol 974P, tyloxapol, édétate disodique, chlorure de sodium, acide chlorhydrique et/ou hydroxyde de sodium (ajustement du pH), eau puri ée.
Forme pharmaceutique: Collyre en suspension (collyre). Suspension uniforme blanche à blanchâtre, pH 7,2 (environ).
Indications thérapeutiques: Réduction de la pression intraoculaire (PIO) chez les patients adultes atteints de glaucome à angle ouvert ou d’hypertonie intraoculaire, pour lesquels la réduction de PIO sous monothérapie
est insuf sante.
Posologie et mode d’administration: Utilisation chez les adultes et les sujets âgés: La posologie est d’une goutte d’AZARGA dans le cul de sac conjonctival de l’œil ou des yeux atteint(s) deux fois par jour. Le passage
systémique peut être réduit par une occlusion nasolacrymale ou la fermeture des paupières pendant 2 minutes. Cette méthode peut contribuer à diminuer les effets indésirables systémiques et à augmenter l’ef cacité
locale. En cas d’utilisation de plusieurs médicaments administrés par voie oculaire, les instillations doivent être espacées d’au moins 5 minutes. Si une instillation est oubliée, le traitement doit être poursuivi avec l’instillation suivante comme prévu. La posologie ne doit pas excéder une goutte deux fois par jour dans l’œil (les yeux) atteint(s). En cas de remplacement d’un autre traitement antiglaucomateux ophtalmique par AZARGA,
interrompre l’autre médicament et commencer AZARGA le jour suivant. Population pédiatrique: AZARGA n’est pas recommandé chez les enfants de moins de 18 ans en raison de l’absence de données de tolérance et
d’ef cacité. Utilisation chez les insuf sants hépatiques et rénaux: Aucune étude n’a été effectuée avec AZARGA ou avec timolol 5 mg/ml collyre chez les insuf sants hépatiques ou rénaux. Aucune adaptation posologique
n’est nécessaire chez les insuf sants hépatiques ou chez les insuf sants rénaux légers à modérés. AZARGA n’a pas été étudié chez les patients présentant une insuf sance rénale sévère (clairance de la créatinine <
30 ml/min) ou chez les patients présentant une acidose hyperchlorémique. Etant donné que le brinzolamide et son principal métabolite sont excrétés majoritairement par le rein, AZARGA est contreindiqué chez les
insuf sants rénaux sévères. Mode d’administration: Voie oculaire. Demander aux patients de bien agiter le acon avant usage. Pour éviter la contamination de l’embout comptegouttes et de la solution, il faut faire attention
de ne pas toucher les paupières, les surfaces voisines ou d’autres surfaces avec l’embout comptegouttes du acon. Indiquer aux patients de conserver le acon bien fermé quand il n’est pas utilisé.
Contre-indications: Hypersensibilité aux principes actifs ou à l’un des excipients. Hypersensibilité aux autres bêta-bloquants. Hypersensibilité aux sulfonamides. Pathologies associées à une hyperréactivité bronchique
notamment asthme ou antécédents d’asthme et bronchopneumopathie chronique obstructive sévère. Bradycardie sinusale, maladie du sinus, bloc sino-auriculaire, bloc auriculoventriculaire du second ou du troisième
degré non contrôlé par un pacemaker, insuf sance cardiaque con rmée ou choc cardiogénique. Rhinite allergique sévère. Acidose hyperchlorémique. Insuf sance rénale sévère.
Effets indésirables: Résumé du pro l de tolérance: Dans deux études cliniques de 6 et 12 mois ayant inclus 394 patients traités avec AZARGA, l’effet indésirable le plus fréquemment rapporté était une vision oue
transitoire lors de l’instillation (3,6%) persistant de quelques secondes à quelques minutes. Résumé des effets indésirables: Les effets indésirables suivants ont été classés de la façon suivante: très fréquents ( 1/10),
fréquents ( 1/100 à <1/10), peu fréquents ( 1/1000 à <1/100), rares ( 1/10000 à <1/1000), très rares (<1/10000) ou indéterminés (ne peuvent être estimés sur la base des données disponibles). Dans chaque groupe
de fréquence, les effets indésirables sont présentés dans l’ordre décroissant de gravité. Affections psychiatriques: Peu fréquente: insomnie. Fréquence indéterminée: dépression. / Affections du système nerveux: Fréquente: dysgueusie. / Affections oculaires: Fréquentes: vision oue, douleur oculaire, irritation oculaire, sensation de corps étranger dans les yeux. Peu fréquentes: érosion cornéenne, kératite ponctuée, œil sec, écoulement oculaire, prurit oculaire, hyperhémie oculaire, blépharite, conjonctivite allergique, affection de la cornée, in ammation de la chambre antérieure de l’œil, hyperhémie conjonctivale, formation de croûtes sur le bord
de la paupière, asthénopie, sensation anormale dans l’œil, prurit des paupières, blépharite allergique, érythème de la paupière. / Affections vasculaires: Peu fréquente: diminution de la pression artérielle. / Affections
respiratoires, thoraciques et médiastinales: Peu fréquentes: bronchopneumopathie chronique obstructive, douleur pharyngolaryngée, rhinorrhée, toux. / Affections de la peau et du tissu sous-cutané: Peu fréquentes:
troubles de la pilosité, lichen plan. Description de certains effets indésirables: Un effet indésirable systémique fréquemment rapporté au cours des études cliniques avec AZARGA a été la dysgueusie (goût amer ou inhabituel dans la bouche après instillation). Il est probablement dû au passage du collyre dans le nasopharynx par le canal nasolacrymal et il est imputable au brinzolamide. L’occlusion nasolacrymale ou la fermeture
douce des paupières après l’instillation peut contribuer à réduire la fréquence de cet effet. AZARGA contient du brinzolamide qui est un sulfonamide inhibiteur de l’anhydrase carbonique absorbé par voie systémique.
Les effets gastrointestinaux, affectant le système nerveux, hématologiques, rénaux et métaboliques sont généralement associés aux inhibiteurs de l’anhydrase carbonique systémiques. Les effets indésirables des inhibiteurs de l’anhydrase carbonique par voie orale peuvent être observés avec la voie locale. AZARGA contient du brinzolamide et du timolol (sous forme de maléate de timolol). Comme pour d’autres médicaments à usage
ophtalmique administrés par voie locale, le timolol peut passer dans la circulation générale. Cela peut entraîner des effets indésirables semblables à ceux des bêta-bloquants pris par voie systémique. Les réactions indésirables mentionnées comprennent des réactions rencontrées dans la classe des bêta-bloquants ophtalmiques. D’autres effets indésirables liés à l’utilisation d’un des composants, qui peuvent éventuellement survenir
avec AZARGA, incluent ceux détaillés ci-dessous. L’incidence des effets indésirables systémiques après une administration topique ophtalmique est inférieure à celle d’une administration systémique. Infections et infestations: Brinzolamide 10 mg/ml: rhinopharyngite, pharyngite, sinusite, rhinite. / Affections hématologiques et du système lymphatique: Brinzolamide 10 mg/ml: diminution du nombre de globules rouges, augmentation du
taux de chlorure dans le sang. / Affections du système immunitaire: Timolol 5 mg/ml: réaction allergique systémique incluant angiœdème, urticaire, rash localisé et généralisé, prurit, anaphylaxie. / Troubles du métabolisme et de la nutrition: Timolol 5 mg/ml: hypoglycémie. / Affections psychiatriques: Brinzolamide 10 mg/ml: apathie, dépression, troubles de l’humeur, diminution de la libido, cauchemars, nervosité. Timolol 5 mg/ml:
cauchemars, pertes de mémoire. / Affections du système nerveux: Brinzolamide 10 mg/ml: somnolence, troubles de l’appareil locomoteur, amnésie, troubles de la mémoire, paresthésie, tremblements, hypoesthésie,
agueusie. Timolol 5 mg/ml: ischémie cérébrale, accident cérébrovasculaire, syncope, majoration des signes et symptômes de myasthénie gravis, parésthésie, maux de tête, étourdissement. / Affections oculaires: Brinzolamide 10 mg/ml: kératite, kératopathie, augmentation du ratio cup/disc du nerf optique, anomalie de l’épithélium cornéen, affection de l’épithélium cornéen, augmentation de la pression intraoculaire, dépôt oculaire,
coloration cornéenne, œdème cornéen, conjonctivite, meibomite, diplopie, éblouissements, photophobie, photopsie, baisse d’acuité visuelle, ptérygion, gêne oculaire, kératoconjonctivite sèche, hypœsthésie oculaire,
pigmentation sclérale, kyste sousconjonctival, larmoiement augmenté, trouble visuel, gon ement oculaire, allergie oculaire, madarose, troubles de la paupière, œdème de la paupière. Timolol 5 mg/ml: signes et symptômes d’irritation oculaire (par exemple: brûlure, picotements, démangeaisons, larmoiement, rougeur), kératite, décollement de la choroïde après une chirurgie ltrante, diminution de la sensibilité cornéenne, ptôsis, diplopie. / Affections de l’oreille et du labyrinthe: Brinzolamide 10 mg/ml: tinnitus, vertiges. / Affections cardiaques: Brinzolamide 10 mg/ml: détresse respiratoire, angine de poitrine, bradycardie, rythme cardiaque irrégulier,
arythmie, palpitations, tachycardie, accélération du rythme cardiaque. Timolol 5 mg/ml: bradycardie, douleur thoracique, palpitations, œdème, arythmie, insuf sance cardiaque congestive, bloc auriculo-ventriculaire,
arrêt cardiaque, insuf sance cardiaque. / Affections vasculaires: Brinzolamide 10 mg/ml: hypertension. Timolol 5 mg/ml: hypotension, syndrome de Raynaud, mains et pieds froids. / Affections respiratoires, thoraciques
et médiastinales: Brinzolamide 10 mg/ml: dyspnée, asthme, hyperactivité bronchique, épistaxis, irritation de la gorge, congestion nasale, congestion des voies respiratoires supérieures, sécrétions rétronasales, éternuements, sécheresse nasale. Timolol 5 mg/ml: bronchospasme (principalement chez les patients ayant une maladie bronchospastique préexistante), dyspnée. / Affections gastrointestinales: Brinzolamide 10 mg/ml: bouche
sèche, oesophagite, vomissement, dyspepsie, gêne abdominale, maux d’estomac, selles fréquentes, troubles gastrointestinaux, hypoesthésie orale, paresthésie orale, atulences. Timolol 5 mg/ml: nausée, dyspepsie,
diarrhée, bouche sèche, douleur abdominale, vomissements. / Affections hépatobiliaires: Brinzolamide 10 mg/ml: bilan hépatique anormal. / Affections de la peau et du tissu sous-cutané: Brinzolamide 10 mg/ml: urticaire,
rash maculopapuleux, prurit généralisé, alopécie, tiraillements cutanés, dermatite, érythème. Timolol 5 mg/ml: alopécie, éruption psoriasiforme ou exacerbation de psoriasis, éruption cutanée. / Affections musculo-squelettiques et systémiques: Brinzolamide 10 mg/ml: maux de dos, spasmes musculaires, myalgie, arthralgie, douleur des extrémités. Timolol 5 mg/ml: myalgies. / Affections du rein et des voies urinaires: Brinzolamide 10
mg/ml: douleurs rénales, pollakiurie. / Affections des organes de reproduction et du sein: Brinzolamide 10 mg/ml: dysfonction érectile. Timolol 5 mg/ml: dysfonction sexuelle, diminution de la libido. / Troubles généraux
et anomalies au site d’administration: Brinzolamide 10 mg/ml: douleurs, asthénie, gêne thoracique, fatigue, sensation de malêtre, sensation de nervosité, irritabilité, douleur thoracique, oedème périphérique, malaise,
résidu médicamenteux. Timolol 5 mg/ml: asthénie, fatigue. / Lésions, intoxications et complications liées aux procédures: Brinzolamide 10 mg/ml: corps étranger dans l’œil. Population pédiatrique: AZARGA n’est pas
recommandé chez les enfants de moins de 18 ans en raison de l’absence de données de tolérance et d’ef cacité.
Prix public incl. TVA: 3 x 5 ml: 51,56 €.
Titulaire d’enregistrement: Alcon Laboratories (UK) Ltd., Pentagon Park, Boundary Way, Hemel Hempstead, Herts HP2 7UD, Royaume-Uni.
Fabricant: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, Belgique.
Numéro d’enregistrement: EU/1/08/482/002.
Délivrance: Médicament soumis à prescription médicale.
Date de mise à jour du texte: 17 février 2012.
Mai 2012
DuoTrav® 3x2,5 ml : 68,93 €
DISCOVER THE DIFFERENCE
THE ALCON® NEW WAY:
WITHOUT BAK - NOW WITH POLYQUAD®
Travatan® 3x2,5 ml : 52,10 €
CHANGING THE WAY YOU LOWER IOP
Summary of product characteristics of DuoTrav® and Travatan® are included in the current publication
may 2012
es
Not
109
TRAVATAN®
Naam van het geneesmiddel : TRAVATAN 40 microgram/ml oogdruppels, oplossing
Kwalitatieve en kwantitatieve samenstelling : Iedere ml oplossing bevat 40 microgram travoprost. Lijst van hulpstoffen: polyquaternium-1, polyoxyethyleen gehydrogeneerde castorolie 40 (HCO-40), boorzuur (E284), mannitol (E421), natriumchloride,
propyleenglycol (E1520), natriumhydroxide en/of zoutzuur (voor het instellen van de pH), gezuiverd water.
Farmaceutische vorm : Oogdruppels, oplossing. Heldere, kleurloze oplossing.
Therapeutische indicaties
Verlaging van verhoogde intraoculaire druk bij patiënten met oculaire hypertensie of open kamerhoekglaucoom.
Dosering en wijze van toediening
Gebruik bij volwassenen, inclusief ouderen
De dosis bedraagt eenmaal daags één druppel TRAVATAN in de conjunctivale zak van het (de) aangedane oog (ogen). Het beste resultaat wordt behaald wanneer de dosis ‘s avonds wordt toegediend. Nasolacrimale occlusie of het zachtjes sluiten van het
ooglid na toediening wordt aanbevolen. Dit kan de systemische absorptie van oculair toegediende geneesmiddelen verminderen en leiden tot een vermindering van de systemische bijwerkingen.
Indien meer dan één topisch oftalmisch geneesmiddel wordt gebruikt, moeten deze geneesmiddelen met een tussenperiode van minimaal 5 minuten worden toegediend. Als een dosis wordt vergeten, wordt de behandeling volgens schema voortgezet met
de volgende dosis. De dagelijkse dosis mag niet hoger zijn dan één druppel in het (de) aangedane oog (ogen). Wanneer een ander oftalmisch antiglaucoommiddel wordt vervangen door TRAVATAN, moet het gebruik van het andere middel worden
stopgezet en de volgende dag met TRAVATAN worden gestart.
Pediatrische patiënten
De werkzaamheid en veiligheid van TRAVATAN bij patiënten jonger dan 18 jaar werden niet vastgesteld en het gebruik wordt niet aanbevolen bij deze patiënten tot er meer gegevens beschikbaar zijn.
Lever- en nierfunctiestoornissen
TRAVATAN werd bestudeerd bij patiënten met matige tot ernstige leverfunctiestoornissen en bij patiënten met matige tot ernstige nierfunctiestoornissen (creatinineklaring zo laag als 14 ml/min). Een aanpassing van de dosis is niet nodig bij deze patiënten.
Wijze van toediening
Voor oculair gebruik.
Het beschermende foliezakje moet vlak vóór het eerste gebruik worden verwijderd door de patiënt. Om besmetting van de druppelaar en de oplossing te voorkomen, mag de druppelaar van het flesje niet in contact komen met de oogleden, het omringende
gedeelte of andere oppervlakken.
Contra-indicaties : Overgevoeligheid voor het werkzame bestanddeel of voor één van de hulpstoffen.
Bijwerkingen : In klinische studies met meer dan 4400 patiënten werd TRAVATAN (met benzalkoniumchloride als conserveermiddel) eenmaal daags toegediend als monotherapie of als aanvullende therapie bij timolol 0,5%. Er werden in geen van de
klinische studies ernstige oftalmische of systemische bijwerkingen met het product gemeld. De meest gemelde bijwerking die met de behandeling van TRAVATAN (met benzalkoniumchloride als conserveermiddel) als monotherapie in verband kon worden
gebracht, was hyperemie van het oog (22,0%), waaronder oculaire, conjunctiva of sclerale hyperemie. De hyperemie was mild bij 83,6% van de patiënten bij wie deze bijwerking zich voordeed. Bijna alle patiënten (98%) die hyperemie ondervonden,
beëindigden de behandeling als gevolg van deze bijwerking niet. In fase III klinische studies, variërend in duur van 6 tot 12 maanden, verminderde de hyperemie na verloop van tijd.
In een 5 jaar-durende post-autorisatie klinische studie waarbij bij 502 patiënten eenmaal daags TRAVATAN werd toegediend, werden geen ernstige oftalmische of systemische bijwerkingen die in verband konden worden gebracht met TRAVATAN gemeld.
De meest voorkomende bijwerking die in verband kon worden gebracht met de behandeling met TRAVATAN was hyperpigmentatie van de iris (29,5%). Hyperemie van het oog dat in verband werd gebracht met het gebruik van TRAVATAN werd gemeld
met een incidentie van 10,0%, waarbij 2% van de patiënten die hyperemie van het oog meldden hun deelname aan de studie stopzette als gevolg van de bijwerking.
De volgende bijwerkingen konden in verband worden gebracht met de behandeling met TRAVATAN (met benzalkoniumchloride als conserveermiddel) als monotherapie. Zij zijn volgens de volgende conventie ingedeeld: zeer vaak ( 1/10), vaak (>1/100 tot
<1/10), soms (>1/1.000 tot 1/100), zelden (>1/10.000 tot 1/1.000), of zeer zelden ( 1/10.000). Binnen iedere frequentiegroep worden bijwerkingen gerangschikt naar afnemende ernst.
TRAVATAN (met benzalkoniumchloride als conserveermiddel)
Infecties en parasitaire aandoeningen : Soms: herpes simplex, keratitis herpetisch
Immuunsysteemaandoeningen : Soms: overgevoeligheid, geneesmiddelenovergevoeligheid, seizoensgebonden allergie
Zenuwstelselaandoeningen : Vaak: hoofdpijn. Soms: dysgeusie, duizeligheid, gezichtsvelduitval
Oogaandoeningen : Zeer vaak: oculaire hyperemie, iris hyperpigmentatie. Vaak: keratitis punctata, voorste oogkamerontsteking, oogpijn, fotofobie, oogafscheiding, ongemak in het oog, scherpzien gereduceerd, gezichtsvermogen wazig, droog oog, oog
pruritis, traanproductie verhoogd, erytheem van het ooglid, ooglidoedeem, groei van de wimpers, wimperverkleuring. Soms: cornea-erosie, uveïtis, keratitis, oogontsteking, fotopsie, blefaritis, conjunctivaal oedeem, halogezicht, conjunctivitis, conjunctivale
follikels, ooghypo-esthesie, meibom-ontsteking, ectropion, voorste oogkamer pigmentatie, mydriase, cataract, schilferige ooglidrand, asthenopie
Hartaandoeningen : Soms: hartfrequentie onregelmatig, hartkloppingen, hartfrequentie verlaagd
Bloedvataandoeningen : Soms: bloeddruk verlaagd, bloeddruk verhoogd, hypotensie, hypertensie
Ademhalingsstelsel-, borstkas- en mediastinumaandoeningen : Soms: dyspnoea, astma, luchtwegaandoening, orofaryngeale pijn, hoesten, dysfonie, neusverstopping, keelirritatie
Maagdarmstelselaandoeningen : Soms: peptisch ulcus gereactiveerd, maagdarmstelselaandoening, constipatie
Huid- en onderhuidaandoeningen : Vaak: huidhyperpigmentatie (perioculair). Soms: dermatitis allergisch, periorbitaal oedeem, contactdermatitis, erytheem, rash, haarkleurveranderingen, haartextuur abnormaal, hypertrichose, madarose
Skeletspierstelsel- en bindweefselaandoeningen : Soms: skeletspierstelselpijn
Algemene aandoeningen en toedieningsplaatsstoornissen : Soms: asthenie, malaise
Tijdens de ontwikkeling van TRAVATAN (met polyquaternium als conserveermiddel) werden in 2 klinische studies 201 patiënten tot 3 maanden blootgesteld. In geen van de klinische studies werden ernstige oftalmische of systemische bijwerkingen gemeld
die in verband konden worden gebracht met het product. De meest gemelde bijwerking die in verband kon worden gebracht met TRAVATAN (met polyquaternium als conserveermiddel) was hyperemie van het oog (18,9%), waaronder oculaire of
conjunctiva hyperemie. Eén patient (0,5%) zette de deelname aan de studie stop vanwege hyperemie van het oog.
De volgende bijwerkingen konden in verband worden gebracht met de behandeling (met TRAVATAN (met polyquaternium-1 als conserveermiddel) als monotherapie) en zijn ingedeeld volgens de volgende conventie: zeer vaak ( 1/10), vaak (>1/100 tot
<1/10), soms (>1/1.000 tot 1/100), zelden (>1/10.000 tot 1/1.000), of zeer zelden ( 1/10.000). Binnen iedere frequentiegroep worden bijwerkingen gerangschikt naar afnemende ernst.
TRAVATAN (met polyquaternium-1 als conserveermiddel)
Zenuwstelselaandoeningen: Soms: hoofdpijn.
Oogaandoeningen: Zeer vaak: oculaire hyperemie. Vaak: keratitis punctata, oogpijn, fotofobie, ongemak in het oog, droog oog, oog pruritus. Soms: scherpzien gereduceerd, traanproductie verhoogd, erytheem van het ooglid, schilferige ooglidrand.
Maagdarmstelselaandoeningen: Soms: droge mond.
Huid- en onderhuidaandoeningen: Vaak: huidhyperpigmentatie, huidverkleuring.
De volgende bijwerkingen werden vastgesteld tijdens post-marketing ervaringen en werden niet eerder in klinische studies met TRAVATAN als monotherapie gemeld :
Oculair: macula-oedeem
Systemisch: bradycardie, tachycardie, astma verergerd, vertigo, tinnitus, PSA verhoogd, haargroei abnormaal.
Publieksprijs inclusief BTW: 3 x 2,5 ml : 52,10 .
Registratiehouder: Alcon Laboratories (UK), Ltd. Boundary Way, Hemel Hempstead, Herts HP2 7UD, Verenigd Koninkrijk.
Fabrikant: SA ALCON-COUVREUR NV, Rijksweg 14, 2870 Puurs, België.
Aflevering: Geneesmiddel op medisch voorschrift.
Datum van herziening van de tekst: 14 april 2011.
Mei 2012
TRAVATAN®
Dénomination du médicament : TRAVATAN 40 microgrammes/ml collyre en solution.
Composition qualitative et quantitative : Chaque ml de solution contient 40 microgrammes de travoprost. Liste des excipients: polyquaternium-1, huile de ricin hydrogénée polyoxyéthylénée 40 (HCO-40), acide borique (E284), mannitol (E421), chlorure
de sodium, propylène glycol (E1520), hydroxyde de sodium et/ou acide chlorhydrique (ajustement du pH), eau purifiée.
Forme pharmaceutique : Collyre en solution. Solution incolore et limpide.
Indications thérapeutiques : Réduction de la pression intraoculaire élevée chez les patients atteints d’hypertonie intraoculaire ou de glaucome à angle ouvert.
Posologie et mode d’administration
Utilisation chez les adultes et les sujets âgés : La posologie est de une goutte de TRAVATAN dans le cul de sac conjonctival de l’œil ou des yeux atteint(s) une fois par jour. L’effet est optimal si le traitement est administré le soir. Une occlusion
nasolacrymale ou une fermeture douce des paupières après administration est recommandée. Ceci peut réduire l’absorption systémique des médicaments administrés par voie oculaire et conduire à une diminution des effets indésirables systémiques. En
cas d’utilisation de plusieurs collyres, les médicaments doivent être administrés avec au moins 5 minutes d’écart. Si une instillation est oubliée, le traitement doit être poursuivi avec l'instillation suivante comme prévu. La posologie ne doit pas dépasser une
goutte par jour dans l’œil ou les yeux atteint(s). En cas de remplacement d’un autre traitement antiglaucomateux ophtalmique par TRAVATAN, l’autre traitement doit être interrompu et TRAVATAN doit être commencé le jour suivant.
Sujets pédiatriques
L’efficacité et la tolérance de TRAVATAN chez les patients de moins de 18 ans n’ont pas été établies et son utilisation n’est pas recommandée chez ces patients jusqu’à ce que de nouvelles données soient disponibles.
Insuffisants hépatiques et rénaux
TRAVATAN a été étudié chez les insuffisants hépatiques modérés à sévères et chez les insuffisants rénaux modérés à sévères (clairance de la créatinine jusqu’à 14 ml/min). Aucune adaptation de la posologie n’est nécessaire chez ces patients.
Mode d’administration
Voie oculaire
Le patient doit retirer le sachet protecteur juste avant la première utilisation. Pour éviter la contamination de l’embout compte-gouttes et de la solution, il faut faire attention de ne pas toucher les paupières, les surfaces voisines ou d’autres surfaces avec
l’embout compte-gouttes du flacon.
Contre-indications : Hypersensibilité au principe actif ou à l’un des excipients.
Effets indésirables : Au cours des études cliniques incluant plus de 4400 patients, TRAVATAN (conservé avec du chlorure de benzalkonium) a été administré, une fois par jour, en monothérapie ou en association avec du timolol 0,5%. Aucun effet
indésirable grave, ophtalmique ou systémique, lié au produit n’a été rapporté dans aucune des études cliniques. L’effet indésirable, lié à TRAVATAN (conservé avec du chlorure de benzalkonium) en monothérapie, le plus fréquemment rapporté était une
hyperémie oculaire (22,0 %) incluant hyperémie oculaire, conjonctivale ou sclérale. L’hyperémie était légère chez 83,6 % des patients. Chez la plupart des patients (98 %), l'hyperémie n’a pas entraîné d’arrêt du traitement. Dans les études cliniques de
phase III d’une durée de 6 à 12 mois, l’hyperémie a diminué avec le temps.
Lors d’une étude clinique post-AMM à long terme d’une durée de 5 ans incluant 502 patients, TRAVATAN a été administré une fois par jour. Aucun effet indésirable grave, ophtalmique ou systémique, lié à TRAVATAN n’a été rapporté au cours de l’étude
clinique. L’effet indésirable lié au traitement avec TRAVATAN le plus fréquemment rapporté était une hyperpigmentation de l’iris (29,5 %). L’hyperémie oculaire considérée comme liée à l’utilisation de TRAVATAN a été rapportée avec une incidence de 10,0
%, et 2 % des patients rapportant une hyperémie oculaire ont interrompu leur participation à l’étude en raison de cet effet indésirable.
Les effets indésirables suivants ont été considérés comme liés au traitement avec TRAVATAN (conservé avec du chlorure de benzalkonium) en monothérapie et ont été classés de la façon suivante : très fréquents ( 1/10), fréquents (>1/100, <1/10), peu
fréquents (>1/1.000, 1/100) et rares (>1/10.000, 1.000) ou très rares ( 1/10.000). Dans chaque groupe de fréquence, les effets indésirables sont présentés dans l’ordre décroissant de gravité.
TRAVATAN (conservé avec du chlorure de benzalkonium)
Infections et infestations: Peu fréquentes : herpès simplex, kératite herpétique
Affections du système immunitaire : Peu fréquentes : hypersensibilité, hypersensibilité médicamenteuse, allergie saisonnière
Affections du système nerveux: Fréquentes : céphalées. Peu fréquentes : dysgueusie, sensation vertigineuse, anomalie du champ visuel
Affections oculaires : Très fréquentes : hyperémie oculaire, hyperpigmentation de l’iris. Fréquentes : kératite ponctuée, inflammation de la chambre antérieure, douleur oculaire, photophobie, sécrétions oculaires anormales, gêne oculaire, baisse d’acuité
visuelle, vision trouble, sécheresse oculaire, prurit oculaire, augmentation de la sécrétion lacrymale, érythème des paupières, œdème des paupières, croissance des cils, coloration des cils. Peu fréquentes : érosion de la cornée, uvéite, kératite,
inflammation oculaire, photopsie, blépharite, œdème conjonctival, effet de halo, conjonctivite, follicules conjonctivaux, hypo-esthésie oculaire, meibomite, ectropion, pigmentation de la chambre antérieure, mydriase, cataracte, bord de la paupière croûteux,
asthénopie
Affections cardiaques : Peu fréquentes : fréquence cardiaque irrégulière, palpitations, fréquence cardiaque diminuée
Affections vasculaires : Peu fréquentes : diminution ou augmentation de la pression artérielle, hypotension, hypertension
Affections respiratoires, thoraciques et médiastinales :Peu fréquentes : dyspnée, asthme, trouble respiratoire, douleur oro-pharyngée, toux, dysphonie, congestion nasale, irritation de la gorge.
Affections gastro-intestinales : Peu fréquentes : réactivation d’ulcère gastro-duodénal, affection gastro-intestinale, constipation
Affections de la peau et du tissus sous-cutané : Fréquentes : hyperpigmentation cutanée (péri-oculaire). Peu fréquentes : dermatite allergique, œdème péri-orbital, dermatite de contact, érythème, rash, modification de la couleur des cheveux, texture
anormale des cheveux, hypertrichose, madarose
Affections musculo-squelettiques et systémiques : Peu fréquentes : douleur musculo-squelettique
Troubles généraux et anomalies au site d’administration : Peu fréquentes : asthénie, malaise
Dans 2 études cliniques réalisées pour le développement de TRAVATAN (conservé avec du polyquaternium), 201 patients ont été traitées sur une période allant jusqu’à 3 mois. Aucun effet indésirable grave, ophtalmique ou systémique, lié au produit n’a
été rapporté dans ces études cliniques. L’effet indésirable lié à TRAVATAN (conservé avec du polyquaternium) le plus fréquemment rapporté était une hyperémie oculaire (18,9 %) incluant hyperémie oculaire ou conjonctivale. Un patient (0,5%) a
interrompu sa participation à l’essai pour hyperémie oculaire.
Les effets indésirables suivants ont été considérés comme liés au traitement (avec TRAVATAN (conservé avec du polyquaternium-1) en monothérapie) et ont été classés de la façon suivante : très fréquents ( 1/10), fréquents (>1/100, <1/10), peu fréquents
(>1/1 000, 1/100) et rares (>1/10 000, 1/1 000) ou très rares ( 1/10 000). Dans chaque groupe de fréquence, les effets indésirables sont présentés dans l’ordre décroissant de gravité.
TRAVATAN (conservé avec du polyquaternium-1)
Affections du système nerveux : Peu fréquentes : céphalées
Affections oculaires : Très fréquentes : hyperémie oculaire. Fréquentes : kératite ponctuée, douleur oculaire, photophobie, gêne oculaire, sécheresse oculaire, prurit oculaire. Peu fréquentes : baisse d’acuité visuelle, augmentation de la sécrétion lacrymale,
érythème des paupières, bord de la paupière croûteux
Affections gastro-intestinales : Peu fréquentes : bouche sèche
Affections de la peau et du tissu sous-cutané : Fréquentes : hyperpigmentation cutanée, dyschromie cutanée
Des effets indésirables identifiés après la commercialisation et non rapportés précédemment lors des études cliniques avec TRAVATAN en monothérapie sont les suivants : oculaire : œdème maculaire ; Systémique : bradycardie, tachycardie, asthme
aggravé, vertiges, bourdonnement d’oreilles, augmentation de la PSA, croissance des cheveux anormale.
Prix public incl. TVA : 3 x 2,5 ml : 52,10 .
Titulaire d’enregistrement : Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts HP2 7UD, Royaume Uni.
Fabricant : SA ALCON-COUVREUR NV, Rijksweg 14, 2870 Puurs, Belgique.
Numéro d’enregistrement : EU/1/01/199/002.
Délivrance : Médicament soumis à prescription médicale.
Date de mise à jour du texte: 14 avril 2011.
Mai 2012
Rev 05/2012
DUOTRAV®
Naam van het geneesmiddel: DuoTrav 40 microgram/ml + 5 mg/ml oogdruppels, oplossing
Kwalitatieve en kwantitatieve samenstelling: Iedere ml oplossing bevat 40 microgram travoprost en 5 mg timolol (als timololmaleaat). Lijst van hulpstoffen: polyquaternium-1, mannitol (E421), propyleenglycol (E1520), polyoxyethyleen
gehydrogeneerde castorolie 40 (HCO-40), boorzuur, natriumchloride, natriumhydroxide en/of zoutzuur (om de pH in te stellen), gezuiverd water.
Farmaceutische vorm: Oogdruppel, oplossing (oogdruppel). Heldere, kleurloze oplossing.
Therapeutische indicaties: Verlaging van de intraoculaire druk (IOD) bij volwassen patiënten met openkamerhoekglaucoom of oculaire hypertensie die onvoldoende reageren op topische bètablokkers of prostaglandine-analogen.
Dosering en wijze van toediening: Dosering: Gebruik bij volwassenen, inclusief ouderen: De dosis is één druppel DuoTrav eenmaal daags, ’s morgens of ’s avonds, in de conjunctivale zak van het (de) aangedane oog (ogen). Het moet
iedere dag op hetzelfde tijdstip worden toegediend. Als een dosis wordt vergeten, wordt de behandeling volgens schema voortgezet met de volgende dosis. De dagelijkse dosis mag niet hoger zijn dan één druppel in het (de) aangedane oog
(ogen).
Bijzondere patiëntengroepen: Lever- en nierfunctiestoornissen: Er is geen onderzoek verricht met DuoTrav of met timolol 5 mg/ml oogdruppels bij patiënten met lever- of nierfunctiestoornissen. Travoprost is onderzocht bij patiënten met lichte tot
ernstige leverfunctiestoornissen en bij patiënten met lichte tot ernstige nierfunctiestoornissen (creatinineklaring zo laag als 14 ml/min). Bij deze patiënten was aanpassing van de dosis niet nodig. Het is onwaarschijnlijk dat de dosis DuoTrav
aangepast moet worden bij patiënten met lever- of nierfunctiestoornissen. Pediatrische patiënten: De veiligheid en werkzaamheid van DuoTrav bij kinderen en jongeren onder de 18 jaar werden niet vastgesteld. Er zijn geen gegevens
beschikbaar. Wijze van toediening: Voor oculair gebruik. Het beschermende foliezakje moet vlak vóór het eerste gebruik worden verwijderd door de patiënt. Om besmetting van de druppelaar en de oplossing te voorkomen, mag de druppelaar
van het flesje niet in contact komen met de oogleden, het omringende gedeelte of andere oppervlakken. De systemische absorptie wordt verminderd wanneer nasolacrimale occlusie wordt toegepast of wanneer de oogleden 2 minuten worden
gesloten. Hierdoor kunnen systemische bijwerkingen verminderen en kan de lokale werkzaamheid toenemen. Indien meer dan één topisch oftalmisch geneesmiddel wordt gebruikt, moeten deze geneesmiddelen met een tussenperiode van
minimaal 5 minuten worden toegediend. Wanneer een ander oftalmisch antiglaucoommiddel wordt vervangen door DuoTrav, moet het gebruik van het andere middel worden stopgezet en moet de volgende dag met DuoTrav worden begonnen.
Patiënten moeten geïnstrueerd worden hun zachte contactlenzen te verwijderen vóór toediening van DuoTrav en 15 minuten te wachten na indruppeling van de dosis voordat zij hun contactlenzen weer kunnen inzetten.
Contra-indicaties: Overgevoeligheid voor de werkzame bestanddelen of voor één van de hulpstoffen. Overgevoeligheid voor andere bètablokkers. Reactieve luchtwegaandoeningen, waaronder astma bronchiale of een anamnese van astma
bronchiale, ernstige chronische obstructieve longziekte. Sinus bradycardie, sick-sinus syndroom inclusief sino-atriaal blok, tweede- of derdegraads atrioventriculair blok niet gereguleerd door een pacemaker. Manifest hartfalen, cardiogene
shock. Ernstige allergische rhinitis en corneale dystrofie.
Bijwerkingen: In klinisch onderzoek bij 938 patiënten werd DuoTrav (met benzalkoniumchloride als conserveermiddel) eenmaal daags toegediend. De meest gemelde bijwerking die met de behandeling in verband kon worden gebracht was
oculaire hyperemie (15,0%). Bijna alle patiënten (96%) beëindigden de behandeling als gevolg van deze reactie niet.
De volgende bijwerkingen, hieronder opgesomd, zijn waargenomen in klinische studies of zijn door postmarketing-ervaringen vastgesteld. Zij zijn gerangschikt naar systeem/orgaanklasse en ingedeeld volgens de volgende conventie: zeer vaak
( 1/10), vaak ( 1/100 tot <1/10), soms ( 1/1.000 tot < 1/100), zelden ( 1/10.000 tot < 1/1.000), zeer zelden (< 1/10.000), of niet bekend (kan met de beschikbare gegevens niet worden bepaald). Binnen iedere frequentiegroep worden
bijwerkingen gerangschikt naar afnemende ernst.
DuoTrav (met benzalkoniumchloride als conserveermiddel) Psychische stoornissen: Vaak: zenuwachtigheid. Niet bekend: depressie. / Zenuwstelselaandoeningen: Vaak: duizeligheid, hoofdpijn. Niet bekend: cerebrovasculair accident,
syncope, paresthesie. / Oogaandoeningen: Zeer vaak: ongemak in het oog, oculaire hyperemie. Vaak: keratitis punctata, voorste oogkamerontsteking, oogpijn, fotofobie, oogzwelling, conjunctiva hemorragie, scherpzien gereduceerd, visuele
stoornis, gezichtsvermogen wazig, droog oog, oogpruritus, conjunctivitis, traanproductie verhoogd, erytheem van het ooglid, blefaritis, asthenopie, groei van de wimpers. Soms: cornea-erosie, keratitis, oogallergie, conjunctivaal oedeem,
ooglidoedeem. Zelden: iritis. Niet bekend: macula-oedeem, ooglidptose, cornea-aandoening. / Hartaandoeningen: Vaak: hartfrequentie onregelmatig, hartfrequentie verlaagd. Soms: aritmie. Niet bekend: hartfalen, tachycardie. /
Bloedvataandoeningen: Vaak: bloeddruk verhoogd, bloeddruk verlaagd. / Ademhalingsstelsel-, borstkas- en mediastinumaandoeningen: Vaak: bronchospasme. Soms: dyspnoea, hoesten, orofaryngeale pijn, keelirritatie, neusongemak,
postnasale drip. Niet bekend: astma. / Lever- en galaandoeningen: Soms: alanine-aminotransferase verhoogd, aspartaataminotransferase verhoogd. / Huid- en onderhuidaandoeningen: Vaak: urticaria, huidhyperpigmentatie (perioculair). Soms:
contactdermatitis. Zelden: alopecia. Niet bekend: rash. / Skeletspierstelsel- en bindweefselaandoeningen: Vaak: pijn in extremiteit. / Nier- en urinewegaandoeningen: Soms: chromaturie. / Algemene aandoeningen en
toedieningsplaatsstoornissen: Soms: dorst. Niet bekend: borstkaspijn.
Tijdens de ontwikkeling van DuoTrav (met polyquaternium-1 als conserveermiddel) werden in 3 klinische studies 372 patiënten/proefpersonen tot 12 maanden blootgesteld. De meest gemelde bijwerking die in verband kon worden gebracht met
de behandeling met DuoTrav (met polyquaternium-1 als conserveermiddel) was hyperemie van het oog (11,8%), waaronder oculaire of conjunctiva hyperemie. De meeste patienten (91%) die hyperemie van het oog ondervonden, stopten niet
met de therapie vanwege deze reactie.
De volgende bijwerkingen, hieronder opgesomd, zijn waargenomen in de klinische studies:
DuoTrav (met polyquaternium-1 als conserveermiddel) Immuunsysteemaandoeningen: Soms: overgevoeligheid. / Zenuwstelselaandoeningen: Soms: hoofdpijn. / Oogaandoeningen: Vaak: oogpijn, ongemak in het oog, droog oog,
oogpruritus, oculaire hyperemie. Soms: keratitis punctata, iritis, fotofobie, gezichtsvermogen wazig, conjunctivitis, meibom-ontsteking, schilferige ooglidrand, asthenopie, traanproductie verhoogd, groei van de wimpers. / Hartaandoeningen:
Soms: bradycardie. / Bloedvataandoeningen: Soms: hypotensie. / Huid- en onderhuidaandoeningen: Soms: huidverkleuring, haargroei abnormaal. / Algemene aandoeningen en toedieningsplaatsstoornissen: Soms: vermoeidheid. /
Onderzoeken: Soms: hartfrequentie verlaagd.
Aanvullende bijwerkingen die voor één van de werkzame bestanddelen werden vastgesteld en die mogelijk kunnen voorkomen met DuoTrav:
Travoprost: Oogaandoeningen: uveïtis, conjunctiva-aandoening, conjunctivale follikels, irishyperpigmentatie. / Huid- en onderhuidaandoeningen: huidexfoliatie.
Timolol: Zoals andere topisch toegediende oftalmische geneesmiddelen wordt timolol systemisch geabsorbeerd. Hierdoor kunnen dezelfde bijwerkingen optreden als bij systemische bètablokkers. De aanvullende bijwerkingen die hieronder
genoemd worden, bevatten de reacties waargenomen binnen de klasse van oftalmische bètablokkers. De incidentie van systemische bijwerkingen na topische oftalmische toediening is lager dan na systemische toediening.
Immuunsysteemaandoeningen: systemische allergische reacties waaronder angio-oedeem, urticaria, gelokaliseerde en gegeneraliseerde uitslag, pruritus, anafylaxie. / Voedings- en stofwisselingsstoornissen: hypoglykemie. / Psychische
stoornissen: insomnia, nachtmerries, geheugenverlies. / Zenuwstelselaandoeningen: cerebrale ischemie, verergering van de verschijnselen en symptomen van myasthenia gravis. / Oogaandoeningen: verschijnselen en symptomen van oculaire
irritatie (zoals branden, prikken, jeuken, tranen, roodheid), choroïdloslating na filtratiechirurgie, verminderde corneagevoeligheid, diplopie. / Hartaandoeningen: borstkaspijn, hartkloppingen, oedeem, congestief hartfalen, atrioventriculair blok,
hartstilstand. Bloedvataandoeningen: fenomeen van Raynaud, koude handen en voeten. / Ademhalingsstelsel-, borstkas- en mediastinumaandoeningen: bronchospasmen (voornamelijk bij patiënten met een bestaande bronchospastische
aandoening). / Maagdarmstelselaandoeningen: dysgeusie, nausea, dyspepsie, diarree, droge mond, buikpijn, braken. / Huid- en onderhuidaandoeningen: psoriasisachtige uitslag of verergering van psoriasis. / Skeletspierstelsel- en
bindweefselaandoeningen: myalgie. / Voortplantingsstelsel- en borstaandoeningen: seksuele disfunctie, verminderd libido. / Algemene aandoeningen en toedieningsplaatsstoornissen: asthenie.
Publieksprijs inclusief BTW: 3 x 2,5 ml: 68,93 .
Registratiehouder: Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts HP2 7UD, Verenigd Koninkrijk.
Fabrikant: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, België.
Aflevering: Geneesmiddel op medisch voorschrift.
Datum van herziening van de tekst: 17 februari 2012.
Mei 2012
DUOTRAV®
Dénomination du médicament: DuoTrav 40 microgrammes/ml + 5 mg/ml collyre en solution
Composition qualitative et quantitative: Chaque ml de solution contient 40 microgrammes de travoprost et 5 mg de timolol (sous forme de maléate de timolol). Liste des excipients: polyquaternium-1, mannitol (E421), propylène glycol
(E1520), huile de ricin hydrogénée polyoxyéthylénée 40 (HCO-40), acide borique, chlorure de sodium, hydroxyde de sodium et/ou acide chlorhydrique (ajustement du pH), eau purifiée.
Forme pharmaceutique: Collyre en solution (collyre). Solution incolore et limpide.
Indications thérapeutiques: Réduction de la pression intraoculaire (PIO) chez les patients adultes atteints de glaucome à angle ouvert ou d’hypertonie intraoculaire et qui présentent une réponse insuffisante aux bêta-bloquants ou aux
analogues des prostaglandines administrés localement.
Posologie et mode d’administration: Posologie: Utilisation chez les adultes et les sujets âgés: La posologie est d'une goutte de DuoTrav dans le cul de sac conjonctival de l’œil ou des yeux atteint(s), une fois par jour, le matin ou le soir. Il
doit être administré tous les jours à la même heure. Si une instillation est oubliée, le traitement doit être poursuivi avec l’instillation suivante. La posologie ne doit pas dépasser une goutte par jour dans l’œil ou les yeux atteint(s).
Population particulières: Insuffisants hépatiques et rénaux: Aucune étude n’a été effectuée avec DuoTrav ou avec timolol 5 mg/ml collyre chez les insuffisants hépatiques ou rénaux. Travoprost a été étudié chez les insuffisants hépatiques
modérés à sévères et chez les insuffisants rénaux modérés à sévères (clairance de la créatinine jusqu’à 14 ml/min). Aucune adaptation de la posologie n’est nécessaire chez ces patients. Les patients insuffisants hépatiques ou rénaux ne
nécessitent pas d’adaptation de la posologie avec DuoTrav. Population pédiatrique: La sécurité et l’efficacité de DuoTrav chez les enfants et adolescents de moins de 18 ans n’ont pas été établies. Aucune donnée n’est disponible. Mode
d’administration: Voie oculaire. Le patient doit retirer le sachet protecteur juste avant la première utilisation. Pour éviter la contamination de l’embout compte-gouttes et de la solution, il faut faire attention de ne pas toucher les paupières, les
surfaces voisines ou d’autres surfaces avec l’embout compte-gouttes du flacon. Le passage systémique peut être réduit par une occlusion nasolacrymale ou la fermeture des paupières pendant 2 minutes. Cette méthode peut contribuer à
diminuer les effets indésirables systémiques et à augmenter l’efficacité locale. En cas d’utilisation de plusieurs collyres, les instillations doivent être espacées d’au moins 5 minutes. En cas de remplacement d’un autre médicament
antiglaucomateux ophtalmique par DuoTrav, interrompre l’autre médicament et commencer DuoTrav le jour suivant. Les patients doivent enlever leurs lentilles de contact avant instillation de DuoTrav et attendre 15 minutes après l’instillation
avant de poser des lentilles de contact.
Contre-indications: Hypersensibilité aux substances actives ou à l’un des excipients. Hypersensibilité aux autres bêta-bloquants. Pathologies associées à une hyperréactivité bronchique notamment asthme ou antécédents d'asthme et
bronchopneumopathie chronique obstructive sévère. Bradycardie sinusale, maladie du sinus, bloc auriculo-ventriculaire du second ou du troisième degré non contrôlé par un pacemaker. Insuffisance cardiaque confirmée, choc cardiogénique.
Rhinite allergique sévère et dystrophies cornéennes.
Effets indésirables: Au cours des études cliniques incluant 938 patients, DuoTrav (conservé avec du chlorure de benzalkonium) a été administré une fois par jour. L’effet indésirable le plus fréquent lié au traitement était l’hyperhémie oculaire
(15,0%). La plupart des patients atteints d’hyperhémie (96%) n’a pas arrêté le traitement pour cette raison.
Les effets indésirables recensés ci-dessous ont été observés lors des essais cliniques ou après commercialisation. Ils sont présentés par classe de systèmes d’organes et listés ci-après de la façon suivante: très fréquents ( 1/10), fréquents (
1/100 à < 1/10), peu fréquents ( 1/1.000 à 1/100), rares ( 1/10.000 à < 1/1.000), très rares (< 1/10.000) ou fréquence indéterminée (ne peut être estimée sur la base des données disponibles). Au sein de chaque fréquence de groupe, les
effets indésirables sont présentés suivant un ordre décroissant de gravité.
DuoTrav (conservé avec du chlorure de benzalkonium) Affections psychiatriques: Fréquente: nervosité. Indéterminée: dépression. / Affections du système nerveux: Fréquentes: étourdissement, maux de tête. Indéterminées: accident
cérébrovasculaire, syncope, paresthésie. / Affections oculaires: Très fréquentes: gêne oculaire, hyperhémie oculaire. Fréquentes: kératite ponctuée, inflammation de la chambre antérieure (effet Tyndall cellulaire et protéique), douleur oculaire,
photophobie, gonflement oculaire, hémorragie conjonctivale, acuité visuelle réduite, trouble visuel, vision floue, sécheresse oculaire, prurit oculaire, conjonctivite, larmoiement augmenté, érythème des paupières, blépharite, asthénopie,
croissance des cils. Peu fréquentes: érosion cornéenne, kératite, allergie oculaire, œdème conjonctival, œdème des paupières. Rare: iritis. Indéterminées: œdème maculaire, ptosis des paupières, affection cornéenne. / Affections cardiaques:
Fréquentes: rythme cardiaque irrégulier, diminution du rythme cardiaque. Peu fréquente: arythmie. Indéterminées: insuffisance cardiaque, tachycardie. / Affections vasculaires: Fréquentes: augmentation de la pression artérielle, diminution de la
pression artérielle. / Affections respiratoires, thoraciques et médiastinales: Fréquente: bronchospasme. Peu fréquentes: dyspnée, toux, douleur oro-pharyngée, irritation de la gorge, gêne nasale, rhinopharyngite. Indéterminée: asthme. /
Affections hépatobiliaires: Peu fréquentes: augmentation des alanine-aminotransférases, augmentation des aspartate-aminotransférases. / Affections de la peau et du tissu sous-cutané: Fréquentes: urticaire, hyperpigmentation de la peau
(péri-oculaire). Peu fréquente: dermatite de contact. Rare: alopécie. Indéterminée: éruption cutanée. / Affections musculo-squelettiques et systémiques: Fréquente: douleurs aux extrémités. / Affections du rein et des voies urinaires: Peu
fréquente: chromaturie. Troubles généraux et anomalies au site d'administration: Peu fréquente: soif. Indéterminée: douleur thoracique.
Dans 3 études cliniques réalisées pour le développement de DuoTrav (conservé avec du polyquaternium-1), 372 patients/sujets ont été traités sur une période allant jusqu’à 12 mois. L’effet indésirable le plus fréquemment rapporté comme lié à
DuoTrav (conservé avec du polyquaternium-1) était une hyperhémie oculaire (11,8 %) incluant hyperhémie oculaire ou conjonctivale. Chez la plupart des patients qui présentaient une hyperhémie (91%), le traitement n’a pas été arrêté pour
cette raison.
Les effets indésirables listés ci-dessous ont été rapportés lors des essais cliniques.
DuoTrav (conservé avec du polyquaternium-1) Affections du système immunitaire: Peu fréquente: hypersensibilité. / Affections du système nerveux: Peu fréquente: maux de tête. / Affections oculaires: Fréquentes: douleur oculaire, gêne
oculaire, sécheresse oculaire, prurit oculaire, hyperhémie oculaire. Peu fréquentes: kératite ponctuée, iritis, photophobie, vision floue, conjonctivite, meibomite, croûtes sur le bord de la paupière, asthénopie, larmoiement augmenté, croissance
des cils. / Affections cardiaques: Peu fréquente: bradycardie. / Affections vasculaires: Peu fréquente: hypotension. / Affections de la peau et du tissu sous-cutané: Peu fréquentes: dyschromie cutanée, croissance des cheveux anormale. /
Troubles généraux et anomalies au site d’administration: Peu fréquente: fatigue. / Examens: Peu fréquente: fréquence cardiaque diminuée.
Effets indésirables supplémentaires qui ont été observés avec l’un des principes actifs et peuvent éventuellement survenir avec DuoTrav:
Travoprost: Affections oculaires: uvéite, affection conjonctivale, follicules conjonctivaux, hyperpigmentation de l'iris. / Affections de la peau et du tissu sous-cutané: exfoliation cutanée.
Timolol: Comme pour d'autres médicaments à usage ophtalmique administrés par voie locale, ce médicament peut passer dans la circulation générale. Cela peut entrainer des effets indésirables semblables à ceux des bêta-bloquants pris par
voie systémique. Les effets indésirables liés à la classe des bêta-bloquants ophtalmiques sont listés ci-dessous. L'incidence des effets indésirables systémiques après une administration topique ophtalmique est inférieure à celle d’une
administration systémique. Affections du système immunitaire: réactions allergiques systémiques incluant angiœdème, urticaire, rash localisé et généralisé, prurit, anaphylaxie. / Troubles du métabolisme et de la nutrition: hypoglycémie. /
Troubles psychiatriques: insomnie, cauchemars, pertes de mémoire. / Affections du système nerveux: ischémie cérébrale, majoration des signes et symptômes de myasthénie gravis. / Affections oculaires: signes et symptômes d’irritation
oculaire (par exemple, brûlure, picotements, démangeaisons, larmoiement, rougeur), décollement de la choroïde après une chirurgie filtrante, diminution de la sensibilité cornéenne, diplopie. / Affections cardiaques: douleur thoracique,
palpitations, œdèmes, insuffisance cardiaque congestive, bloc auriculo-ventriculaire, arrêt cardiaque. Troubles vasculaires: syndrome de Raynaud, mains et pieds froids. / Affections respiratoires, thoraciques et médiastinales: bronchospasme
(prinicipalement chez les patients ayant une maladie bronchospastique préexistante). / Affections gastro-intestinales: dysgueusie, nausée, dyspepsie, diarrhée, bouche sèche, douleurs abdominales, vomissements. / Affections de la peau et du
tissu sous-cutané: éruption psoriasiforme ou exacerbation d’un psoriasis. / Affections musculo-squelettiques et des tissus conjonctifs: myalgies. / Troubles des organes de reproduction et des seins: troubles sexuels, diminution de la libido. /
Troubles généraux et anomalie au site d'administration: asthénie.
Prix public incl. TVA: 3 x 2,5 ml: 68,93 .
Titulaire d’enregistrement: Alcon Laboratories (UK) Ltd., Boundary Way, Hemel Hempstead, Herts HP2 7UD, Royaume-Uni.
Fabricant: SA ALCON-COUVREUR NV, Rijksweg 14, B-2870 Puurs, Belgique.
Numéro d’enregistrement: EU/1/06/338/002.
Délivrance: Médicament soumis à prescription médicale.
Date de mise à jour du texte: 17 février 2012.
Mai 2012
Rev 05/2012
x
th
au
irst
F
nde
i
r
o
All first authors are listed alphabetically.
If the author has submitted an abstract, the abstract number is marked pink.
If there is no abstract submitted, the abstract number is marked grey italic.
AL-SABAI, N: 3002, P119
ARDEN, G: 2020
BALIKOVA, I: P111
BEACONSFIELD, M: 1017
BEIRNAERT, V: 3003
BLANCKAERT, J: 2025, 3006
BLEYEN, I: 3026
BOECKAERT, J: P125
BORRUAT, F: 2010
BOSCHI, A: 1026, 3011
BUYCK, A: 3010
CASSIMAN, C: 2014
CASSIMAN, JJ: 2021
CHAVES, A: 2026
CLAERHOUT, I: 1002, 3004, 3021
CLAOUE DE GOHR, CMP: P101
COECKELBERGH, T: 3015
CORDONNIER, M: 1024
DE GROEF, L: P129
DE GROOT, V: 1009, 1029, 2005
DE KEIZER, R: 1028
DE LEPELEIRE, K: 1011
DE NIJS, E: 1036
DE POTTER, P: 1020
DE SMEDT, SK: 1043
DEBROUWERE, V: P136
DECOCK, C: 1012, 1030
DECONINCK, H: 1034
DEPASSE, F: 1023, 1025
DEPLA, J: 3031
DEWILDE, E: 1044
DEWILDE, J: P127
DIERICKX, L: 3017
DIRVEN, W: 3030
DUCHESNE, B: 1001
EHONGO, A: 2004
FRITZ, L: 3016
GENICOT, G: 2017
GERARD, P: 1022
GERTEN, G: 2011
GODTS, DJM: P121
GOES, F JR: 2008
GOES, Fjr: 2023
GOMEZ DE LIANO, R: 1008, 1033
HAMAIDE, S: 3038
HOENRAET, D: 3039
HOLDER, G: 2019
HOLLANDERS, K: P128
HONDEGHEM, K: 2006
JANSEN, J: P126
JONCKHEERE, P: 1015
JOURDAN, C: 3037
KAIMBO WA KAIMBO, D: P102
KESTELYN, P: 1003, 2001
KOPPEN, C: 3001, 3023
LANE, N: 1021
LEMAGNE, JM: 1018, 3027
LEPUITS, G: 3018
LEWKOWICZ, D: P108
LEYS, A: 1019
LEYS, E: 1039, P110
LEYSEN, I: 1010, 3020
LHOIR, S.: P113
MARINESCU, C: 1038, P106
MATTHEEUWS, S: 2016
MEIRE, F: 3009
MEIRLEIR, L: 2012
MERTENS, ELJG: 2024
MISSOTTEN, G: P117
NOUVET, L: 1027
OEHRENS, AM: P114
PALLIKARIS, I: 2022
PINXTEN, I: 1045
POURJAVAN, S: 2002
RABEUX, E: P109
RAKIC, JM: 1006, 1007
RAUS, P: 1016
ROSAPELLY, B: P105
ROULEZ, F: 1037, 3007
ROULEZ, FM: P103
SAELENS, S: 2018
SANTOS, A: 3005
SELLIER, J: 3033, 3035, P104
SIJNAVE, D: P122
112
SILBERBERG, D: P107
STALMANS, I: 2003, P118
STALMANS, P: 1004, 1005, 1042,
2009
STEVENS, A: 2007
STEVENS, AM: P138
STREEL, C: 3019
TASSIGNON, MJ: 3028
TRAU, R: 3029
UVIJLS, A: P137
VAN BERGEN, T: P134
VAN BOL, L: P112
VAN CALSTER, J: 1041, 3032
VAN CLEYNENBREUGEL, H: 3022,
3025
VAN DAELE, O: 3008
VAN DE VELDE, S: P131
VAN GINDERDEUREN, R: P120
VAN LAMMEREN, M: 1032, 3014
VAN LOEY, S: P133
VAN LOOVEREN, J: 1040
VAN NISPEN, RMA: 3036
VAN WAVEREN: 3013
VANDEKERCKHOVE, G: P124
VANDELANOTTE, S: 1014
VANDENBROUCKE, S: P132
VANDEWALLE, E: P115
VANDEWEYER, E: P123
VANLERBERGHE, V: P135
VERHELLE, V: 3012
VRYGHEM, J: 3024
WALRAEDT, S: 2015
WEYNS, M: P130
XHAUFLAIRE, G: 1013
YUKSEL, D: 1031, 1035, 3034
ZEEVAERT, R: 2013
Johnson & Johnson Vision Care heet u van harte welkom op OB 2012.
Ontdek op onze stand het belang van UV-bescherming voor de ogen.
Johnson & Johnson Vision Care vous accueille chaleureusement à OB 2012.
Découvrez sur notre stand l'importance de se protéger les yeux contre les UV.
www.jnjvisioncare.be www.fr.jnjvisioncare.nl
© Johnson & Johnson Vision Care 2012, een afdeling van Johnson & Johnson Medical N.V. © Johnson & Johnson Vision Care 2012, une division de Johnson & Johnson Medical S.A.
OB 2012
WEDNESDAY
Nov. 28, 2012
Nov. 29, 2012
THURSDAY
Nov. 30, 2012
FRIDAY
17:30
15:30
16:00
14:00
12:30
10:30
11:00
09:00
22:00
17:30
15:30
16:00
14:00
12:30
10:30
11:00
09:00
17:30
15:30
16:00
14:00
12:30
10:30
11:00
09:00
BSCRS
BSCRS
BSCRS
BSCRS
ACAD. SESSION 20 Y
BBO-UPBMO
BGS
BGS
OBAO
OBAO
OBAO
Hall A
NOC
NOC
Hall D
PED & LOW
PED & LOW
ICC-W5
AOB Free Papers
Interactive Surgical Course in Hall A
BIO
FAB
Poster session in O’Bistro
FAB
FAB
Hall C
ICC-T8
ICC-T6
ICC-T5
ICC-W4
ICC-W3
ICC-W2
ICC-W1
Hall E - ICC
BSONT NL
BSONT NL
BOV-ABO
BOV-ABO
BSONT FR
ICC-F14
BVVB-OBPC
Award Ceremony in Hall A
BSONT FR
ICC-F13
ICC-F12
ICC-F11
ICC-F10
EYE in the SKY: celebration of 20th Anniversary of OB in Pal 6 in Brussels EXPO
BOG and SBO
BOG and SBO
BSA
BSA
BSOPRS
BSOPRS
Hall B
Wetlab - 10
Wetlab - 9
Wetlab - 8
Wetlab - 7
Wetlab - 6
Wetlab - 5
Wetlab - 4
Wetlab - 3
Wetlab - 2
Wetlab - 1
Hall F - Wetlab
Wetlab - Eyelid 2
Wetlab - Eyelid 1
Hall G - Eyelid

Programme book Brussels EXPO Nov 28-30, 2012

Transcription

Similar documents

Sparender bestraling van de axilla?

Klik hier - ThromboGenics

Abstracts Najaarsvergadering 6 november 2009

WORKING FOR RARE AND GENETIC DISEASES

W NEWSFLASH nr°17 HOSPITHERA,

ONederlands Tijdschrift voor - Nederlands Tijdschrift voor Orthopaedie

Netherlands Heart Journal Supplements

Tijdschrift in pdf, 2016-01

NTvDV 2014-01

Abstract

10 jaar Master EBP - Lustrum Abstractboek

Woord vooraf…………………………..

2011 - Amphia Ziekenhuis

A single-molecule view on protein aggregation

long term outcomes and laparoscopic

PDF hosted at the Radboud Repository of the Radboud University

Anemoon project KULEUVEN

L-Z - Viscopy